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Abstract 
Obesity is a major growing cause of death with no effective long-term treatment apart 
from surgical procedures such as Roux-en-Y gastric bypass (RYGB). The sustained 
weight loss following surgery is thought to be due in part to the increased levels of 
circulating anorexigenic gut hormones such as peptide YY3-36 (PYY3-36). Peripheral 
administration of PYY3-36 suppresses appetite in rodents and man and represents a 
potential therapy for obesity however its effects on feeding are transient. Here I have 
characterized a long-lasting PYY3-36 analogue; PYY3-36 latrotoxin (PYY3-36 (LT)) which 
demonstrated greater longevity than PYY3-36 in acute feeding studies and that produced a 
10% reduction in bodyweight following once daily peripheral administration in a one 
month chronic feeding study performed on diet induced obese mice.  
Manganese enhanced MRI (MEMRI) has been used previously to assess the effects of 
nutritional status and gut hormones on brainstem and hypothalamic neuronal activity in 
vivo. I revealed through the MEMRI technique that the anorexigenic hormone pancreatic 
polypeptide (PP) modulates hypothalamic neuronal activity in fasted mice. Following this 
work, I performed more in-depth MEMRI experiments that revealed differential temporal 
effects of PYY3-36 and PYY3-36 (LT) on hypothalamic neuronal activity in fasted mice 
after treatment that corresponded to the effects seen with these peptides in feeding 
stuides. I also performed pharmacological MEMRI studies with the food additive 
monosodium glutamate (MSG) and confirmed its excitatory effect on neurons of the 
arcuate nucleus of the hypothalamus (ARC) following peripheral administration to mice. 
Roux-en-Y gastric bypass has been shown to increase energy expenditure possibly via a 
brown adipose tissue (BAT) mediated mechanism. I performed positron emission 
tomography-computed tomography (PET-CT) experiments on a rodent model of RYGB. 
I observed no differences in the activity of BAT of RYGB animals compared to sham-
operated controls, indicating means other than increased BAT activity account for the 
weight loss seen in this bariatric model.  
The work in this thesis demonstrates that long-lasting PYY3-36 analogues represent a 
viable obesity therapy. Furthermore, I have further developed both MEMRI and PET-CT 
techniques for the study of energy balance. 
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1 Introduction 
1.1 The obesity pandemic 
Obesity is a major growing health concern affecting both wealthy and poor nations with 1 
billion adults in the world today thought to be obese (defined as having a body mass 
index (BMI) greater than 30 kg/m2) (Haslam and James, 2005). In the UK alone, almost a 
quarter of adults are obese which is expected to increase to a third by 2012 (Zaninotto et 
al., 2009) and it is estimated that over 30 000 deaths a year are attributed to the disease 
(National Audit Office 2000: Tackling Obesity in England). In the US, over 100 000 
people die a year due to obesity associated comorbidities (Flegal et al., 2005) which 
include cardiovascular disease, type II diabetes, and various cancers (Flegal et al., 2007). 
To date there are no effective long-term treatments for obesity apart from surgical 
procedures. Therefore, a thorough understanding of energy homeostasis is essential in 
order to provide new treatments which can tackle the huge burden associated with 
obesity. 
1.2 Energy homeostasis and causes of obesity 
Obesity results from an imbalance between energy intake and energy expenditure. Energy 
intake is governed by feeding whilst energy expenditure depends on physical activity, 
basal metabolic rate, and adaptive thermogenesis (Lowell and Spiegelman, 2000). Energy 
balance is regulated in a similar way to other homeostatic mechanisms such as body 
temperature. Studies have shown that a ‘set-point’ is closely defended such that when 
subjects voluntarily lose 10% of their bodyweight they show a compensatory decrease in 
energy expenditure; when they gain 10% of their bodyweight they show a compensatory 
increase in energy expenditure (Leibel et al., 1995). Obesity appears to result when this 
set-point is disrupted.  
The causes of obesity are due to a complex interaction between environmental and 
genetic factors. In recent generations, the increased access to high caloric foods 
(increased energy intake) coupled with a more sedentary lifestyle (decreased energy 
expenditure) represent the major environmental factors that contribute to obesity 
(Friedman, 2003). Recent evidence obtained from studies conducted on mice has shown 
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that consuming a high fat diet (HFD) induces an inflammatory response in the brain that 
precedes the development of obesity and preventing this inflammatory response protected 
against weight gain (Zhang et al., 2008). These observations highlight that the 
consumption of fatty foods, which represent an environmental factor, causes 
pathophysiological processes that ultimately lead to obesity. The effects of maternal and 
postnatal nutrition on the development of obesity have also received attention. For 
instance, mothers obese at the time of gestation have an increased likelihood of having 
obese offspring (Catalano, 2003). Conversely, men whose mothers were exposed to the 
Dutch Hunger Winter Famine in the early phases of pregnancy were more obese (Ravelli 
et al., 1976). Similar observations have been made from studies in animal models. The 
consumption of a HFD during gestation and lactation results in obesity in offspring 
(Bayol et al., 2005) and a low protein diet during gestation and lactation produce 
offspring that are more prone to obesity on a HFD (Stocker et al., 2004). Therefore, it 
seems that both malnutrition and overnutrition in mothers at a critical period during 
gestation and weaning increases the likelihood of the development of obesity in 
offspring.  
Twin studies have revealed a genetic basis for obesity (Stunkard et al., 1990) but the 
identification of genes clearly involved in the aetiology of the disease in the general 
population has been slow. There are numerous examples of mutations in genes that code 
for key neurotransmitters, hormones and receptors as well as key enzymes which will be 
mentioned throughout this text. However, these mutations account for only 0.01% of 
obese individuals (Farooqi and O’Rahilly, 2006). Recently, a large scale genome wide 
study conducted on approximately 30 000 individuals, identified single nucleotide 
polymorphisms (SNPs) in the fat mass and obesity associated (FTO) gene located on 
chromosome 16 which provides the strongest evidence for a genetic cause for obesity in 
the general population. Approximately a fifth of those adults homozygous for the risk 
allele were on average 3kg heavier (Frayling et al., 2007). The FTO gene was 
subsequently shown to code for an enzyme expressed in the brain that demethylates DNA 
(Gerken et al., 2007) and deletion of the FTO gene in mice has pointed to a role of the 
enzyme in energy expenditure rather than to food intake (Fischer et al., 2009).  
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1.3 Anatomy of the hypothalamus and its role in energy homeostasis 
The hypothalamus was initially implicated in the regulation of energy homeostasis 
through clinical observations in patients with adipsogenital syndrome. These patients 
became obese following pituitary tumors that extended to and damaged the hypothalamus 
(Frohlich, 1901). The hypothalamus is located at the base of the brain in between the 
cerebral cortex and the midbrain. It can be subdivided into four regions in the 
anteroposterior axis each containing discrete neuronal populations or nuclei (Swanson, 
1987) (Figure 1.1). The most anterior region of the hypothalamus is the preoptic area 
which includes the preoptic nuclei. Posterior to the preoptic region is the anterior region 
which contains the suprachiasmatic nucleus (SCN) situated below the third ventricle and 
the paraventricular nucleus (PVN) at the roof of the third ventricle (Figure 1.2). More 
posterior is the tuberal region, which overlies the pituitary stalk and contains the arcuate 
nucleus (ARC) at the floor of the third ventricle, the ventromedial nucleus (VMN), and 
the dorsomedial nucleus (DMN). The supraoptic nucleus (SON) and the lateral 
hypothalamic area (LHA) lie on the lateral side of the VMN (Figure 1.2). Finally the 
most posterior region, the mammilary region, contains the tuberomammilary nucleus 
(TMN). 
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Figure 1.1 Organisation of the hypothalamus 
A schematic representation of the morphological organisation of the hypothalamus, 
showing the known functions of its zones, areas and nuclei. Adapted from Paxinos and 
Watson, 1998. 
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Figure 1.2 Anatomy of the hypothalamus 
Anatomy of the rat hypothalamus with the nuclei of the anterior and tuberal regions 
highlighted. 
Top: Saggital section of the rat brain, the anterior slice contains the anterior region of the 
hypothalamus and the posterior slice contains the tuberal region of the hypothalamus. 
Left: Coronal section of the rat brain containing the anterior region of the hypothalamus. 
Right: Coronal section of the rat brain containing the tuberal region of the hypothalalmus. 
PVN: Paraventricular nucleus, 3V: 3rd Ventricle, OC: Optic Chiasm, SCN: 
Suprachiasmatic nucleus, DMN: Dorsomedial Nucleus, VMN: Ventromedial Nucleus, 
ARC: Arcuate Nucleus, LHA: Lateral Hypothalamic Area, ME: Median eminence. 
Adapted from Schwartz 2000.  
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Extensive connections exist between these hypothalamic nuclei and with other parts of 
the CNS which allows for neuronal processing within the hypothalamus and with the rest 
of the CNS. The ARC forms major connections with the PVN, VMN, and DMN (Bouret 
et al., 2004a). The DMN has connections with the PVN and the brainstem (Thompson et 
al., 1996). The LHA has extensive connections with the cortex and ventral tegmental area 
(VTA) of the midbrain (Saper et al., 1979). The VMN and PVN have connections with 
the intermediolateral cell column of the spinal cord where the cell bodies of the 
sympathetic nervous system are situated (Saper et al., 1976; Sawchenko and Swanson, 
1982). Therefore, these connections represent the major anatomical and functional link 
between the hypothalamus and autonomic processing such as sympathetic nervous 
system mediated lipolysis in white adipose tissue and thermogenesis in brown adipose 
tissue (BAT). 
Experiments in various species revealed that ablation and stimulation of neurons in the 
various nuclei of the hypothalamus resulted in changes in feeding and bodyweight. Such 
studies implicated the ARC, PVN, and VMN in the promotion of a negative energy 
balance and the LHA and DMN in the promotion of a positive energy balance (Bellinger 
and Bernardis, 2002; Elmquist et al., 1999). With the refinement in techniques employed 
in medical science, this strictly neuroanatomical model of energy homeostasis has been 
modified. The neurons of these hypothalamic nuclei have now been shown to express 
various neuropeptides and neurotransmitters and receptors for circulating factors that 
signal the long-term and short-term energy stores of an organism. These characteristics 
firmly place these nuclei in the involvement in the regulation of energy homeostasis of an 
organism.  
1.3.1 The Arcuate nucleus of the hypothalamus (ARC) 
The ARC is situated adjacent to the median eminence (ME) where the blood brain barrier 
(BBB) is absent allowing circulating factors to gain access to the brain (Broadwell and 
Brightman, 1976). This places the ARC in an ideal position to receive both humoral and 
neural signals that communicate the energy status of the organism and to play a pivotal 
role in energy homeostasis. In the late 1960s Olney et al conducted a series of 
experiments on various species with the food additive monosodium glutamate (MSG). 
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They observed that peripheral administration of MSG to neonatal animals ablated ARC 
neurons which resulted in obesity in adulthood (Olney, 1969; Olney and Sharpe, 1969). 
These observations further implicated the ARC in energy balance along with the earlier 
ablation studies (Elmquist et al., 1999).  
Within the ARC of rodents there are two main populations of opposing neurons 
comprised of an orexigenic medially located group that co-express neuropeptide Y 
(NPY) and agouti related peptide (AgRP) and an anorexigenic laterally positioned group 
that co-express proopiomelanocortin (POMC) and cocaine and amphetamine regulated 
transcript (CART) (Broberger et al., 1998b; Hahn et al., 1998). These populations of 
neurons are often referred to as first order neurons as they are the first site of interaction 
with the hypothalamus of both long-term and short-term circulating regulators of energy 
balance (Schwartz et al., 2000) and have received enormous attention in the field of 
energy homeostasis.   
1.3.2 The paraventricular nucleus of the hypothalamus (PVN) 
The PVN plays a role in various neuroendocrine responses and in energy homeostasis. 
Disruption of the development of the PVN in mice and humans through 
haploinsufficiency in the transcription factor single minded 1 (Sim1) results in 
hyperphagia and obesity (Michaud et al., 2001; Holder, Jr. et al., 2004) confirming the 
role in the maintenance of a negative energy balance suggested by early lesioning studies 
(Elmquist et al., 1999).  The PVN is the major site where first order neurons of the ARC 
terminate and as such is the principal source of second order neurons involved in energy 
balance (Schwartz et al., 2000). These second order neurons express corticotrophin 
releasing hormone (CRH) and thyrotropin releasing hormone (TRH) which have been 
shown to promote a negative energy balance. Unlike visual and nociceptive pathways in 
the CNS, the location and identity of third order neurons in the energy homeostasis 
circuit is not well characterized and much further neuroanatomical and 
neurophysiological work needs to be performed.  
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1.3.3 The supraoptic nucleus of the hypothalamus (SON) 
The SON plays a role in uterine and mammary gland contraction, electrolyte balance and 
blood pressure, and also in energy homeostasis (Markakis, 2002). The neuropeptides 
oxytocin and vasopressin are expressed in the magnocellular neurons of the SON which 
are released into the general circulation in response to physiological stimuli to interact 
with receptors expressed in peripheral organs such as the uterus and kidney respectively. 
Oxytocin has also been shown to promote a negative energy balance. 
1.3.4 The lateral hypothalamic area (LHA) 
The LHA is situated in close proximity to the medial forebrain bundle which is a fibre 
tract traditionally associated with arousal and feeding (Elmquist et al., 1999). Two 
orexigenic peptidergic non-overlapping neuronal populations have been identified in the 
LHA; orexin containing neurons and melanocortin concentrating hormone (MCH) 
containing neurons (Bittencourt et al., 1992; Broberger et al., 1998a; Peyron et al., 1998). 
The effects of these peptides confirmed the early ablation studies that the LHA plays a 
role in the maintenance of a positive energy balance and arousal (Elmquist et al., 1999). 
1.3.5 The ventromedial nucleus of the hypothalamus (VMN) 
The VMN plays a role in energy and glucose homeostasis. Knockout of the nuclear 
receptor steroidogenic factor 1 (SF1) in mice results in decreased cell mass in this 
nucleus and the development of obesity (Ikeda et al 1995; Majdic et al., 2002) consistent 
with the role in promoting a negative energy balance suggested by earlier lesioning 
studies (Elmquist et al., 1999). Pituitary adenylate cyclase activating peptide (PACAP) 
and brain derived neurotrophic factor (BDNF) are two anorexigenic factors that are 
expressed in the VMN which also further support its role in promoting a negative energy 
balance. Glucose sensing neurons have been described in the VMN which are stimulated 
or inhibited by glucose as shown by in vitro electrophysiological studies (Miki et al., 
2001; Song et al., 2001). Loss of glucose sensing in these neurons results in loss of 
glucagon secretion in response to hypoglycemia and to a reduction in feeding in reponse 
to neuroglycoponia (Miki et al., 2001). These results suggest that the same neuronal 
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population in the VMN is involved in overall glucose and energy homeostasis in an 
organism.  
1.3.6 The dorsomedial nucleus of the hypothalamus (DMN) 
The DMN plays a role in energy homeostasis and in the generation and maintenance of 
food-entrainable circadian rhythms. The orexigenic peptide neuropeptide Y (NPY) is 
expressed in the DMN consistent with the role the DMN has on promoting a positive 
energy balance that was shown through lesioning and stimulation studies (Bellinger and 
Bernardis, 2002). The DMN contains neurons that respond to circulating glucose levels 
and stimulation of gastric vagal afferents suggesting that the DMN is an independent 
integrator of appetite related signals (Zhu et al., 2007).  The DMN has also been proposed 
to play a critical role in food-entrainable circadian rhythms as animals with an ablated 
DMN no longer show adjustments to changes in the availability of food (Gooley et al., 
2006).  
1.3.7 The suprachiasmatic nucleus of the hypothalamus (SCN) 
The SCN is not traditionally associated with the regulation of energy homeostasis but 
rather has been described as the central bodyclock of mammals as ablation of the SCN 
results in loss of light-entrainable circadian rhythms (Stephan and Zucker, 1972). The 
SCN receives prominent input from retinal ganglion cells of the retina that express the 
photopigment melanopsin and which forms the retinohypothalamic tract (Hattar et al., 
2002). The SCN expresses various transcription factors that are critical in the 
maintanence of circadian rhythms. One such transcription factor is BMAL 1 (Bunger et al 
2000). Interestingly reexpression of BMAL 1 in BMAL 1 KO mice via adeno associated 
virus (AAV) mediated gene transfer into the SCN is sufficient to rescue light entrainable 
circadian rhythms, whilst into the DMN is sufficient to rescue food-entrainable circadian 
rhythms (Fuller et al., 2008).  
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1.4 Hypothalamic neuropeptides and neurotransmitters involved in energy 
homeostasis 
In the last 30 years various neuropeptides and neurotransmitters have been characterised 
in the hypothalamus. These factors can be catergorised into two groups; those that reduce 
food intake (anorexigens) and/or increase energy expenditure thus promoting an overall 
negative energy balance, and those that increase food intake (orexigens) and/or decrease 
energy expenditure thus promoting a positive energy balance.  
1.4.1 Anorexigenic factors 
1.4.1.1 Proopiomelanocortin (POMC) 
Proopiomelanocortin is a 241 amino acid precursor polypeptide found in the 
hypothalamus, the anterior pituitary gland, the kidney and in melanocytes of the skin. The 
proteolytic enzymes prohormone convertases 1 and 2 (PC1 and PC2) and 
carboxypeptidase E (CPE) cleave POMC (Benjannet et al., 1991) generating β- and γ-
lipotropin, β-endorphin and the melanocortins (Figure 1.3). The melanocortins are 
comprised of α-MSH, β-MSH, γ-MSH, and adrenocorticotrophin (ACTH) which bind to 
the melanocortin receptors (MCRs). α-MSH binds to the MC1R whilst ACTH binds to 
the MC2R which are found in the melanocytes and adrenal cortex and which are involved 
in pigment colouration and glucocorticoid release respectively (Mountjoy et al., 1992). 
All the melanocortins bind with high affinity to the MC3R found mainly in the amygdala 
and hypothalamus (Roselli-Rehfuss et al., 1993). Adrenocorticotrophin, α-MSH, and β-
MSH bind the MC4R and the MC5R which are also expressed widely throughout the 
brain and particularly in the hypothalamus (Gantz et al., 1993; Chhajlani et al., 1993). 
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Figure 1.3 The products of proopiomelanocortin (POMC) cleavage. 
POMC is first cleaved into γ-melanocyte stimulating hormone (γ-MSH), 
adrenocorticotrophin (ACTH), and β-lipotropin. ACTH is further cleaved in to α-MSH 
and corticotropin- like intermediate lobe peptide (CLIP). β-lipotropin is further cleaved 
into γ-lipotropin and β-endorphin. Beta-MSH is generated from the further cleavage of γ-
lipotropin. Adapted from Catania et al., 2004. 
 
Initial observations that implicated the melanocortin system in energy balance came from 
mice with dominant mutations in the Agouti gene. These animals ectopically overexpress 
the Agouti protein and show coat discolouration due to Agouti antagonising α-MSH 
activation of the MC1R at the hair follicle. These animals are also obese and it was 
hypothesized that this was due to Agouti interacting with a MCR in the CNS (Bultman et 
al., 1992). Agouti was subsequently demonstrated to be an antagonist of the MC4R (Lu et 
al., 1994) and intracerebroventricular (ICV) administration of a non-selective MCR 
agonist inhibited food intake whilst ICV administration of a selective MC3/4R antagonist 
increased food intake (Fan et al., 1997). Subsequently, acute ICV administration of the 
endogenous agonist of the MC4R, α-MSH, was demonstrated to reduce food intake 
(Rossi et al., 1998) and to increase energy expenditure (Brito et al., 2007). These results 
demonstrated that α-MSH/MC4R signalling promotes a negative energy balance. This is 
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strongly supported by molecular studies. The MC4R KO mouse is severely hyperphagic 
and obese (Huszar et al., 1997) and several mutations for the MC4R in humans are also 
associated with obesity (Vaisse et al., 1998). Individuals with mutations in the POMC 
gene are obese (Krude et al., 1998) as are mice deficient in POMC (Yaswen et al., 1999). 
Inactivating mutations of the enzymes involved in cleavage of POMC also result in 
obesity. Mice expressing an inactive form of PC1 are obese (Lloyd et al., 2006) as are 
mice with the naturally occurring mutation of the CPE gene (Naggert et al., 1995). In 
humans, a mutant form of PC1 has been reported which results in retention of the enzyme 
in the endoplasmic reticulum (ER) and in severe obesity (Jackson et al., 1997). 
Carboxypeptidase E mutations in humans have also been shown to result in obesity 
(Chen et al., 2001).  
1.4.1.2 Corticotropin releasing hormone (CRH) and thyrotropin releasing hormone 
(TRH) 
Corticotropin releasing hormone is a 41 amino acid peptide hormone first isolated form 
ovine hypothalamus (Vale et al., 1981) and is found in the parvocellular cells of the 
lateral part of the PVN (Bloom et al., 1982). Thyrotropin releasing hormone is a 3 amino 
acid peptide hormone also first isolated from ovine hypothalamus (Boler et al., 1969) and 
is found in the parvocellular cells of the medial part of the PVN (Lechan and Jackson, 
1982). The endocrine functions of these neuropeptides were traditionally associated with 
aspects of homeostasis other than energy balance. However, roles in the promotion of a 
negative energy balance for these two peptides are steadily being supported. Fasting 
reduces the expression of proCRH and proTRH in the PVN (Fekete et al., 2000b; Blake 
et al., 1991) and ICV administration of CRH and TRH reduces food intake in rats (Benoit 
et al., 2000; Morley and Levine, 1980). Agouti related peptide neurons innervate CRH 
and TRH neurons in the PVN as do ARC POMC neurons (Legradi and Lechan, 1999; 
Fekete et al., 2000a; Fuzesi et al., 2007; Wittmann et al., 2005). Corticotropin releasing 
hormone neurons and TRH neurons express the MC4R and ICV administration of an 
MC4R agonist increases CRH and TRH expression. Furthermore, ICV coadministration 
of a CRH receptor antagonist partially prevents the anorexigenic effects of ICV 
administration of α-MSH (Lu et al., 2003; Harris et al., 2001). These observations 
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suggest that the anorexigenic effect of ARC α-MSH is upstream of CRH and TRH 
signalling consistent with POMC and CRH/TRH neurons constituting first order and 
second order neurons respectively in energy balance circuitry of the hypothalamus.   
1.4.1.3 Oxytocin 
Oxytocin is a 9 amino acid peptide expressed in the magnocellular cells of the SON with 
roles traditionally involved in uterine and mammary gland contraction (De Vigneaud et 
al., 1954). Studies support a role for oxytocin in promoting a negative energy balance. 
Intracerebroventricular administration of oxytocin inhibits food intake in rats (Arletti et al 
1990; Olson et al 1991) and KO of the oxytocin receptor results in obesity in mice 
(Takayanagi et al., 2008). Melanocortin 4 receptors are expressed in the SON (Mountjoy 
et al 1994) and ICV administration of α-MSH induces Fos expression in oxytocin 
neurons (Caquineau et al., 2006). Indeed the anorexigenic effects of ICV administration 
of α-MSH are abolished with coadministration of an oxytocin receptor angatonist (Yosten 
and Samson, 2010). These results suggest that oxytocin neurons of the SON are another 
source of second order neurons in the hypothalamus downstream of POMC. Oxytocin 
seems to signal via local circuits in the SON and also the brainstem to promote a negative 
energy balance; this is supported by the observations that the release of oxytocin from 
dendrites in the SON is potentiated by α-MSH (Sabatier et al 2003) and transaction of 
oxytocinergic terminals in the brainstem results in obesity (Kirchgessner et al., 1988) 
respectively.   
1.4.1.4 Pituitary adenylate cyclase activating peptide (PACAP) 
Pituitary adenylate cyclase activating peptide was first isolated from the ovine 
hypothalamus and exists as 27 or 38 amino acid forms (Kimura et al., 1990; Miyata et al., 
1990). Pituitary adenylate cyclase activating peptide binds to the PACAP 1 receptor 
(PAC1R) and the vasoactive intestinal peptide (VIP) PACAP 1 receptor (VPAC1) 
(Gourlet et al., 1995). Both PACAP and its receptors are expressed throughout the 
hypothalamus (Masuo et al., 1993; Gourlet et al., 1995). Studies support a role of PACAP 
in promoting a negative energy balance. Intracerebroventricular administration of 
PACAP to mice and rats reduces food intake (Morley et al 1992; Mizuno et al 1998) and 
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KO of PACAP or PAC1R in mice results in obesity (Hashimoto et al., 2000). Pituitary 
adenylate cyclase activating peptide was subsequently characterised in the VMN (Segal 
et al., 2005) being coexpressed with SF-1. It was shown that VMN PACAP levels 
decrease following fasting (Hawke et al., 2009) suggesting the VMN PACAP specifically 
is involved in promoting a negative energy balance. 
1.4.1.5 Brain derived neurotrophic factor (BDNF) 
Brain derived neurotrophic factor is a 121 amino acid peptide that was first identified to 
be critical for the survival of sensory neurons (Hofer and Barde, 1988; Leibrok et al., 
1989). Brain derived neurotrophic factor binds with highest affinity to the tyrosine 
receptor kinase B (trkB); both distributed throughout the hypothalamus and hindbrain, 
and the former is especially dense in the VMN and notably absent in the ARC (Conner et 
al., 1997; Yan et al., 1997). Studies support a role for BDNF in promoting a negative 
energy balance. Intracerebroventricular administration of BDNF decreases food intake 
and bodyweight in rats (Pelleymounter et al., 1995b). Fasting decreases BDNF 
expression in the VMN (Xu et al., 2003) and microinjection of BDNF into the VMN and 
PVN decreases feeding (Wang et al., 2007c; Wang et al., 2007a). Microinjection of 
BDNF into the PVN or VMN also increases energy expenditure (Wang et al., 2007b; 
Wang et al., 2010). Studies suggest an extra-ARC function of BDNF in energy balance. 
Third ventricular administration of glucose increases BDNF expression in the VMN, 
DMN, and LHA but not the ARC and administration of BDNF induces Fos in the VMN, 
DMN and LHA but also not the ARC (Unger et al., 2007). Based on these observations, 
BDNF has been proposed to act as an autocrine in the hypothalamus, where instead of 
synaptic release of a neurotransmitter from the ARC to the PVN regulating the activity of 
the next neuron in the energy balance circuit as is the case with α-MSH for instance, 
BDNF is released by neurons in the VMN, PVN, and LHA to regulate their own activity 
and subsequently the activity of neurons they form synapses with. Molecular studies also 
support the role of BDNF in the promotion of a negative energy balance. Knockout of 
BDNF in mice results in hyperphagia and obesity (Lyons et al., 1999) as does KO of trkB 
(Xu et al., 2003). Specific deletion of BDNF in the VMN and DMN via injection of AAV 
expressing CRE recombinase in mice results in hyperphagia and obesity (Unger et al., 
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2007). In humans BDNF mutations are associated with obesity (Gray et al., 2006) as are 
trkB mutations (Yeo et al., 2004). 
1.4.2 Orexigenic factors 
1.4.2.1 Neuropeptide Y (NPY) 
Neuropeptide Y is a 36 amino acid peptide first isolated from porcine brain (Tatemoto et 
al., 1982) and is amongst the most abundant peptides in the rat and human brains 
particularly in the hypothalamus (Adrian et al., 1983; Allen et al., 1983). Studies support 
a role for NPY in promoting a positive energy balance. Acute ICV administration of NPY 
increases food intake (Clark et al., 1984) and microinjection of NPY into several of the 
target hypothalamic nuclei of the ARC such as the PVN, VMN, and LHA increases food 
intake (Stanley et al., 1985a). Furthermore, chronic ICV administration of NPY increases 
food intake and adiposity in rats (Stanley et al., 1986) and ICV administration of 
antibodies to NPY decreases fasting induced refeeding in rats; supporting a physiological 
role of NPY in feeding (Stanley et al., 1992). Regarding energy expenditure, ICV 
administration of NPY to rats decreases energy expenditure (Billington et al., 1991) as 
does microinjectin of NPY into the PVN (Billington et al., 1994).  
Molecular studies have yielded conflicting results on the physiological role of NPY on 
promoting a positive energy balance. Neuropeptide Y KO mice exhibit normal food 
intake, adiposity and bodyweight (Erickson et al., 1996). These results may be due to the 
developmental compensation that can occur with embryonic KO models and the global 
nature of the deletion. Reconciling these findings, microinjection of AAV expressing 
antisense mRNA for NPY specifically into the ARC of adult rats decreases food intake 
and protects from DIO (Gardiner et al., 2005). As mentioned NPY is also expressed in 
the DMN and chronic food restriction increases DMN NPY expression (Bi et al., 2003). 
Also, administration of AAV expressing sense NPY mRNA into the DMN increases food 
intake and bodyweight in rats (Yang et al., 2009). 
Neuropeptide Y binds to the Y family of receptors which are G-protein coupled and 
negatively regulate the activity of adenylate cyclase to decrease the concentrations of 
intracellular cyclic adenosine monophosphate (cAMP). Five receptors have been cloned 
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including the Y1, Y2, Y4, Y5, and y6 receptors (designated with a lower case as it is a 
pseudogene in primates) (Lin et al., 2004).  
Pharmacological studies support an orexigenic role for the Y1 receptor. Acute ICV 
administration of specific Y1 receptor agonists to rats increases food intake (Mullins et 
al., 2001) whereas acute ICV administration of Y1 receptor antagonists to rats decreases 
food intake (Kanatani et al., 1996). Chronic administration of an oral Y1 receptor 
antagonist that crosses the BBB to rats also prevents weight gain on a HFD (Ishihara et 
al., 2002). Molecular studies have yielded conflicting results with regards to the role the 
Y1 receptor has on promoting a positive energy balance. The Y1 receptor KO mouse is 
paradoxically overweight due to decreased energy expenditure (Pedrazzini et al., 1998)  
Similar to Y1 receptor agonists, acute ICV administration of Y5 receptor agonists to rats 
increases food intake whereas chronic intraperitnoeal (i.p.) administration of BBB 
penetrant Y5 receptor antagonists to rats decreases food intake and prevented weight gain 
on a HFD (Li et al., 2008). Again, molecular studies have yielded conflicting results with 
regards to the role the Y5 receptor has on promoting a positive energy balance. The Y5 
receptor KO mouse is paradoxically obese but in contrast to the Y1 receptor KO mouse, 
this is due to hyperphagia (Marsh et al., 1998). However, ICV administration of Y5 
receptor AS oligonucleotides to adult rats results in decreases in food intake 
(Schaffhauser et al., 1997). 
Based on the pharmacological observations from preclinical studies supporting an 
orexigenic role for the Y5 receptor, a randomised 52 week clinical trial comparing obese 
patients receiving placebo and an oral BBB penetrant Y5 receptor antagonist was 
designed. There was a clinically insignificant weight loss which did not match that 
observed with the current treatment for obesity orlistat. This may be due to residual Y1 
receptor signalling which as mentioned promotes feeding and so targeting both receptors 
may provide more useful anti-obesity therapy (Erondu et al., 2006).  
1.4.2.2 Agouti related peptide (AgRP) 
Agouti related peptide was discovered when screening for peptides with sequence 
homology to Agouti and exists as 3 forms; A, B, and C which are 107, 81-85, and 60-62 
amino acids in length respectively and which are localised to the hypothalamus and 
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adrenal glands. Agouti related peptide does not act as an agonist to its own receptor but 
instead was demonstrated to be an endogenous antagonist of the MC3R and an inverse 
agonist of MC4R. This was confirmed in the AgRP transgenic mouse which is 
overweight but does not exhibit changes in coat colour which as mentioned depends on 
the antagonism of the MC1R (Ollmann et al., 1997). Pharmacological studies support a 
potent orexigenic role of AgRP. Intracerebroventricular administration of AgRP to rats 
produces an increase in food intake that lasts for as long as one week (Hagan et al., 
2000). Also, ICV administration of AgRP decreases energy expenditure (Goto et al., 
2003). Based on these pharmacological data and the near identical projections of AgRP 
and POMC neurons (Cone, 2005), AgRP is thought to physiologically oppose POMC 
signalling to promote a positive energy balance.  
Animals with dual KO of AgRP and NPY show no changes in bodyweight which may be 
due to developmental compensation (Qian et al., 2002). Several groups therefore adopted 
ingenious strategies to ablate these neurons in adulthood to confirm that this population 
of neurons is essential for promoting a positive energy balance. Bewick et al., selectively 
ablated NPY/AgRP neurons through expressing the neurotoxin ataxin 3 under the AgRP 
promoter. This resulted in a loss of 50% of AgRP/NPY neurons by adulthood, 
hypophagia, decreased energy expenditure, and a resulting bodyweight loss (Bewick et 
al., 2005).  Luquet et al., achieved more success by expressing the diphtheria toxin 
receptor under the AgRP promoter. Peripheral administration of diphtheria toxin to adult 
mice resulted in greater than 80% AgRP neuron ablation and almost a complete arrest of 
feeding to the extent of death from starvation (Luquet et al., 2005). This model has also 
enabled the elucidation of important second order neurons that receive synaptic input 
from the ARC other than the PVN. The parabrachial nucleus (PBN) situated in the 
midbrain is a region involved in visceral malaise following LiCl administration (Rinaman 
and Dzmura, 2007) and has been demonstrated previously to be innervated by AgRP 
neurons of the ARC (Broberger et al., 1998b). Animals with ablated AgRP neurons 
showed marked increases in neuronal activation in the PBN as shown by Fos expression 
(Wu et al., 2008). Since AgRP neurons also express the major inhibitory amino acid 
neurotransmitter γ amino butyric acid (GABA) (Cowley et al., 2001) it was speculated 
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that GABAergic mediated inhibition of PBN neurons is essential to promote feeding. 
Consistent with this idea systemic injection of a GABA receptor agonist betranezil 
restored feeding in the AgRP neuron ablated animal and this was only replicated with 
microinjection of betranizil into the PBN as opposed to injection into various other target 
nuclei of AgRP neurons. Furthermore, microinjection of a GABA receptor antagonist 
into the PBN of normal mice decreased feeding. Therefore, PBN neurons seem to 
tonically inhibit feeding and AgRP neurons seem to counteract this via GABA release 
(Figure 1.4) (Wu et al., 2009).  
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Figure 1.4 Opposing first order neuronal populations of the ARC. 
Orexigenic NPY/AgRP neurons (Yellow) inhibit anorexigenic POMC neurons (Green) 
and other second order neurons by synaptic release of the amino acid neurotransmitter 
GABA. These neurons also express receptors for circulating long term regulators of 
appetite such as leptin which binds to the Lep-R and for short term regulators of appetite 
such as PYY3-36 which binds to the Y2-R. The Y1-R and the MC3-R are thought to act as 
receptors for neuropeptides released in the ARC such as NPY and the product of POMC, 
α-MSH. NPY: Neuropeptide Y, AgRP: Agouti Related Peptide, POMC: Pro 
opiomelanocortin, GABA: Gamma amino butyric acid, Y1-R: NPY 1 receptor, Y2-R: 
NPY 2 receptor, Lep-R; Leptin receptor; MC3-R: Melanocortin 3 receptor. Adapted from 
Cone 2005.   
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1.4.2.3 Melanocortin concentrating hormone (MCH) 
Melanocortin concentrating hormone is a 19 amino acid brain peptide first isolated from 
salmon pituitary (Kawauchi et al., 1983) and was so named because it caused the 
aggregation of melanin in the melanophores of fish (Nahon, 1994). Melanocortin 
concentrating hormone expression was subsequently demonstrated specifically in the 
LHA of the mammalian CNS (Bittencourt et al., 1992). Melanocortin concentrating 
hormone binds to the the MCH1 receptor (MCH1R) (Saito et al., 1999) and the MCH2 
receptor (MCH2R) which are both specifically expressed in the CNS (Sailer et al., 2001). 
Studies support that MCH promotes a positive energy balance. ProMCH expression in 
the LHA increases with fasting (Bittencourt et al., 1992; Qu et al., 1996) and acute ICV 
administration of MCH increases food intake (Rossi et al., 1997) whilst acute ICV 
administration of an MCH1R antagonist decreases food intake (Borowsky et al., 2002). 
Chronic ICV administration of MCH increases food intake and adiposity (Marsh et al., 
2002). Molecular and lesioning studies further confirm the role of MCH in the promotion 
of a positive energy balance. Melanocortin concentrating hormone and MCH1R KO mice 
results are hypophagic and lean (Marsh et al., 2002; Shimada et al., 1998) and ablation of 
MCH neurons with promoter specific expression of ataxin 3 also results in hypophagia 
and leanness (Alon and Friedman, 2006). Conversely, transgenic mice overexpressing 
MCH are hyperphagic and obese (Ludwig et al., 2001).  
1.4.2.4 Orexins 
The orexins were discovered in a large scale screening study in an attempt to identify the 
natural ligands of over 50 orphan GPCRs. Orexin A and orexin B were subsequently 
purified from rat brain extracts and are 33 and 28 amino acids in length respectively. 
Orexin receptors 1 and 2 (OXR1 and OXR2) were then characterised and were shown to 
be exclusively expressed in the brain. Orexin A binds with high affinity to both OXR1 
and OXR2 whilst orexin B binds selectively to OXR2. Intracerebroventricular 
administration of orexin A and orexin B increases food intake and fasting increases the 
expression of prepro orexin expression in the LHA supporting a role for the orexins in 
promoting a positive energy balance (Sakurai et al., 1998). However, the role of orexins 
in energy balance has come under question as they have also been shown to play a pivotal 
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role in arousal. Knockout of orexin results in narcolepsy in mice (Chemelli et al., 1999; 
Hara et al., 2001) and orexin concentrations are lower in the CSF of narcoleptic human 
subjects (Nishino et al., 2000). Elaborate studies designed to stimulate orexin neurons 
through the use of surgically implanted diodes in mice that express receptors that 
depolarize in response to light also causes arousal (Adamantidis et al., 2007). Thus the 
effect of orexins on arousal is likely to influence feeding behaviour. Paradoxically 
opposite to what would be expected for a factor that promotes a positive energy balance, 
post embryonic ablation of orexin neurons through the use of diphtheria toxin results in 
obesity (Hara et al., 2001) and transgenic overexpression of orexin protects from DIO 
(Funato et al., 2009). Therefore the precise role of orexins in energy balance requires 
further investigation.   
1.5 Other neurotransmitters 
1.5.1 Endocannabinoids (ECs) 
Anecdotal evidence has long supported the orexigenic effect of marijuana. 
Tetrahydrocannabinol (THC) is a polyphenol that is the active component derived from 
marijuana (Mechoulam and Gaoni, 1965).  The cannabinoid 1 receptor (CB1R) was 
cloned based on binding sites of THC in the brain and is widely expressed throughout the 
CNS notably in the hypothalamus (Matsuda et al., 1990). The cannabinoid 2 receptor 
(CB2R) was then cloned based on sequence homology to the CB1R and is mainly 
expressed in the peripheral nervous system (Munro et al., 1993). Endocannabinoids such 
as anandamide were subsequently indentified which are lipid neuromodulators derived 
from the long chain fatty acid arachidonic acid (Devane et al., 1992). Pharmacological 
and molecular studies support that as with THC, ECs promote a positive energy balance.  
Intracerebroventricular administration of ECs dose-dependently stimulate feeding in rats 
and hypothalamic EC synthesis and release is increased by fasting and inhibited by 
feeding (Kirkham et al., 2002). Intracerebroventricular administration of a CB1R 
antagonist decreases food intake (Colombo et al., 1998) and CB1R KO mice are leaner 
than wild type controls on a regular diet (Cota et al., 2003). A hypothalamic mechanism 
of action for the orexigenic effects of ECs is supported by various studies. Incubation of 
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hypothalamic explants with anandamide and a CB1R antagonist increases and decreases 
NPY release respectively (Gamber et al., 2005). In the PVN, ECs act presynaptically to 
decrease glutamate release onto CRH neurons and inhibit them (Di et al., 2003) and in 
the LHA, ECs act presynaptically to decrease GABA release onto MCH neurons and 
excite them (Huang et al., 2007). These results reveal that ECs inhibit anorexigenic and 
stimulate orexigenic peptidergic neuronal populations respectively via distinct 
presynaptic mechanims. 
1.5.2 Serotonin  
Serotonin or 5 hydroxytyptamine (5-HT) is a monoamine neurotransmitter traditionally 
associated with anxiety and depression. However the antidepressents sibrutamine and 
fenfluoramine which are serotonin reuptake inhibitors (SSRIs) are also effective anti-
obesity treatments (Padwal et al., 2003; Weintraub et al., 1992). Serotonin is synthesized 
from the essential amino acid tryptophan in serotonergic raphe neurons in the brainstem 
which send projections throughout the brain including the ARC. There are 7 subypes of 
5-HT receptors (5-HT1-7) all of which are GPCRs apart from the 5-HT3 receptor which 
is an ionotropic receptor. These receptor subtypes are further subdivided (5-HT1A-F and 
5-HT2A-B) and are widely expressed throughout the brain and body. Studies support a 
role for 5-HT in promoting a negative energy balance. Peripheral administration of a 
selective 5-HT1B/2C agonist decreases food intake (Somerville et al., 2007) and 
peripheral administration of 5-HT1A receptor agonist which decreases 5-HT release from 
neurons via autoinhibition increases food intake (Dourish et al., 1985). An ARC 
mechanism of action for 5-HT has been suggested by anatomical, electrophysiological 
and molecular studies. The ARC receives afferents from the raphe and NPY/AgRP 
neurons are electrically inhibited by 5-HT via the 5-HT1B receptor (Heisler et al., 2002) 
whilst POMC neurons are electrically stimulated by 5-HT via the 5-HT2C receptor 
(Heisler et al., 2006). Molecular studies also support a role for 5-HT in promoting a 
negative energy balance. Knockout of the 5-HT2C receptor in mice results in hyperphagia 
and obesity (Tecott et al., 1995) and restoration of the 5-HT2C receptor specifically in 
POMC neurons reverses this phenotype and animals regain sensitivity to the anorexigenic 
effects of SSRIs (Xu et al., 2008). 
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1.5.3 Dopamine  
Dopamine is a neurotransmitter traditionally associated with reward and addiction. 
Dopamine has also been implicated in the control of hedonic food intake which is defined 
as feeding beyond the needs of an organism and is thought to involve higher brain centres 
outside the hypothalamus (Palmiter, 2007). Dopamine is stored in dopaminergic neurons 
in the brain including the substantia nigra and the VTA which project to the dorsal 
striatum and ventral striatum/pre-frontal cortex (PFC) respectively (Moore and Bloom, 
1978). Dopamine activates GPCRs which comprise D1-like receptors (D1 and D5 
receptors) that stimulate the production of cAMP and D2-like receptors (D2, D3, and D4 
receptors) that inhibit the production of cAMP. Studies support a role for dopamine in 
promoting a negative energy balance. The expression of D2 receptors is lower in the 
dorsal striatum of both obese rodents (South and Huang, 2008; Thanos et al., 2008) and 
obese individuals shown through positron emission tomography (PET) studies (Wang et 
al., 2001). Functional MRI (fMRI) studies in humans show a blunted dorsal striatal 
response to a high calorie drink in obese individuals (Stice et al., 2008). These 
observations suggest that blunted dopaminergic signalling in the dorsal striatum is 
associated with obesity and that obese individuals overeat to compensate for 
hypodopaminergic neurotransmission (Wang et al., 2002). Conversely, D2 receptor levels 
in the dorsal striatum of patients suffering from anorexia nervosa (Frank et al 2005) and 
individuals after gastric bypass are higher (Wang et al 2008). It seems that 
hypodopaminergic signalling is a result of obesity rather than a cause as a HFD in rats 
decreases D2 receptor expression in the dorsal striatum whilst knockdown of the D2 
receptor in the dorsal striatum via AAV injection of short interfering RNA (siRNA) does 
not cause changes in food intake or bodyweight (Johnson and Kenny, 2010).  
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Table 1.1 CNS factors involved in appetite regulation 
 
 
 
 
 
 
 
 
 
 
 
 
APPETITE REGULATING FACTOR 
OREXIGENIC      
 
 
 
 
 
 
1. Neuropeptide Y (NPY) 
2. Agouti-related peptide (AgRP) 
3. Orexins? 
4. Melanin concentrating hormone (MCH) 
5. Endocannabinoids (ECs) 
6. γ amino butyric acid (GABA) 
 
ANOREXIGENIC 
 
 
 
 
 
 
 
1. Melanocortins 
2. Corticotropin releasing hormone (CRH) 
3. Thyrotropin releasing hormone (TRH) 
4. Oxytocin 
5. Pituitary adenylate cyclase activating peptide (PACAP) 
6. Brain derived neurotrophic factor (BDNF) 
7. Serotonin 
8. Dopamine 
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1.6 Brainstem control of energy homeostasis 
The early clinical and ablation studies strongly implicated the hypothalamus in the 
regulation of energy homeostasis. This is also supported by the expression of 
neurotransmitters and neuropeptides in the hypothalamus that regulate feeding and 
energy expenditure as discussed. However, the brainstem has also been implicated in 
feeding; particularly in the termination of feeding and in meal duration (Cummings and 
Overduin, 2007). The brainstem makes up the lower part of the brain, adjoining and 
structurally continuous with the spinal cord. The nucleus tractus solitarius (NTS) located 
in the dorsal region of the medulla oblongata in the brainstem is the major site of 
termination of vagal afferents arising from the viscera and sends prominent projections to 
the hypothalamus (Swanson et al., 1981). By interfacing with hypothalamic circuits, the 
brainstem plays a pivotal role in energy homeostasis (Figure 1.5). 
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Figure 1.5 The peripheral circuitry of appetite control. 
(A) A schematic showing the circuits connecting the hypothalamus and brainstem, as 
well as the termination of the vagus in the nucleus of the solitary tract (NTS). (B) A 
cross-section of the brainstem showing the dorsal vagal complex (DVC) containing the 
area postrema (AP) and NTS, and the many target organs of the vagus nerve.  
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The NTS is comprised of several nuclei including (medial-lateral) the commissural 
nucleus, the subnucleus gelatinosus, the medial nucleus, the solitary tract itself, and the 
lateral nucleus. The dorsal motor nucleus of the vagus (DMV) is where the cell bodies of 
the efferent part of the vagus nerve are situated and lies adjacent to the medial nucleus of 
the NTS. The entire set of nuclei is referred to as the dorsal vagal complex (DVC). 
Various lines of evidence support that the brainstem is integral to energy homeostasis. 
Early work demonstrated that rats that have undergone surgery to sever the connections 
between the brainstem and forebrain still experienced satiation from food suggesting that 
brainstem processing is sufficient for this process (Grill and Norgren, 1978). Also the 
effects on feeding of peripheral administration of peptide tyrosine tyrosine3-36 (PYY3-36) 
and ghrelin are lost following brainstem transaction (Abbott et al., 2005a; Date et al., 
2006). These results suggest that brainstem processing is a necessary step for these 
factors upsteam of hypothalamic processing.  
The NTS is adjacent to the area postrema (AP) which lies next to the floor of the 4th 
ventricle and which, similar to the median eminence, lacks a BBB (Murabe et al., 1981). 
This places the NTS in a similar position to the ARC such that it receives both neural and 
humoral information regarding the energy status of the organism and to play an important 
role in energy hoemeostasis. Indeed various receptors for circulating factors such as the 
leptin receptor (ObR) and the glucagon like peptide-1 receptor (GLP-1R) are found in the 
NTS and microinjection of leptin and GLP-1 into the NTS inhibits feeding (Grill et al., 
2002; Hayes et al., 2008).  
Hypothalamic neuropeptides involved in energy homeostasis are also expressed in the 
brainstem. A noradrenergic population of neurons in the NTS that coexpresses NPY 
innervate the TRH and CRH expressing neurons of the PVN (Fuzesi et al., 2007; 
Wittmann et al., 2005). These neurons are activated by fasting which suggests that as 
well as ARC NPY neurons promoting a positive energy balance brainstem NPY neurons 
may play a similar role.  Proopiomelanocortin neurons have also been characterized in 
the commissural nucleus of the brainstem (Joseph et al., 1983) and the MC4R is highly 
expressed in this region (Mountjoy et al., 1994). Administration of an MC4R agonist into 
the 4th ventricle decreases food intake whilst administration of an MC4R antagonist 
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increases food intake (Grill et al., 1998). These observations support that as well as ARC 
POMC neurons promoting a negative energy balance, brainstem POMC neurons may 
also play a similar role. Interestingly, molecular studies suggest a more dominant role of 
POMC in the brainstem as opposed to the ARC in promoting a negative energy balance; 
microinjection of AAV expressing sense mRNA for POMC into the NTS in rats caused 
decreased food intake and protected from DIO which was not observed with ARC 
microinjection (Zhang et al., 2010).  
1.7 Vagus nerve  
The vagus nerve forms part of the parasympathetic nervous system and is the major 
neuro-anatomical link between the gastrointestinal tract and the brain. The vagus nerve is 
formed of afferents whose cell bodies are located in the nodose ganglia and whose 
terminals are found in the various nuclei of the NTS and efferents whose cell bodies lie in 
the DMV and whose terminals innervate various peripheral organs such as the gut and 
liver (Rinamen et al., 1989; Appleyard et al., 2007). Signals from the vagus nerve are 
thought to be relayed via the NTS to the hypothalamus and studies support that the vagus 
nerve plays a role in energy balance. Vagal afferents arising from stomach are excited by 
gastric distension (Mathis et al., 1998; Rinaman et al., 1998) and the satiation gastric 
distension causes is lost following vagotomy (Gonzalez and Deutsch, 1981). Vagal 
afferents express a number of receptors for appetite regulating hormones such as ghrelin, 
cholecystokinin (CCK), GLP-1 and PYY3-36 and their effects on feeding following 
peripheral administration are abolished in animals subjected to surgical vagotomy 
(Abbott et al., 2005a; Date et al., 2002; Garlicki et al., 1990; Koda et al., 2005a). 
Additionally a vagal dependent mechanism has been proposed for ECs. As well as in the 
CNS, ECs are found in peripheral tissues and expression increases in the small intestine 
of rats following a fast. Peripheral administration of anandamide increases feeding whilst 
that of a CB1R antagonist decreases feeding; both effects are lost following vagotomy. 
These results suggest that ECs work as a paracrine in the intestine to stimulate feeding 
via the vagus nerve (Gomez et al., 2002). Hypothalamic factors involved in feeding such 
as MCH have also been characterised in vagal afferents. Expression of MCH in vagal 
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neurons increases following fasting similar to the pattern observed in the LHA, and 
decreased by peripheral administration of the anorexigenic hormone CCK (de Lartigue et 
al., 2007). 
1.8 Circulating peripheral mediators of appetite 
Given that the CNS is critical to the control of energy homeostasis, mechanisms need to 
be in place that communicates the nutritional status of an organism to the CNS. This is 
achieved by changes in factors in the circulation according to nutritional status. Two 
types of circulating factors that regulate energy homeostasis exist; those involved in the 
long-term mediation of energy homeostasis and that remain relatively stable unless 
changes in long-term energy stores occur and those that are involved in the short-term 
mediation of energy homeostasis and that show variation between meals.  
1.8.1 Long-term mediators of appetite 
More than 50 years ago Kennedy introduced the “adiposity negative-feedback” model of 
energy homeostasis, based upon the principle that circulating signals inform the brain of 
changes in body fat mass and the brain subsequently mounts appropriate adjustments in 
energy balance to achieve the long-term stability of fat stores (Kennedy, 1953). Proposed 
criteria for a candidate negative feedback signal include; 1) the signal circulates at levels 
proportional to body fat content and enters the brain, 2) the signal promotes weight loss 
by acting upon neuronal systems involved in energy homeostasis, 3) blockade of the 
these neuronal actions results in increased food intake and body weight. To date only 
insulin and leptin satisfy all three of these criteria (Morton et al., 2006). 
1.8.1.1 Leptin 
Classic parabiotic experiments conducted in the early 70s by Douglas Coleman revealed 
that the severely hyperphagic, overweight, infertile, and diabetic obese (ob/ob) mouse 
lacked a circulating factor whilst the diabetic (db/db) mouse which has an identical 
phenotype, was resistant to it (Coleman, 1973). The obese (ob) gene was cloned in 1994 
and was shown to code for a 167 amino acid peptide expressed highly in white adipose 
tissue and to have the features of a secreted peptide (Zhang et al., 1994). This was a 
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significant landmark in the field of energy homeostasis as it paved way for the more 
detailed molecular understanding of energy balance that is currently held. The term leptin 
was given to the product of the obese gene and was shown to circulate in the blood of 
normal but not ob/ob mice (Halaas et al., 1995). The leptin receptor (ObR) was soon 
cloned and five splice variants were identified (ObRa-e) (Tartaglia et al., 1995). Indeed 
the leptin receptor was found to be mutated in the db/db mouse (Chen et al., 1996). 
Leptin receptor mRNA is distributed throughout the hypothalamus (Mercer et al., 1996b) 
and is found in both the POMC/CART (Cheung et al., 1997) and NPY/AgRP neuronal 
populations (Mercer et al., 1996a). Studies were then conducted to confirm the role of 
leptin in promoting a negative energy balance. Acute peripheral and ICV administration 
of leptin was shown to decrease food intake whilst chronic administration was shown to 
decrease food intake and bodyweight in normal and ob/ob mice (Halaas et al., 1995). 
Furthermore, peripheral and ICV administration of leptin was also shown to increase 
energy expenditure in ob/ob mice and normal rats (Pelleymounter et al., 1995a; Scarpace 
et al., 1997). The effect of peripheral administration of leptin on feeding was shown to be 
dependent on interaction with the CNS as mice lacking the long form of the leptin 
receptor (ObRb) in the brain are unresponsive to leptin treatment (Cohen et al., 2001).  
Congenital leptin deficiency in humans also results in severe obesity (Montague et al., 
1997) as does receptor mutation (Clement et al., 1998) and administration of recombinant 
leptin to leptin deficient individuals results in a marked weight loss (Farooqi et al., 1999). 
However, leptin deficiency is very rare and accounts for a minority of obesity cases. 
Indeed, treating obese individuals with pharmacological doses of leptin for 28 weeks did 
not result in significant weight loss (Heymsfield et al., 1999). This has led to the idea that 
obese people suffer from leptin resistance and for this reason leptin has not proved to be 
an effective therapy for obesity. Work is now aimed at reversing this state of leptin 
resistance so that leptin therapy may be a viable treatment for obesity (Ozcan et al., 
2009). 
The mechanism of action of leptin in the brain has provided insight into the effects of 
other anorexenic agents and has further emphasized the role the ARC has in energy 
homeostasis. Acute leptin administration decreases mRNA expression of NPY (Stephens 
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et al., 1995) and AgRP (Mizuno and Mobbs, 1999) and increases the mRNA expression 
of POMC (Thornton et al., 1997) and CART (Kristensen et al., 1998) in the ARC of 
ob/ob mice. Furthermore, leptin increases the action potential frequency of anorexigenic 
POMC neurons of mice (Cowley et al., 2001) and decreases the action potential 
frequency of orexigenic NPY/AgRP neurons of rats as shown by in vitro 
electrophysiological studies (van den et al., 2004). Leptin is no longer effective in the 
MC4R KO mouse suggesting this system is largely required for leptin’s effects (Marsh et 
al., 1999). 
Despite the large size of the molecule, leptin readily gains access to the brain and crosses 
the BBB via a saturable transport mechanism (Banks et al., 1996). Therefore other 
regions of the hypothalamus and indeed the brain, distant from the circumventricular 
organs may play a significant role in mediating leptin’s effects on feeding. This is 
supported by the observations that microinjection of leptin into the VMN (Jacob et al., 
1997), LHA (Leinninger et al., 2009) and VTA (Hommel et al., 2006) inhibits feeding 
and deletion of the ObRb in the VMN (Dhillon et al., 2006) and raphe nucleus (Yadav et 
al., 2009) results in obesity.  
Leptin is also synthesized in the gastric mucosa of the stomach and is released 
postprandially (Bado et al., 1998). The anorexigenic effects of leptin interacting with 
stomach afferents (via injection into the celiac artery) is lost following vagotomy (Peters 
et al., 2005) whilst that of peripheral administration is maintained (Sachot et al., 2007). 
These results suggest that the physiological anorexigenic effects of leptin released by the 
stomach and not by adipose tissue is dependent on vagal signaling. With regards to the 
brainstem, leptin receptors are found in the mNTS (Ellacott et al., 2006) and these 
neurons are activated by peripheral administration of leptin and gastric distension (Huo et 
al., 2007). Microinjection of leptin into the NTS is sufficient to decrease food intake 
(Grill et al., 2002) and microinjection of AAV expressing antisense mRNA to the ObRb 
into the mNTS results in increased food intake and bodyweight in rats (Hayes et al., 
2010).    
An early postnatal surge of leptin has been observed in neonatal rats (Ahima et al., 1998) 
at a time when they are resistant to its anorexigenic effects (Mistry et al., 1999). It is 
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thought that this surge is an important developmental signal that protects against the 
development of obesity. Consistent with this, neonatal treatment of leptin protects against 
the development of obesity in later life (Vickers et al., 2005) and antagonising leptin at 
the stage of the post-natal surge results in the development of obesity in later life (Attig et 
al., 2008). Based on these preclinical observations, it has been recommended that leptin is 
added to baby’s diets. This is supported by the observation that breast milk which 
contains leptin (Savino et al., 2002) promotes leanness whilst preparations do not 
(Plagemann and Harder, 2005). The effects of leptin at the postnatal period are thought to 
be due to ARC neuron projections. Leptin deficient mice showed a marked derangement 
in ARC projections which is only rescued when leptin is administered neonatally rather 
than in adulthood (Bouret et al., 2004b).  
1.8.1.2 Insulin  
Insulin is a peptide hormone produced by the β-cells of the pancreatic Islets of 
Langerhans and in addition to a role as the primary effector in carbohydrate homeostasis, 
is a major metabolic hormone. The insulin receptor was first cloned in 1985 by two 
separate groups and is a tyrosine receptor kinase with two α and two β subunits (Ebina et 
al., 1985; Ullrich et al., 1985).  The insulin receptor is widely distributed throughout the 
brain, with the highest concentrations found in the olfactory bulb and ARC as well as the 
DMN, PVN, and SCN (Corp et al., 1986; Marks et al., 1990). Insulin enters the CNS via 
receptor-mediated transport across the BBB (Baura et al., 1993). Studies support that 
inslulin promotes a negative energy balance. Intacerebroventricular administration of 
insulin decreases food intake and bodyweight (Woods et al., 1979). Conversely, ICV 
administration of insulin antibodies increases food intake in rats (McGowan et al., 1992). 
Molecular studies also support insulin signalling in the brain promotes a negative energy 
balance as neuronal specific deletion of the insulin receptor results in hyperphagia and 
obesity (Bruning et al., 2000). An ARC mechanism of action for insulin in suppressing 
feeding has been proposed. Intracerebroventricular administration of insulin to rats 
decreases fasting induced increases in NPY in the ARC (Schwartz et al., 1992) and third 
ventricular administration of insulin also increases POMC expression in the ARC and the 
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anorexigenic effects of insulin are lost with coadministration of an MC4R antagonist 
(Benoit et al., 2002).  
Despite the promising observations supporting a role for insulin in the promotion of a 
negative energy balance, chronic insulin administration for the treatment of diabetes 
actually results in an increase in bodyweight in patients and therefore insulin does not 
represent a viable treatment for obesity (Baggio and Drucker, 2007).  
1.8.2 Short-term mediators of appetite 
Feeding and starvation result in fluctuations in the levels of circulating nutrients in the 
blood which have been demonstrated to exert direct effects on neurons and to play a role 
in the acute control of appetite. Also, numerous hormones are released either pre or 
postprandially that acutely effect food intake and the list is continuing to grow. These 
include gut hormones such as ghrelin, CCK, PYY, GLP-1, GLP-2, oxyntomodulin and 
pancreatic polypeptide (PP). 
1.8.2.1 Glucose 
Intravenous administration of glucose decreases food intake in man and rodents (Van 
Ittalie et al., 1953; Walls and Koopmans, 1989) and interfering with glucose uptake in the 
CNS increases food intake (Miselis and Epstein, 1975). These results suggest that rather 
than post-ingestive factors secondary to glucose consumption inhibiting feeding, glucose 
inhibits feeding directly and this requires glucose uptake in the CNS. Brain glucose levels 
are 10-30% that of the blood (Routh, 2002) and is in the range of 1-5mM in the ARC 
approaching plasma levels found posprandially (de Vries et al., 2003). This places the 
ARC in an ideal position to respond accurately to fluctuations in plasma glucose. The 
influence on neuronal excitability of glucose depends first on glucose entering neurons 
mediated by the glucose transporters (GluT) GluT2 and GluT3 (Kang et al., 2004) and 
second that glucose is metabolized by the glycolytic pathway to generate ATP (Dunn-
Meynell et al., 2002). Orexigenic NPY neurons of the ARC are inhibited by physiological 
concentrations of glucose (Fioramonti et al., 2007) whilst anorexigenic POMC neurons of 
the ARC have been shown to be excited by physiological concentrations of glucose 
(Parton et al., 2007) as shown by in vitro electrophysiological studies. These observations 
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are consistent with the effects of glucose on feeding. The differences in the effects of 
glucose on the neuronal excitability of these two subpopulations of neurons are possibly 
due to the differences of the effects of ATP generated by the oxidation of glucose on 
specific ion channels. In NPY neurons, increases in the levels of ATP causes the gating 
of Cl- channels resulting in hyperpolarisation of these neurons (Fioramonti et al., 2007) 
whilst in POMC neurons, increases in the levels of ATP causes the closing of K+ 
channels resulting in depolarisation of these neurons (Parton et al., 2007).  
Glucose regulated neurons have also been described in the LHA. Orexin neurons are 
inhibitted by glucose whilst MCH neurons are excited by glucose (Burdakov et al., 2005). 
These observations are different to those found in the ARC as in the LHA orexigenic 
MCH neurons are excited which is inconsistent with the inhibitory effects of glucose on 
feeding. These results suggest that the inhibition of feeding by glucose is primarily an 
ARC mediated effect and the effects of glucose on neurons of the LHA may cause other 
physiological processes. For instance, the drowsiness that often occurs postprandially 
may be due to the inhibition of orexin neurons by glucose.  
1.8.2.2 Amino acids 
Intravenous administration of amino acids potently inhibits food intake in rats (Walls and 
Koopmans, 1989). These results also suggest that rather than post-ingestive factors 
secondary to protein consumption inhibiting feeding, amino acids can inhibit feeding 
directly.  Of all the amino acids derived from proteins obtained in meals, leucine is suited 
to be a marker of high nutrient availability. This is because leucine escapes first-pass 
metabolism and its levels are increased in the postprandial state and transport of leucine 
across the BBB is efficient (Brosnan and Brosnan, 2006). Intracerebroventricular 
administration of leucine decreases food intake (Cota et al., 2006) suggesting leucine’s 
effects on feeding are due to interactions with the brain.  These studies do not identify 
which part of the hypothalamus leucine is acting in to exert its effects. To address this 
issue, specific administration of leucine into the mediobasal hypothalamus (MBH) which 
comprises the ARC and VMN, was shown to inhibit food intake. Leucine was also shown 
to electrically excite POMC neurons by in vitro electrophysiological studies and MBH 
administration of leucine induces FOS expression in the ARC and PVN. The effect of 
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MBH leucine is abolished when coadministered ICV with an MC4R antagonist and an 
oxytocin receptor antagonist in the 4th ventricle implicating an ARC-PVN-brainstem 
circuit in regulating feeding (Blouet et al., 2009).  
As described, Olney et al characterised ARC lesions in neonatal animals following 
systemic administration of MSG which caused obesity in adulthood (Olney et al., 1969). 
As glutamate doesn’t cross the BBB (Hawkins, 2009) this is thought to be due to 
circulating glutamate passing through the median eminence and then gaining access to 
and activating glutamate receptors expressed in neurons in the ARC (Lehmann and 
Jonsson, 1992; Olney et al., 1981). A possible explanation for the obesity caused by MSG 
is that the weight attenuating effects of leptin are lost following MSG treatment (Dawson 
et al., 1997). 
The observations by Olney et al prompted a huge effort to understand the effects of MSG 
in various species to determine its potential toxicity in man. However doses used in 
animal studies that cause neurotoxicity are pharmacological. Also circulating glutamate is 
normally transaminated in the liver such that plasma levels raise only slightly even with 
high doses of MSG. Therefore, in 1988 the world health organisation (WHO) joint expert 
committee on food additives (JECFA) concluded that MSG is safe to use as a food 
additive (Walker and Lupien 2000). However, it was shown in a recent study conducted 
on approxiamately 700 Chinese adults that regular consumption of MSG (0.33g on 
average) is positively associated with obesity.  Despite the amounts received compared to 
animal studies (approximately two orders of magnitude lower) these results suggest that 
ARC neurons are susceptible to regulation by circulating glutamate at doses consumed in 
diets which could result in a disturbed energy balance (He et al., 2008). 
1.8.2.3 Fats  
Intravenous administration of lipids decreases food intake in various species (Walls and 
Koopmans, 1989). Once in the bloodstream fatty acids bind to chylomicrans, albumin, 
and lipoproteins which are all sources of fatty acids for the brain and the concentration of 
fatty acids in the brain reflects circulating amounts (Lam et al., 2005). This suggests that 
the anorexigenic effects of lipids occurs independent of post-ingestive effects and 
through direct interaction with the CNS. Consistent with this idea, ICV administration of 
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the long chain fatty acid oleic acid (OA) decreases food intake in rats (Obici et al., 2002). 
Following ICV infusion of OA, it is rapidly converted into acyl-coenzyme A (acyl-CoA) 
by the enzyme acyl-CoA synthetase. Acyl-CoA levels in the MBH are thought to signal 
the energy surfeit required to decrease food intake (Lam et al., 2005). Pharmacological 
and molecular studies on carnitine palmitoyl transferase-1 (CPT-1) support this idea. 
Carnitine palmitoyl transferase-1 is a mitochondrial protein that transfers acyl-CoA from 
the cytoplasm into the mitochondria for the oxidation of lipids. Therefore, activation and 
inhibition of this enzyme decreases and increases cytoplasmic acyl-CoA levels 
respectively and would be expected to have effects on food intake in the brain based on 
the aforementioned model. Indeed, pharmacological activation of this enzyme in the 
VMN stimulates food intake (Lopez et al., 2008) and molecular and pharmacological 
inhibition of this enzyme (via injection of a plasmid containing a ribozyme for CPT-1 
mRNA or an inhibitor of CPT-1) into the ARC inhibits food intake (Obici et al., 2003).  
1.8.2.4 Ghrelin 
Ghrelin is a 28 amino acid peptide hormone first isolated from the rat stomach in the 
search for natural ligands to the orphan growth hormone secretagogue receptor 1 
(GHSR1) (Kojima et al., 1999). The GHSR1 is distributed throughout the hypothalamus 
and in the nodose ganglia in mice and rats (Date et al., 2002; Zigman et al., 2006) and is 
found in NPY neurons of the ARC of rats (Willesen et al., 1999). Ghrelin is released by 
the oxyntic X/I cells of the gastric fundus (Date et al., 2000) at peak concentrations 
before meals and plasma levels are suppressed post-prandially; suggesting that ghrelin 
plays a role as a meal initiator (Cummings et al., 2001). Studies support that ghrelin 
promotes a positive energy balance. Peripheral or ICV administration of ghrelin to rats 
increases food intake (Wren et al., 2001b) as does peripheral administration to man 
(Wren et al., 2001a). Chronic peripheral (Tschop et al., 2000) or ICV (Kamegai et al., 
2001) administration of ghrelin increases bodyweight and adiposity in rodents. 
Conversely, chronic peripheral administration of a GHSR1 antagonist decreases food 
intake and bodyweight supporting a physiological role for ghrelin in promoting a positive 
energy balance (Asakawa et al., 2003a). Molecular studies also support the role of ghrelin 
in promoting a positive energy balance. Knockout of ghrelin or its receptor in mice 
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protects from diet induced obesity (Zigman et al., 2005; Wortley et al., 2005) and mice 
overexpressing ghrelin are hyperphagic and obese and exhibit decreased energy 
expenditure (Bewick et al., 2009).  
Studies suggest that the vagus nerve, brainstem, ARC and PVN are important sites of 
interaction for ghrelin’s effects on feeding. The orexigenic effects of peripherally 
administered ghrelin in rats are lost following vagotomy or brainstem transectioning. 
Furthermore, microinjection of adrenergic receptor antagonists into the ARC prevents the 
effects of peripherally administered ghrelin. This suggests that ghrelin increases food 
intake by activating GHSR1 expressed in vagal afferents and/or the noradrenergic 
neurons of the NTS to ultimately signal in the ARC (Date et al., 2002; Date et al., 2006).  
A single ICV injection of ghrelin increases AgRP (Kamegai et al., 2000) and NPY 
mRNA expression in the ARC of rats (Shintani et al., 2001) and peripheral administration 
of ghrelin also stimulates NPY/AgRP neurons in the ARC of rats shown through 
induction of Fos immunoreactivity (Wang et al., 2002b). Ghrelin does not stimulate food 
intake in animals with an ablated ARC (Tamura et al., 2002) and ICV coadministration of 
a Y1 receptor antagonist also prevents the effects of ghrelin (Shintani et al., 2001). These 
results suggest the the ARC is an important site of action for ghrelin. The orexigenic 
effect of ICV administration of ghrelin is not observed in the CB1R KO mouse. It was 
shown that ghrelin causes the release of ECs from parvocelluar cells of the PVN which 
via presynaptic CB1Rs decrease excitatory input onto these cells. Therefore, ghrelin 
decreases the activity of possibly anorexigenic cells in the PVN (Koda et al., 2008) and 
this may be mediated by ghrelin directly accessing the PVN as it has been shown to cross 
the BBB (Banks et al 2002).   
Ghrelin is uniquely octanoylated at the serine residue in position 3 which is required for 
biological activity. Recently the enzyme that octanolyates ghrelin has been cloned and 
termed ghrelin O acyl transferase (GOAT) (Yang et al., 2008a). Ghrelin O acyl 
transferase KO mice are leaner than mice fed on a HFD and overexpression of GOAT 
results in obesity (Kirchner et al., 2009). As no other substrates of the enzyme have been 
discovered, inhibition of this enzyme represents a promising therapeutic strategy to treat 
obesity (Yang et al., 2008b).   
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1.8.2.5 Cholecystokinin (CCK) 
ProCCK is a peptide highly expressed in the gut and brain and is processed into smaller 
peptides ranging from 8 to 83 amino acids in length. The most common forms of CCK 
are CCK8, CCK22, CCK33, and CCK58 with the octapeptide carboxy terminal sequence 
and sulphated tyrosine being necessary for biological activity. Cholecystokinin binds to 
two GPCRs; the CCK1 receptor (CCK1R) which is predominantly expressed in the brain 
and the CCK2 receptor (CCK2R) which is predominantly expressed in the periphery 
(Cummings and Overduin, 2007). Cholecystokinin is mainly released by the I-cells of the 
duodenum from ingested food particularly fat and protein (Schaffalitzky de Muckadell et 
al., 1986; Lewis and Williams, 1990). Studies support that CCK promotes a negative 
energy balance. Peripheral administration of CCK to rats (Gibbs and Smith, 1977) and 
humans (Lieverse et al., 1994) decreases food intake whilst peripheral administration of a 
CCK1R antagonist to rats (Reidelberger et al., 1991) and humans (Beglinger et al., 2001) 
increases food intake implicating a physiological role for CCK in feeding. Molecular 
studies however provide conflicting results. Rats lacking the CCK1R are obese (Moran et 
al., 1998) but CCK1R KO mice are not obese (Bi et al., 2004).  
Studies suggest that the vagus nerve, brainstem and DMN are important sites of 
interaction for CCK’s effects on feeding. Vagotomy abolishes the anorexigenic effects of 
peripherally administered CCK (Garlicki et al., 1990). Peripheral administration of CCK 
induces Fos expression in POMC expressing neurons in the NTS and administration of an 
MC4R antagonist into the 4th ventricle abolishes the anorexigenic effects of peripheral 
administration of CCK (Fan et al., 2004). It has been shown that CCK1Rs are expressed 
in the DMN (Bi et al., 2004) and peripheral administration of CCK induces Fos in this 
nucleus (Kobelt et al., 2006). Indeed lesioning the DMN prevents the anorexigenic 
actions of CCK (Bellinger and Bernardis, 1984). These results suggest that CCK directly 
interacts with neurons in the DMN to inhibit feeding.  
As CCK was the first gut peptide demonstrated to inhibit feeding, it was proposed as a 
novel antiobesity therapy; however continuous administration of CCK leads to tolerance 
(Crawley and Beinfeld, 1983) and chronic administration does not result in weight loss in 
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rats (West et al., 1984). Therefore, the interest of using CCK as an obesity treatment was 
dismissed.   
1.8.2.6 Proglucagon peptides 
Proglucagon is a 180 amino acid peptide found in the pancreas, intestine and CNS. 
Proglucagon experiences differential post-translational processing in different organs. In 
the α-cells of the Islets of Langerhans of the pancreas, glucagon, intervening peptide 1 
(IP1) and major proglucagon fragment (MPGF) are generated mainly by the catalytic 
action of PC-2 (Furuta et al., 2001). In the L-cells of the small intestine and the brainstem 
neurons of the CNS, GLP-1, GLP-2, oxyntomodulin, glicentin and intervening peptide 2 
(IP2) are generated mainly by the catalytic action of PC-1 (Figure 1.6) (Rouille et al., 
1997). 
 
Figure 1.6 The products of proglucagon cleavage. 
Abbreviations: GLP-1 and GLP-2 – glucagon-related peptides 1 and 2; IP-1 and IP-2- 
intervening peptides 1 and 2; GRPP, glicentin-related polypeptide; MPGF, major 
proglucagon fragment. Taken from Baggio and Drucker, 2007. 
1.8.2.6.1 Glucagon like peptide 1 (GLP-1) 
Glucagon like peptide-1 is a 37 amino acid peptide found in the intestinal L-cells of the 
ileum (li-Rachedi et al., 1984) and is released postprandially mainly as a result of 
digestion of fats and carbohydrates (Elliott et al., 1993; Herrmann et al., 1995). Glucagon 
like peptide-1 circulates as GLP-11-37 and GLP-17-37 and after amidation at the carboxy 
terminus at the expense of the terminal amino acid also as GLP-11-36 amide and GLP-17-36 
amide. The truncated forms of GLP-1 are biologically active with GLP-17-36 amide being 
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the main circulating form of GLP-1 (Orskov et al., 1994). Glucagon like peptide-1 binds 
to the GLP-1 receptor (GLP-1R) which is expressed widely in the periphery, the nodose 
ganglia, the NTS, and widely throughout the hypothalamus and the brain (Merchenthaler 
et al., 1999).  
Glucagon like peptide-1 is the major promoter of glucose-dependent insulin secretion in 
man (Kreymann et al., 1987) and rats (Wang et al., 1995) but also has been shown to 
promote a negative energy balance. Intacerebroventricular administration of GLP-1 
reduces food intake in rats (Turton et al., 1996) whereas ICV administration of the GLP-
1R antagonist exendin 9 increases food intake (Meeran et al., 1999) suggesting a 
physiological role for GLP-1 in feeding. Also, peripheral administration of GLP-1 
decreases food intake in lean and obese humans (Naslund et al., 2004) and in lean and 
obese rats (Chelikani et al., 2005). Molecular studies provide conflicting results as to the 
role of GLP-1 in promoting a negative energy balance. Consistent with a role of GLP-1 in 
glucose homeostasis, GLP-1R KO mice are hyperglycaemic however they show normal 
bodyweight and food intake (Scrocchi et al., 1996).  
Studies suggest that the vagus nerve, brainstem and PVN are important sites of 
interaction for GLP-1’s effect on feeding. The anorexigenic effect of peripheral 
administration of GLP-1 is lost following vagotomy in rats (Abbott et al., 2005a). Gastric 
distension activates GLP-1 neurons in the NTS shown by the expression of Fos (Vrang et 
al., 2004) and the satiating effects of gastric distension are lost following 4th ventricular 
administration of a GLP-1R antagonist (Hayes et al., 2009). These results suggest that 
GLP-1 acting as a neurotransmitter in the brainstem contributes to the satiety induced by 
gastric distension. With regards to the hypothalamus, microinjection of GLP-1 into the 
ARC does not inhibit feeding (Sandoval et al., 2008) and microinjection of a GLP-1R 
antagonist also into the ARC does not prevent the anorexigenic effects of peripheral 
administration of GLP-1 (Dakin., et al 2004) suggesting an extra-ARC mechanism for 
GLP-1. Glugacon like peptide-1 crosses the BBB (Kastin et al., 2002) and therefore may 
also work via other regions of the CNS to inhibit feeding. Consistent with this, 
microinjection of GLP-1 into the PVN inhibits feeding in rats (McMahon, 1997).  
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Glucagon like peptide-1 is rapidly cleaved at its amino terminus into inactive products by 
the enzyme dipeptidyl peptidase IV (DPPIV). Therefore GLP-1 has a plasma half-life of 
only 2 minutes in humans (Deacon et al., 1995) thereby limiting the longevity of its 
physiological and pharmacological effects. Various GLP-1 analogues with rational amino 
acid substitutions at the amino terminus that confer resistance to DPPIV have been 
designed which exert long-lasting effects on feeding (Deacon et al., 1998). Liraglutide is 
a GLP-1 analogue with an acyl chain bound to the amino terminus which confers 
resistance to DPPIV by enhancing binding to albumin and which hence has a 
dramatically longer plasma half-life than GLP-1 of approximately 14 hours (Knudsen et 
al., 2000). In phase II clinical trials once daily subcutaneous (s.c.) injection of liraglutide 
produced a 5% weight loss in more than three quarters of participants in a 20 week study 
and 10 % weight loss in nearly half of participants. This amounted to more than 3 times 
the number of individuals exhibiting greater than 10% weight loss with daily orlistat. 
Adverse effects included nausea and vomiting but this was transient and did not prevent 
patients from taking treatment (Astrup et al., 2009). These results suggest that liraglutide 
is a promising anti-obesity therapy. 
1.8.2.6.2 Glucagon like peptide 2 (GLP-2) 
Glucagon like peptide-2 is a 34 amino acid peptide that binds specifically to the GLP-2 
receptor (GLP-2R) found in the brain and gut (Munroe et al., 1999). Glucagon like 
peptide-2 has mainly been shown to have an intestinotrophic role similar to glicentin 
(Myojo et al., 1997; Drucker et al., 1996) however an anorexigenic effect has been 
documented following central administration (Tang-Christensen et al., 2000). 
1.8.2.6.3 Oxyntomdulin 
Oxyntomodulin is a 37 amino acid peptide first isolated from porcine distal intestine 
(Bataille et al., 1982). Intracerebroventricular administration oxyntomodulin decreases 
food intake in rats as well as microinjection into the ARC and PVN (Dakin et al., 2001; 
Dakin et al., 2004). Also, peripheral administration of oxyntomodulin inhibits food intake 
in lean and obese men (Cohen et al., 2003) and lean and obese rats (Dakin et al., 2004; 
Wynne et al., 2005).  Although the binding to the GLP-1R is two orders of magnitude 
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lower than that for GLP-1 (Dakin et al., 2001), the anorexigenic effect of peripheral 
administration of oxyntomodulin is blocked by microinjection of a GLP-1R antagonist 
into that ARC suggesting that this receptor mediates the effects on feeding and an ARC 
mechanism of action (Dakin et al., 2004).  
1.8.2.7 Pancreatic Polypeptide (PP) 
Pancreatic polypeptide is a 36 amino acid peptide first isolated from chicken pancreas 
(Langslow et al., 1973). Pancreatic polypeptide is stored in the P-cells surrounding the 
Islets of Langerhans and is released in proportion to the calorie intake of a meal (Adrian 
et al., 1976). Pancreatic polypeptide selectively binds to the Y4 receptor which is 
expressed in the AP, NTS, ARC, LHA and PVN (Parker and Herzog 1999) as well as in 
peripheral tissues such as the the pancreas, intestine, colon, heart, and liver (Bard et al 
1995). 
Studies suggest that PP promotes a negative energy balance. Low circulating levels are 
found in obese subjects (Zipf et al., 1981) and higher circulating levels in anorexics (Uhe 
et al., 1992). Peripheral administration of PP decreases food intake in lean and obese 
mice and humans in acute feeding studies and decreases bodyweight in chronic feeding 
studies (Berntson et al., 1993; Asakawa et al., 2003; Batterham et al., 2003c). Molecular 
studies yield conflicting results. Knockout of the Y4 receptor actually results in a lean 
phenotype (Sainsbury et al., 2002b) however transgenic overexpression of PP in mice 
results in a reduction in food intake and protection from diet induced obesity (Ueno et al 
1994). 
Studies suggest that the vagus nerve and ARC are important sites of interaction for PP’s 
effects on feeding. Vagotomy in mice abolishes the anorexigenic effects of peripheral 
administration of PP (Asakawa et al., 2003b) suggesting that activation of vagal afferents 
is necessary for the effects of PP on food intake. Also the anorexigenic effect of PP is lost 
in MC4R KO mice (Lin et al., 2009).  
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1.8.2.8 Peptide YY (PYY) 
Peptide YY is a 36 amino acid polypeptide first isolated from porcine ileum (Tatemoto 
and Mutt, 1980) that belongs to the Pancreatic Polypeptide (PP) fold family which 
includes NPY and PP (Tatemoto, 1982; Tatemoto et al., 1988). The PP-fold family 
requires amidation at their carboxy termini for biological efficacy (Tatemoto et al., 1988).  
1.8.2.8.1 Pharmacology of the PP-fold family 
Peptide YY and NPY bind to all members of the Y family of receptors with high affinity 
(Bard et al., 1995; Gehlert et al., 1996; Hu et al., 1996; Larhammar et al., 1992) whilst PP 
binds selectively to the Y4 receptor (Bard et al., 1995). Amino terminally truncated PYY 
and NPY show selectivity to the Y2 receptor, so that for example PYY3-36 and NPY13-36 
bind to the Y1 receptor with a 10-fold lower affinity than PYY and NPY, but still bind 
with a high affinity to the Y2 receptor (Gehlert et al., 1996). 
1.8.2.8.2 Location of PYY containing cells 
Peptide YY is expressed highly in the L-cells of the distal ileum and expression increases 
to reach its peak amount further down the digestive track in various species such as dogs 
(Taylor, 1985) and rats (Lundberg et al., 1982). In humans, the concentration of PYY in 
the proximal intestine is about 10pmol/g whereas in the rectum it is about 500pmol/g of 
tissue (Adrian et al., 1985).  
Peptied YY is colocalised with other peptides in the intestinal L-cell including the 
proglucagon peptides (Nilsson et al., 1991) and neurotensin (Upchurch et al., 1996). 
Peptide YY is also expressed in the pancreas of rats (Myrsen-Axcrona et al., 1997), mice 
(Upchurch et al., 1994) and humans (Ali-Rachedi et al., 1984) being coexpressed with 
glucagon in the α-cells of the islets of langerhans. Peptide YY containing neurons have 
also been localized in the brain to the gigantocellular reticular nucleus in the rostral 
medulla in mice, rats, and non-human primates (Glavas et al., 2008). Peptide YY is 
expressed throughout the human hypothalamus in the ARC, PVN, and SON (Morimoto et 
al., 2008). The physiological role of PYY within the brain has yet to be determined. 
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1.8.2.8.3 Release of PYY  
Peptide YY is released post-prandially in proportion to the calorie intake of a meal in 
man with an early phase of release (within 15mins) and a late phase of release (2 hours 
and beyond). Fasting levels of PYY in the plasma are 8.5pmol/l and increase to 53.5 
pmol/l following a 4500 kcal meal (Adrian et al., 1985). Meals high in fat, carbohydrates 
(Adrian et al., 1985b; Essah et al., 2007), proteins (Adrian et al., 1985; Batterham et al., 
2006) and fermentable fibres (Gee and Johnson, 2005) are all potent stimulators of PYY 
release in humans. Obese humans have blunted postprandial release of PYY (Le Roux et 
al., 2006b) whilst basal PYY levels are higher in the plasma of anorexic subjects (Misra 
et al., 2006). 
Peptide YY is thought to be released by the L-cells in the distal small intestine when food 
is in the proximal small intestine. This is because intraduodenal lipids cause a release of 
PYY which is lost following ileocolectomy (Greeley, Jr. et al., 1989). These results 
suggested that neural and/or humoral pathways cause the release of PYY from the distal 
gut when nutrients are present in the proximal gut and which would explain the early 
phase of PYY release postprandially. Indeed the release of PYY following intraduodenal 
lipid administration is lost after treatment of the vagal signalling inhibitor atropine in rats 
(Lin and Taylor, 2004) and in man atropine treatment significantly decreases PYY levels 
following a meal (Maier et al., 2008). Furthermore, the release of PYY following 
intraduodenal lipid administration is lost with CCK1R antagonist treatment in rats (Lin et 
al., 2000) and man (Degen et al., 2007) suggesting that release of CCK into the 
bloodstream from the proximal gut mediates the release of PYY from the distal gut.  
Direct intraileal administration of lipids in rats (Aponte et al., 1989) and humans (Pironi 
et al., 1993) cause a release of PYY as does intraileal administration of glucose in pigs 
(Sheikh et al., 1989) and intracolonic administration of short chain fatty acids in the rat 
and rabbit (Longo et al., 1991; Fu-Cheng et al., 1995). This would explain the late phase 
of PYY release postprandially as nutrients eventually reach the distal gut.  
The mechanism of how nutrients in direct contact with the apical membrane of L-cells 
cause the release of PYY through the basal membrane and into the vasculature is being 
unraveled although more work has been performed on GLP-1 release from the L-cell. As 
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these peptides are costored in the same cell, it is safe to assume that what causes GLP-1 
release also causes PYY release but this of course requires formal assessment. Following 
oral consumption, fermentable fibres are digested into short chain fatty acids such as 
acetate and butyrate in the distal gut. The short chain fatty acid receptor GPR43 is 
coexpressed with PYY positive cells in both the distal ileum and colon which suggests 
that this receptor mediates its release at least in the colon by liberated short chain fatty 
acids (Karaki et al., 2006). The breakdown of lipids following intraileal administration 
into free fatty acids by lipoprotein lipase is necessary for the release of PYY in rats 
(Feinle-Bisset et al., 2005) and oral administration of the lipase inhibitor orlistat 
significantly decreases PYY levels in the plasma of humans given test meals 
(Ellrichmann et al., 2008). Free fatty acids of a minimum chain length of 12 are necessary 
for PYY release from the distal ileum in man and rats (Aponte et al., 1985; Feltrin et al., 
2006). GPR120 is a receptor for long chain fatty acids that has been shown to be 
necessary for the medium chain fatty acid mediated release of GLP-1 from an L-cell line 
(Hirasawa et al., 2005) and this may also be the case for PYY from the distal ileum 
following oral consumption of lipids and breakdown by lipases. Green fluorescent protein 
(GFP) labelled L-cells have remarkably been shown to be electrically excited by glucose 
via the Na+/Glucose transporter and the activation of K+ channels. The release of GLP-1 
from the L-cell was prevented with a Na+/Glucose cotransporter inhibitor and a K+ 
channel blocker (Reimann et al., 2008) and similarly this may be the case for the release 
of PYY from the distal ileum in response to oral consumption of carbohydrates.  
1.8.2.8.4 Generation of PYY3-36 
After release into the bloodstream, PYY1-36 is rapidly cleaved at the amino terminus by 
the membrane bound enzyme dipeptidyl peptidase IV (DPPIV) found in the endothelial 
cells of blood vessels supplying the gut (Hansen et al., 1999), generating the Y2 receptor 
specific agonist PYY3-36. Both forms of the peptide (PYY1-36 and PYY3-36) circulate in the 
blood in approximately equal concentrations in humans (Grandt et al., 1994).  
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1.8.2.8.5 Y2 receptor structure and distribution 
The Y2 receptor was first characterized physiologically as a pre-synaptic receptor in 
terminal boutons of the sympathetic nervous system and as such serves to regulate 
neurotransmitter release (Wahlestedt et al., 1986). This has also been observed in the 
CNS. For example, in the hypothalamus Y2 receptor activation reduces NPY release 
(King et al., 1999). However, it is also found post-synaptically in the somatodendritic 
compartment as shown through IHC in the mouse brain albeit to a lesser extent where it 
plays a role in neuronal excitability (Stanic et al., 2006). The Y2 receptor was first cloned 
from human hippocampus in 1995 using an expression cloning technique and was found 
to be comprised of 381 amino acids and to have seven transmembrane domains typical of 
all G-protein coupled receptors (Gerald et al., 1995). In rats Y2 receptor mRNA is 
expressed in the ARC, DMN, VMN, and PVN (Parker and Herzog, 1999). In the mouse 
brain, the Y2 receptor is expressed in the medial ARC, DMN, and the NTS as shown 
through IHC (Stanic et al., 2006). The Y2 receptor is located both in NPY and POMC 
neurons of the ARC, mainly found in the former population (Fetissov et al., 2004). In the 
post-mortem human brain 125IPYY3-36 binding sites have been demonstrated in the ARC 
and NTS (Jacques et al., 1997).  
The Y2 receptor is also found in the peripheral nervous system (Mantyh et al., 1994) and 
in peripheral organs such as in the proximal convoluted tubules of the kidney (Sheikh et 
al., 1989) and in epithelial and non-epithelial cells in the small and large intestine 
(Goumain et al., 1998). 
1.8.2.8.6 Roles for PYY1-36 and PYY3-36 on food intake 
Following the studies of central administration of NPY on food intake, it was shown that 
ICV administration of PYY1-36 produced a potent orexigenic effect in rats (Morley et al., 
1985) as did microinjection into the PVN (Stanley et al., 1985b). Also ICV 
administration of high concentrations of PYY3-36 in mice increases food intake via 
activation of the Y1 receptor (Kanatani et al., 2000). In contrast, it was later shown that 
microinjection of the Y2 receptor agonist NPY13-36 into the PVN decreases food intake in 
rats (Leibowitz and Alexander, 1991). These results first suggested that as opposed to the 
induction of feeding activation of Y1 and Y5 receptors cause, activation of Y2 receptors 
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may inhibit feeding. Based on the potential anorexigenic role of Y2 receptors expressed 
in the hypothalamus, the effects of the endogenous Y2 receptor ligand PYY3-36 was tested 
for its effects on feeding. Peripheral administration of PYY3-36 to rodents and humans 
decreased food intake and this effect was lost in the Y2 receptor KO mouse (Batterham et 
al., 2002). Intravenous administration of PYY3-36 also decreases food intake in obese 
humans (Batterham et al., 2003b) suggesting that obesity does not result in PYY3-36 
resistance as is the case with leptin. Peripheral administration of PYY1-36 to rats 
(Chelikani et al., 2004) and humans (Sloth et al., 2007) also decreases food intake. 
However, PYY1-36 has no effects on food intake in rats lacking DPPIV (Unniappan et al., 
2006) suggesting that the generation of PYY3-36 from PYY1-36 accounts for its 
anorexigenic effects. Chronic peripheral administration of PYY3-36 via osmotic minipump 
or daily injections reduces food intake and decreases bodyweight in diet induced obese 
mice (Pittner et al., 2004; Vrang et al., 2006). Also chronic peripheral administration of 
PYY3-36 via osmotic minipump or daily infusions to normal and diet induced obese rats 
reduces food intake and decreases bodyweight (Chelikani et al., 2006; Chelikani et al., 
2007). Peripheral administration of PYY3-36 has no effect on energy expenditure but does 
increase respiratory quotient such that fats are catabolised in preference over 
carbohydrates (Adams et al., 2006). Molecular studies yield conflicting results on the role 
of PYY3-36 on promoting a negative energy balance. Germline KO or hypothalamic 
deletion of the Y2 receptor does not result in obesity (Sainsbury et al., 2002a). 
Reconciling these findings however, is that PYY KO mice are hyperphagic and obese 
(Batterham et al., 2006) and mice overexpressing PYY are protected against diet induced 
obesity (Boey et al., 2008).  
1.8.2.8.7 Mechanism of action of PYY3-36 in mice and rats 
For circulating PYY3-36 to modulate feeding it needs to interact with Y2 receptors in the 
CNS. Interestingly, there appears to be a species difference in the access to the CNS for 
PYY3-36. In rats, circulating PYY3-36 gains access to the CNS via the area postrema (AP) 
and the median eminence (ME) (Dumont et al., 2007) whilst in mice, PYY3-36 crosses the 
BBB via a non-saturable transport mechanism (Nonaka et al., 2003). This has 
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implications on the mechanism of action of PYY3-36 in inhibiting food intake for the two 
species.  
In rats PYY3-36 is thought to depend on vagus, brainstem and ARC signalling to inhibit 
food intake following peripheral administration (Figure 1.7). Microinjection of fmol 
doses of PYY3-36 into the ARC of rats reduces food intake (Batterham et al., 2002) whilst 
peripheral administration of PYY3-36 in the rat is no longer anorexigenic when a Y2 
receptor antagonist is microinjected into the ARC (Abbott et al., 2005b). These results 
suggest that activation of Y2 receptors located in the ARC is required for the decrease in 
food intake caused by circulating PYY3-36. Consistent with this, peripheral administration 
of PYY3-36 to rats increases Fos expression in the ARC (Blevins et al., 2008). Also, 
peripheral administration of PYY3-36 decreases NPY mRNA expression and produces a 
trend towards increased POMC mRNA expression further suggesting an ARC 
mechanism of action of PYY3-36 (Batterham et al., 2002). In rats 4th ventricular 
administration of PYY increases food intake (Corp et al., 1990) an effect mediated by Y1 
and/or Y5 receptor activation (Corp et al., 2001). To date no experiments on the effects 
on feeding of forth ventricular administration of PYY3-36 or intra NTS administration of 
PYY3-36 have been performed. Peripheral administration of PYY3-36 activates tyrosine 
hydroxylase positive neurons in the NTS in rats (Blevins et al., 2008) suggesting that its 
effects in part may be mediated by the direct activation of these neurons. Consistent with 
this, brainstem transection abolishes the effects on feeding of peripheral administration of 
PYY3-36 (Abbott et al., 2005a). The Y2 receptor is expressed in the nodose ganglion of 
rats and the inhibitory effect of peripheral administration of PYY3-36 on food intake is 
abolished in rats that have been subjected to subdiaphragmatic vagotomy (Koda et al., 
2005). These results suggest that the anorexigenic effects of peripheral administration of 
PYY3-36 require activation of the Y2 receptor expressed on vagal afferents  
In mice signalling via the vagus nerve, the brainstem and the ARC seem not to be 
necessary for the anorexigenic effect of peripheral administration of PYY3-36. Peripheral 
administration of PYY3-36 inhibits food intake in the POMC (Challis et al., 2004) and 
MC4R (Halatchev et al., 2004) KO mice implying that α-MSH release in the ARC is not 
necessary for the actions of PYY3-36 in this species. With regards to the brainstem, 
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peripheral administration of PYY3-36 does not induce Fos expression in the NTS 
(Halatchev et al., 2004). With regards to the vagus nerve neither chemical (Talsania et al., 
2005) nor surgical (Halatchev and Cone, 2005) vagotomy influences the inhibitory effect 
of peripheral administration of PYY3-36 on food intake. These observations highlight a 
species difference in the mechanism of action of PYY3-36 on feeding. 
 
 
Figure 1.7 Different sites of action of PYY3-36 in mediating its effects on appetite in 
the rat. 
PYY3-36 is thought to be dependent on intact vagal signaling via binding to the Y2R 
expressed in primary afferent fibres of the gut. The signal is then passed to the ARC via 
tyrosine hydorxylase positive neurons in the NTS. However direct activation of Y2Rs in 
the ARC is also necessary for peripheral PYY3-36 to decrease food intake. Adapted from 
Ueno et al., 2008. 
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1.9 Treatments for Obesity 
There are three lines of treatment for obesity which are offered according to the severity 
of the condition; lifestyle changes, medicinal treatment and surgery. The first line of 
treatment is recommended lifestyle changes which entail an approved dietary program 
coupled with increased physical activity. However, in the long-term this form of 
treatment is ineffective and patients typically regain the weight they lose (Mun et al., 
2001). The second line of treatments is medical therapies which are often used as an 
adjunct to lifestyle changes. Current medical treatments for obesity include the intestinal 
lipase inhibitor, orlistat, (Torgerson et al., 2004) and the SSRI, sibrutamine, (Padwal et 
al., 2003) both of which only cause a moderate loss of weight of 4-5kg in obese 
individuals when administered over a 52 week period. Additionally, both of these 
compounds produce undesirable side-effects. Orlistat causes steatosis such that only 1% 
of subjects taking the medication remain doing so one year after commencement of 
treatment. Sibrutamine is traditionally used as an anitidepressent and its side-effects 
include an increased risk of heart attack and stroke. Due to this, sibrutamine is currently 
being considered for withdrawal from the market in the UK. Indeed the monoamine 
reuptake inhibitors fenfluoramine-phentermine (fen-phen) (Weintraub et al., 1992) and 
the cannabinoid receptor antagonist, rimonabant (Van Gaal et al., 2005), which had 
previously been commonly prescribed medications for weight loss, have been withdrawn 
from the market as rimonabant and fen-phen cause significant deleterious effects on 
mood (Akbas et al., 2008) and heart valve function respectively (Dahl et al., 2008). 
The third line of treatment is surgical. In 2002 the National Insitute for Clinical 
Excellence (NICE) issued guidelines for bariatric surgical procudures and recommended 
them as a last line treatment when other options were ineffective. According to NICE 
guidelines, bariatric surgery is only recommended for the morbidly obese (BMI>35) with 
hyperglycemia, hypercholesterolemia, and/or hyperlipidimia or individuals with a 
BMI>40. Bariatric surgical procedures represent the only method of producing a 
sustained weight loss (Sjostrom et al., 2004). Furthermore, patients whom underwent 
gastric bypass procedures show decreased mortaility rates associated with heart disease, 
cancer, and diabetes (Adams et al., 2007). Since surgery is not a readily available 
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treatment option for a majority of obese individuals, an understanding of the 
physiological changes that account for the decreased appetite and increased glycemic 
control after surgery may prove valuable in the production of novel anti-obesity 
treatments that mimic the post-surgery state. Indeed Roux-en-Y gut bypass, which 
involves removal of a significant portion of the proximal small intestine and a large part 
of the stomach, results in elevated postprandial plasma levels of PYY3-36 and GLP-1 (Le 
Roux et al., 2006a) and lower levels of ghrelin in human patients (Cummings et al., 
2002). The increased postprandial levels of PYY3-36 and GLP-1 following the procedure 
is thought to be a result of increased amounts of nutrients accessing the distal small 
intestine before they are digested and absorbed. Therefore the changes in gut hormone 
levels involved in appetite control and glucose homeostasis following the gastric bypass 
procedures may be involved in mediating the reduction in appetite and hyperglycemia. 
Mimicking these changes in gut hormone levels in particular with PYY3-36 may be a safe 
and effective means of treating obesity.  
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Aims of work: 
• To demonstrate that long-lasting PYY3-36 analogues are potential treatments for 
obesity through acute and chronic feeding studies conducted on a diet induced 
obese murine model.  
• To demonstrate that any lengthier effects on feeding exerted by a long-lasting 
PYY3-36 analogue corresponds to lengthier effects on hypothalamic and brainstem 
neuronal activity shown through Manganese enhanced MRI (MEMRI) studies.  
• To demonstrate that MEMRI can detect receptor subytpe specific activation in the 
hypothalamus through pharmacological MEMRI experiments with the food 
additive monosodium glutamate (MSG) and the glutamate receptor system.  
• To demonstrate that roux-en-Y gastric bypass (RYGB) influences hypothalamic 
neuronal activity and brown adipose tissue activity in vivo through the use of a 
mouse model of RYGB and MEMRI and positron emission tomography 
computed tomography (PET-CT) experiments respectively.   
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Chapter 2: 
Materials and Methods 
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2 Materials and Methods 
2.1 Peptides  
Peptides were purchased from Bachem (St Helens, UK). Peptides were synthesised, 
purified and analysed by the supplier using established protocols (Wellings and Atherton, 
1997). Synthesis and purification used automated Fluorenyl-Methoxy-Carbonyl solid 
phase peptide synthesis (Fmoc SPSS). Peptides were synthesised on TentaGel® resins, 
derivatised with one of a number of cleavable linkers, using an Fmoc/t-butyl-based solid-
phase synthesis strategy.  Temporary N-amino group protection was afforded by the 
Fmoc-group, with t-butyl ethers being utilised for protection of tyrosine, serine, and 
threonine hydroxyl side chains, whilst t-butyl esters protected the side chains of aspartic 
and glutamic acid residues.  Histidine and lysine side chains were protected as their N- 
and N- Boc derivatives respectively, cysteine as its S-trityl derivative, and arginine 
guanidine moiety as its Pbf derivative. 
Upon completion of the synthesis, peptides were cleaved from the solid support, with 
removal of side chain protecting groups, by treatment with aqueous trifluoroacetic acid 
(TFA) containing triisobutylsilane (TIS) as a scavenger.  After removal of TFA and 
scavengers by evaporation and trituration, peptide purification was carried out by 
reversed-phase preparative high performance liquid chromatography (HPLC) followed by 
lyophilisation.  The purified product was subsequently analysed by reverse-phase HPLC 
and by mass spectrometry.  
 
 
 
 
 
 
 
 
 
80 
 
2.1.1 Amino acid sequences of a PYY dimer and of PYY analogues with stabilised 
tertiary structures 
PYY2-36 (Cys2) was synthesized which forms a homodimer due to a disulfide covalent 
bond that forms between Cys2 of one monomer and Cys2 of the other. PYY2-36 and 
PYY2-36 (Cys2, Cys27) analogues were synthesized the latter analogue has an 
intramolecular disulfide bridge between Cys2 and Cys27. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Amino acid sequences of a PYY dimer and of PYY analogues with 
stabilised tertiary structures 
A) Sequence of hPYY1-36, hPYY3-36 and PYY2-36 (Cys2). Amino acids in red represent 
substitutions. B) Sequences of hPYY1-36, hPYY3-36, PYY2-36, and PYY2-36 (Cys2, Cys27). 
Amino acids in red represent substitutions. a, b, and, c are regions of the PYY analogues 
thought to have hydrophobic or covalent interactions with each other (e.g. a interacts with 
a etc). 
 
 
 
A) 
B) 
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2.1.2  Amino acid sequences of PYY analogues with rational substitutions to confer 
resistance to NEP 
PYY3-36 (Arg30), PYY3-36 (Lys30), PYY3-36 (Asp29, Lys30) analogues were synthesized 
and tested for their resistance to NEP.  
 
 
 
 
 
Figure 2.2 Amino acid sequences of PYY analogues with rational substitutions to 
confer resistance to NEP 
Sequences of hPYY1-36, PYY3-36 (Arg30), PYY3-36 (Lys30), PYY3-36 (Asp29, Lys30). 
NEP is thought to cleave hPYY3-36 at the peptide bond between a and b (Medeiros and 
Turner, 1994a).  
2.1.3 Amino acid sequences of a PYY analogue with a conserved latrotoxin sequence 
PYY3-36  latroxtoin (LT) was synthesized which has six amino acids in common with LT 
(Holz and Habener, 1998) and tested in receptor binding assays, acute and chronic 
feeding studies and hypothalamic imaging studies. PYY3-36 (LT) also has four amino 
acids in common with exendin 4 at a similar position of the molecule (Holz and Habener, 
1998). 
 
 
Figure 2.3 Amino acid sequences of a PYY analogue with a conserved latrotoxin 
sequence 
Sequences of hPYY1-36, PYY3-36, PYY3-36 (LT) with a conserved latrotoxin sequence also 
found in the exendin 4 molecule (Holz and Habener, 1998).  
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2.2 Production of hY2 receptor overexpressing cell lines  
2.2.1 Preperation of hY2R cDNA 
The hY2R cDNA was purchased as an insert in pure plasmid (pCMV6-XL6) (Cambridge 
Bioscience, Cambridge UK). 10µg DNA was dissolved in 100µl ultra pure distilled water 
to obtain a DNA concentration of 0.1µg/µl and stored at -20C. 
2.2.2 Polyethylenimine (PEI) mediated stable transfection of hY2 receptor into 
human embryonic kidney (HEK) 293T cells 
In order to create a readily available source of the human Y2 receptor, the plasmid 
containing the DNA construct of the receptor was transfected into human embryonic 
kidney (HEK) 293T cells using PEI. PEI is a cationic polymer in which every third atom 
is an amine nitrogen residue. In the presence of 0.15M NaCl, PEI and DNA interact to 
form stable complexes which are taken up by endocytosis across the cellular plasma 
membrane (Abdallah et al., 1996).  
2.2.2.1  Method 
HEK 293T (ATCC-LGC Standards, Middlesex, UK) cells were cultured in Dulbecco’s 
modified minimum essential medium (DMEM) without sodium pyruvate containing 
4.5g/l Glucose (Invitrogen Ltd, Paisley, UK) supplemented with 10% Foetal bovine 
serum (FBS) (Invitrogen Ltd, Paisley, UK) and 1% 100IU/ml Penicilin and 100µg/ml 
Streptomycin (p/s) (Invitrogen Ltd, Paisley, UK). Medium was changed every 2-3 days 
and the cells sub-cultured when 70% confluent using non-enzymatic cell dissociation 
buffer (Sigma-Aldrich, Dorset, UK). Briefly, the medium was aspirated from the flask 
and 2ml/50cm2 flask surface area of room temperature non enzymatic cell dissociation 
buffer added. Cells were incubated at room temperature until they detached from the 
flask. Five ml fresh medium was then added to the flask and cells which were transferred 
into 30ml Sterilins (Sterilin Ltd, Caerphilly, UK) and were recovered by centrifugation at 
100g. The cells were resuspended in fresh medium and transferred into a new flask at a 
dilution of 1:5 and stored in a 370C 5% CO2 incubator.  
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2.2.3 Transfection of cells 
Twenty four hours prior to transfection, cells at passage number 8 were sub-cultured and 
plated at a density of 20 000 cells/60 mm plate (Invitrogen Ltd, Paisley, UK) in standard 
media. Transfections were carried out when the cells were 40% confluent.  
PEI/DNA complexes were made with PEI (average Mw ~ 25 000) (Sigma-Aldrich, 
Dorset, UK) according to the method described by (Abdallah et al., 1996). A 0.1M stock 
solution of 25kD PEI pH 7.0 was prepared and filtered through a 0.2µm filter prior to 
use. The plasmid DNA was prepared such that each plate was transfected with 2.2µg 
DNA in 150mM NaCl (the 150mM NaCl solution was also sterilised by passage through 
a 0.2µm filter). The cells were cotransfected with pCMV6-XL5-hY2 receptor + 
20ng/well pCMV6-Neo (plasmid containing neomycin resistance) (Invitrogen Ltd, 
Paisley, UK). The amount of PEI required was calculated according to the ratio of PEI 
amine nitrogen equivalents to DNA phosphate where 1µl of 0.1M PEI contains 100nmol 
amine nitrogen and 1µg DNA contains 3nmol DNA phosphate. Thus for 9 nitrogen 
equivalents 2.2µg DNA (6.6 nmol DNA phosphate) requires 59.4nmol amine nitrogen 
i.e. 0.594 µl of 0.1M PEI.  
Two 60mm plates were co-transfected with receptor plasmid and neo plasmid, and two 
plates were transfected with receptor plasmid only (controls). 0.1M PEI solution was 
slowly added to the DNA and NaCl solution, vortexed for 30 seconds, and allowed to 
stand at room temperature for 10 minutes before use. The PEI/DNA/NaCl mix was 
slowly pippetted in a dropwise manner to the cells and incubated for 3 hours at 370C, 5% 
CO2, after which media was removed and replaced with standard media (DMEM 
supplemented with 10% FBS and 1% antibiotic and cells maintained as previously 
described). Forty eight hours later, media was supplemented with 1mg/ml Geneticin 
(PAA labs, Somerset, UK), and media replaced every 48 hours with fresh Geneticin until 
all control cells were dead, approximately 10 days after the start of treatment. Remaining 
cells from each plate were then transferred to a T-10 flask (1 plate per flask) (Thermo-
scientific, Rokilde, Denmark), and then maintained as previously described.  
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2.3 Receptor binding studies 
Plasma membranes derived from HEK 293T cells stably transfected with the hY2 
receptor were prepared and binding assays performed as previously described (Dakin et 
al., 2001). 
2.3.1 Receptor purification 
The culture medium was removed and the cells detached from the flasks using ice-cold 
0.02M phosphate buffered saline (PBS) (Sigma-Aldrich, Dorset, UK) and scraping. A 
minimum of 30 T 175cm2 flasks (Thermo-scientific, Rokilde, Denmark) were used for a 
membrane preparation. Cells were centrifuged at 200g for 5 minutes at 40C (Sigma 
Laboratory Centrifuges 3, K18, rotor No. 19777-H), the supernatants discarded and the 
pellets resuspended in 5ml 0.02M ice-cold PBS and put onto ice. Cells were then added 
dropwise to spinning 20ml of ice-cold homogenization buffer (1mM HEPES pH7.4 
containing 10 µg/ml soybean trypsin inhibitor, 0.5µg/ml pepstatin, 0.5µg/ml antipain, 
0.5µg/ml leupeptin, 0.1mg/ml benzamide, and 1ml 100KIU/ml aprotinin (All from 
Sigma-Aldrich, Dorset, UK)) at 40C and left for 5mins. Cells were then centrifuged at 
1000g (Beckman J2-21 rotor JS-13.1) for 15 minutes at 40C. Supernatant was discarded 
and pellets were homogenized for 1minute with an Ultra Turax homogenizer (IKA Werke 
GmbH and Co. KG, Staufen, Germany). 20 ml homogenization buffer was then added 
(50mM HEPES solution) and cells were then centrifuged at 1000g (Beckman J2-21 rotor 
JS-13.1) for 15 minutes at 40C. Supernatant was collected and were centrifuged for 1 
hour at 40C 100000g (Sorvall OTD 55B ultra-centrifuge, DuPont). Supernatants were 
discarded and pellets resuspended in homogenization buffer (50mM HEPES solution) 
using a hand-held/Teflon homogenizer (Jencons Scientific Ltd, Bedfordshire, UK). 
Finally, aliquots of membrane were made to a final protein concentration of 1-2mg/ml 
and stored at -800C. Protein concentration was measured by biuret assay.  
2.3.2 Biuret Assay 
Protein concentrations of the membranes were assessed by the biuret method. A stock 
solution of 10mg/ml BSA (Sigma-Aldrich, Dorset, UK) was used to construct a standard 
curve (0, 1, 2, 3, 4, and 5 mg) of protein/500µl with distilled water. Typically 50-200µl of 
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membrane suspension was assayed, volumes adjusted to 500µl with distilled water and 
3ml biuret reagent (appendix I) was added to all tubes. The tubes were then incubated at 
1000C for 2 minutes. Samples were left at room temperature for 30 minutes before the 
absorbance at 540nm was measured in a spectophotometre (UV-160, Shimadzu, Kyoto, 
Japan). The absorbance values of the samples of membrane were converted to mg of 
protein by linear regression using the standard curve.  
2.3.3 Iodination of peptides 
2.3.3.1 The Bolton-Hunter method 
The Bolton and Hunter method (Bolton and Hunter, 1972) was used to iodinate PYY3-36. 
Thirty seven MBq (200µl) of Bolton and Hunter (BH) reagent (Amersham Biosciences, 
Buckinghamshire, UK) was dried under a gentle stream of nitrogen over approximately 1 
hour. PYY1-36 30 µg was dissolved in 50 µl of 0.14M sodium borate buffer pH 8.3 and 
added to the dry BH reagent. The reaction was allowed to proceed for 2 hours at room 
temperature and then stopped by addition of 1ml of 10% (vol/vol) can (Rathburn 
Chemicals Ltd, Walkerburn, Scotland)/water plus 0.05% (vol/vol) TFA (Rathburn 
Chemicals Ltd, Walkerburn, Scotland). Reaction products were purified by reverse phase 
high pressure liquid chromatography (HPLC) using a NovaPak C18 column (Millipore 
Ltd, Watford, UK). The column was equilibrated for 10 mins with 15% (vol/vol) can 
solution in water containing 0.05% (vol/vol) TFA, at a flow rate of 1ml/min before 
addition of the iodinated reaction mixture. The AcN concentration was maintained at 
20% for the first 10minutes and then increased to 45% AcN over the following 90 
minutes. Fractions were collected every 1.5 minutes into tubes containing 1ml 20mM 
HEPOS (pH 11) and 0.3% (vol/vol) BSA (MP Biomedicals Ltd, Cambridge, UK). The 
specific activity (SA) of the iodinated peptide was established by Radioimmunoassay 
(RIA).  
2.3.4 PYY RIA 
Iodinated PYY was measured using a specific and sensitive radioimmunoassay (Adrian et 
al., 1985a). The antiserum (Y21) was raised in rabbits against synthetic porcine PYY 
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(Bachem Ltd. UK) coupled to BSA by gluteraldehyde, and used at a final concentration 
of 1:50,000. The Y21 antibody to PYY did not cross react with pancreatic polypeptide, 
neuropeptide Y or other known gastrointestinal hormones. The assay was performed in a 
total volume of 700μl of 0.06M phosphate buffer with 0.3% BSA using 100μl sample 
volume. The sample was incubated for 3 days at 4°C before separation of free and 
antibody-bound label by secondary antibody (sheep anti-rabbit antibody). The assay 
detected changes of 2 pmol/L (95% confidence limits), with an intra-assay coefficient of 
5.8%. All samples were assayed in duplicate.  
2.3.5 PYY analogue receptor binding studies 
Cell membranes (200ng) from HEK 293T cells overexpressing hY2 receptor were used 
for these studies. Cell membrane was incubated for 90 minutes at room temperature in 
silianized polypropylene tubes (Sigma) with 125I-PYY1-36 (500 Bq:100pM) in binding 
buffer (25mM HEPES pH 7.4, 2mM MgCl2, 2mM CaCl2, 0.025% TWEEN 20 (Sigma-
Aldrich, Dorset, UK), 1% BSA (MP Biomedicals Ltd, Cambridge, UK), 4mM 
phenylmethanesulfonylfluoride (PMSF) (Sigma-Aldrich, Dorset, UK), 0.5mM diprotin A 
(Sigma-Aldrich, Dorset, UK), 0.5mM phosphoramidon (Sigma-Aldrich, Dorset, UK) in a 
final assay volume of 0.5ml. The receptor-125I-PYY1-36 complex was separated from free 
tracer by centrifugation at 15600g (Sigma Laboratory Centrifuges 3, K18 for 3 minutes at 
40C. The supernatant was removed and discarded and the pellet resuspended and washed 
with 500 µl fresh buffer and re-centrifugation. After centrifugation and removal of 
supernatant the bound label was measured using a γ-counter (NE 1600, NE Technology 
Ltd, Reading, Berkshire, UK). Specific binding was calculated as the difference between 
the amount of 125I-PYY1-36 peptide bound in the absence (total) and presence (non-
specific) of labeled peptide. For competition binding curves, membranes were incubated 
as above in the presence of increasing concentrations of unlabelled peptide and results 
expressed as % specific binding. All curves were performed with points in triplicate and 
each curve repeated with different membrane preperations unless stated. IC50 values 
were calculated using Prism (Version 5)(GraphPad Software Inc, CA, USA). 
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2.4 Neutral endopeptidase (NEP) protease assay  
125ul of (100 mM TRIS-HCl, pH 8) containing 2.5nmol of peptide was added to 200ng 
of recombinant human neprilysin-2 (R&D systems, Abingdon, UK) (dissolved in 20ul 
aliquots stored at -20C) and were incubated at 37oC for 4 hours according to optimized 
methods used by the Department of Investigative Medicine Imperial College London. 
2.5nmol of peptide dissolved in 145ul digest buffer alone without NEP was also 
incubated to serve as a negative control. The enzyme reaction was terminated by adding 
10µl of 10% trifluoracetic acid (TFA).  
2.4.1 Reverse phase high performance liquid chromatography (RP-HPLC) 
135ul of peptide solution was injected into a Jupitor C18 column (Phenomenex, 
Macclesfield, UK) and separated by RP-HPLC. The column was eluted with a linear 
gradient of 0.05% TFA (15-60% AcN over 50 min at 1 mL/min). Peptides and their 
degradation products were monitored by their absorbance at 214 nm.  Percentage 
degradation was quantified by integration of peak areas related to undigested peptide 
peaks and corrected for degradation in the absence of enzyme. 
2.5 In vivo studies 
2.5.1  Animals 
For acute feeding studies, C57BL/6 male mice (20-25g, Harlan, UK) were singly-housed 
and maintained under controlled conditions of temperature (21-23oC) and light (lights on 
at 0700, lights off at 1900) with ad libitum access to RM1 diet (Special Diet Services, 
Witham, UK). For chronic feeding studies, C57BL/6 male mice (20-25g, Harlan, UK) 
were singly-housed and maintained under controlled conditions of temperature (21-23oC) 
and light (lights on at 0700, lights off at 1900) with ad libitum access to a high fat diet 
(Special Diet Services, Witham, UK) until these animals became mildly obese (30-39g). 
All animal procedures undertaken were approved by the British Home Office Animals 
(Scientific Procedures) Act 1986 (Project Licence 70/6402 19b2). Animals were 
acclimatised to laboratory conditions for at least one week and handled daily prior to the 
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first study, during which time they received two subcutaneous injections of saline in 
order to minimize stress on the study days.   
2.5.1.1 Acute subcutaneous administration of hPYY3-36 and PYY analogues to investigate 
the effects on food intake in mice. 
For each study animals were fasted from 16:00 hrs the preceding day and bodyweights 
were recorded. Mice were then randomized into groups (n=7-10) with a 0.9% saline 
group used as a negative control and 50-500nmol/kg hPYY3-36 groups used as a positive 
control. The average bodyweights for each group were ensured to be within 0.8g of each 
other. All peptides were weighed out the previous day and stored at -20C overnight. On 
the morning of the study, peptides (50-500nmol/kg) were dissolved in 0.9% saline.  
Subcutaneous (s.c.) injections (100 μl) were administered in the early light phase (08:00-
09:00) via a 1ml syringe with a 28-gauge needle. Following injection, animals were 
returned to their home cages containing a pre-weighed amount of chow which was re-
weighed at 1, 2, 4, 8 and 24 hours post-injection.  
2.5.1.2 Chronic subcutaneous administration of hPYY3-36 and PYY3-36 (LT) to investigate 
the effects on food intake and bodyweight in diet induced obese mice. 
A chronic 28 day feeding study on mildly diet induced obese mice was designed. 
Bodyweights for day 0 of the study were measured at 0700. Mice were randomized into 3 
groups (n=7-10) with a 0.9% saline group used as a negative control and 500nmol/kg 
hPYY3-36 group used as a positive control, and a group receiving 500nmol/kg hPYY3-36 
(LT).  Subcutaneous injections were administered in the early dark phase (19:00-20:00) 
(day 0) via a 1ml syringe with a 28-gauge needle. Following injection, animals were 
returned to their home cages containing a pre-weighed amount of high fat diet which was 
re-weighed the next morning at 0700 as well as bodyweights (day 1). Animals were 
fasted after the morning reweighs until the beginning of the dark phase when they would 
receive their daily SC injection and another pre-weighed amount of high fat diet. The 
same was repeated for the next 27 days.   
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2.5.2  Statistical analysis 
Data are shown as mean and standard error of the mean. Food intake data from acute 
feeding studies was analysed by one-way ANOVA with Bonferroni’s post hoc test (Prism 
5). Food intake and bodyweight data from chronic feeding studies were analysed using 
generalized estimating equations (GEE) and the Mann-Whitney-U test in commercial 
statistical software (Stata 9.1, Statacorp, College Station, TX, USA). In all cases p ≤ 0.05 
was considered to be statistically significant.  
2.6 MEMRI  
2.6.1 Animals 
C57BL/6 male mice (20-29g, Harlan, UK) were singly-housed and maintained under 
controlled conditions of temperature (21-23oC) and light (lights on at 0700, lights off at 
1900) with ad libitum access to RM1 diet (Special Diet Services, Witham, UK). Two 
days before MEMRI scans animals were transferred to a dedicated housing facility 
adjacent to the MRI scanner where animals were acclimatised.  
2.6.2 MEMRI  Scans 
MEMRI scans were performed in accordance to the protocol of Itoh et al., 2007 (Itoh et., 
2007). Mice were anaesthetised using a 2.0% isofluorane-oxygen mixture for induction 
and 1.5% for maintenance (flow rate 1.0 L/min). For glutamate experiments mice 
received two intraperitoneal cannulations with 27G butterfly syringes.  The head was 
centrally located inside a quadrature mouse head coil with an internal diameter of 25mm 
(Magnetic Resonance Laboratories, Oxford, UK) and scanned in a 9.4T horizontal-bore 
MR scanner (Varian, CA, USA). A phantom, consisting of a glass tube containing 0.9% 
saline, was inserted into the head coil holder and scanned simultaneously with each 
animal. The phantom produces a clean, homogenous signal which can be used as a 
control for variation between the signal intensities of different slices. The lateral tail vein 
was cannulated with a 27G butterfly syringe. Intravenous (i.v.) infusion of MnCl2 via the 
tail vein commenced after 5 baseline MRI image acquisitions. Each mouse received 5μl/g 
body weight of 100mM MnCl2 (MnCl2·4H2O, Sigma-Aldrich, Dorset, UK) at a rate of 
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0.2 ml/25g body weight/h (syringe pump PHD 2000, Harvard Apparatus, MA, USA). 
The temperature of each individual mouse was monitored by insertion of a rectal 
temperature probe and maintained at 37 ± 0.5oC unless otherwise stated via a heating 
system (SA Instruments, Inc, NY, USA). All scans were started in the light phase (7am-
5pm).  
2.6.2.1 MRI scan parameters 
Spin-echo multi-slice T1-weighted sequence imaging was carried out with the following 
scanning parameters; repetition time (TR) = 1800 msec, echo time (TE) = 5.2 msec, 
matrix = 256 x 256, field of view (FOV) = 25 mm x 25 mm. The in-plane resolution of 
each voxel was approximately 100 microns. In each acquisition, 46 contiguous transverse 
slices of 0.4mm thickness were imaged giving a scan time of 1min 57sec. Five baseline 
acquisitions were performed prior to MnCl2 infusion followed by a further 63 
acquisitions. Total scanning time was approximately 2 hours.  
2.6.3 Study 1: The effects of varying temperature on Mn2+ uptake in the brain of 
adult mice as measured by T1-weighted MEMRI. 
MEMRI scans were performed on mice either held at room temperature (25 0C 
(n=5/group) or at 37 0C (n=5/group) during the scan.  
2.6.4 Study 2: The effects of fasting on Mn2+ uptake in the hypothalamus and 
brainstem of adult mice as measured by T1-weigthed MEMRI. 
MEMRI scans were performed on fasted mice (food removed 1600 the previous day) 
(n=5/group) or ad libitum fed mice (n=5/group). Both groups received s.c. saline (100µl) 
prior to anaesthesia.  
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2.6.5 Study 3: The effects of subcutaneous administration of pancreatic polypeptide 
(PP) on hypothalamic and brainstem neuronal activity as measured by T1-
weighted MEMRI.  
Fasted mice received a subcutaneous injection of 500nmol/kg PP (Bachem) (dissolved in 
100 μl 0.9% saline) (n=4) prior to anaesthesia and were then prepared as described in 
2.6.2. This dose was selected as it inhibits food intake in mice and matches the dose used 
for PYY3-36 in feeding studies and in the MEMRI studies described in 2.6.6.  
2.6.6 Study 4: The effects of subcutaneous administration of PYY3-36 and PYY3-
36 (LT) on Mn2+ uptake in the hypothalamus and brainstem of fasted 
adult mice as measured by T1-weighted MEMRI 
To test the possible differential effects on hypothalamic neuronal activation that s.c. 
saline, 500nmol/kg PYY3-36, and 500nmol/kg PYY3-36 (LT) have on fasted mice up to 8 
hours following treatment, MEMRI experiments were designed.  
Three animals were fasted from 16:00 hrs the preceding day. The next day, animals were 
weighed and each received s.c. injection of saline (100μl) administered in the early light 
phase (08:00-09:00) via a 1ml syringe with a 28-gauge needle. Following injection, the 
first animal was prepared for the MRI scan whilst the remaining two were returned to 
their cage without access to food. This animal was scanned from 30 minutes after s.c. 
injection for two hours. This represented the first timepoint (0.5 hours to 2.5 hours; t=1). 
The second animal was then scanned from 3 hours after s.c. injection for two hours. This 
represented the second timepoint (3 hours to 5 hours; t=2). The third animal was then 
scanned from 6 hours after s.c. injection for two hours. This represented the third 
timepoint (6 hours to 8 hours; t=3). The same was repeated in alternating days for PYY3-
36 and PYY3-36 (LT). In this way, three treatment groups were assessed for neuronal 
activation at three different timepoints after treatment to see if differences in neuronal 
activity at these timepoints correspond with the differences in feeding observed in acute 
feeding studies at these timepoints (Figure 2.4).  
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Figure 2.4 MEMRI experiments at different timepoints on fasted mice after 
receiving Saline, PYY3-36 or PYY3-36 (LT) 
Fasted mice were injected s.c. with either saline, PYY, or PYY (LT) and scanned 30 
minutes after the injection for two hours (t=1), 3hours after the injection for 2 hours (t=2) 
or 6 hours after the injection for two hours (t=3).  
2.6.7 Study 5: The effects of intraperitoneal administration of varying doses of MSG 
on Mn2+ uptake in the hypothalamus of adult mice as measured by T1-weighted 
MEMRI. 
Monosodium glutamate (Sigma-Aldrich, Dorset, UK) was prepared in 0.9% saline. 
MEMRI scans were performed on mice given bolous i.p. injections of MSG (100mg and 
300mg; 200μl) (n=5/group) or control (0.9% saline; 200μl) (n=5/group) after induction of 
anaesthesia. The 100mg dose of MSG has been demonstrated to ablate neurons in the 
ARC when administered peripherally to neonatal mice (Olney et al., 1969) and was 
expected to simply excite adult hypothalamic neurons rather than ablate them. The 
300mg dose of MSG was used to generate a dose-dependent effect and is closer to the 
dose that has been shown to ablate neurons in the ARC of adult mice (Walker and Lupien 
2000). Intraperitoneal injections of saline were given 20 minutes prior to baseline 
acquisitions and i.p. injections of MSG/saline were given at the start of baseline 
acquisitions according to the protocol of Itoh et al 2008. 
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2.6.8   Study 6: The effects of intraperitoneal administration of MSG and the 
ionotropic glutamate receptor antagonists MK-801 and NBQX on Mn2+ uptake 
in the hypothalamus of adult mice as measured by T1-weighted MEMRI 
MEMRI scans were performed on mice first given either bolous i.p. injections of the 
NMDA receptor antagonist MK-801 (Tocris Bioscience. Bristol, UK) (1mg prepared in 
200μl saline) (n=6/group) or the AMPA receptor antagonist NBQX (Tocris Bioscience. 
Bristol, UK) (1mg prepared with 0.9% saline and dissolved in a few drops of 1M NaOH 
and pH was adjusted to 7.4 with 1M HCl making a total volume of 200μl) (n=5/group), 
and then MSG (100mg) to ascertain whether any neuronal excitation observed from 
100mg MSG alone could be prevented with antagonist pretreatment. Doses of antagonist 
were given in accordance to those used by Itoh et al (Itoh et al., 2008). Intraperitoneal 
injections of antagonist/saline were given 20 minutes prior to baseline acquisitions and 
i.p. injections of agonist/saline were given at the start of baseline acquisitions according 
to the protocol of Itoh et al 2008.  
2.6.9 Study 7: The effects of intraperitoneal administration of varying doses of 
the ionotropic glutamate receptor agonists NMDA and AMPA on Mn2+ 
uptake in the hypothalamus of adult mice as measured by T1-weighted 
MEMRI. 
MEMRI scans were performed on mice given bolous i.p. injections of NMDA (Tocris 
Bioscience. Bristol, UK) (1mg and 10mg prepared in 200μl saline) or control (0.9% 
Saline) (n=4-5/group) and AMPA (Tocris Bioscience. Bristol, UK) (1mg and 5mg 
prepared with 0.9% saline and dissolved in a few drops of 1M NaOH and pH was 
adjusted to 7.4 with 1M HCl making a total volume of 200μl) (n=3-4/group). 
Intraperitoneal injections of saline were given 20 minutes prior to baseline acquisitions 
and i.p. injections of NMDA/AMPA were given at the start of baseline acquisitions 
according to the protocol of Itoh et al 2008. 
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2.6.10 Study 8: The effects of intraperitoneal administration of the NMDA 
receptor antagonist MK-801 and the AMPA receptor antagonist NBQX 
on Mn2+ uptake in the hypothalamus of adult mice as measured by T1-
weighted MEMRI. 
MEMRI scans were performed on mice given bolous i.p. injections of the NMDA 
receptor antagonist MK-801(1mg) or control (0.9% Saline) (n=5/group) and the AMPA 
receptor antagonist NBQX (1mg) (n=4/group). Intraperitoneal injections of MK-
801/NBQX were given 20 minutes prior to baseline acquisitions and i.p. injections of 
saline were given at the start of baseline acquisitions according to the protocol of Itoh et 
al 2008. 
2.6.11 Study 9: The effects of intraperitoneal MSG administration on blood brain 
barrier permeability shown though Evans Blue dye penetration into the adult 
mouse brain. 
Adult C57BL/6 mice were anaesthetized and prepared as above, and received a bolous 
i.p. injection of either saline (n=5) or 300mg monosodium glutamate (MSG) (n=4) 
followed 10 minutes later by an i.v. lateral tail vein infusion of 30mg/kg of Evans Blue 
dye (Han et al., 2002) (Sigma-Aldrich, Dorset, UK); 5μl/g body weight at a rate of 0.2 
ml/25g body weight/h (syringe pump PHD 2000, Harvard Apparatus, MA, USA) 
dissolved in 0.9% saline in order to assess BBB disruption. Temperature was maintained 
at 37 ± 0.5°C. Animals were sacrificed at 45min post infusion to coincide with the peak 
MEMRI SI; brains were removed and rapidly frozen in liquid nitrogen. Brains were 
mounted onto 25mm diameter Leica chucks using O.C.T. compound (V.W.R. 
International Ltd, West Sussex, U.K.) and 60 µm coronal slices of the hypothalamus were 
then obtained using a Leica CM1900 cryostat (Meyer Instruments Inc, TX, U.S.A)  and 
fixed on 25x75mm Superfrost Plus microscope slides (Thermoscientific, Rokilde, 
Denmark). Images were obtained using an Olympus SZX17 bright-field microscope 
(Olympus Ltd, Essex, UK) connected to an Olympus DP71 cooled CCD camera 
(Olympus Ltd, Essex, UK). Images were generated using cell^F software (Olympus Ltd, 
Essex, UK). 
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2.6.11.1 Image Analysis 
Image processing software (Image J 1.3.1, NIH, USA) was used to define and calculate 
the relative signal intensity (SI) within specific regions of interest (ROI) from T1-
weighted scan data. ROI corresponding to the arcuate nucleus (ARC), ventromedial 
hypothalamus (VMN), paraventricular nucleus (PVN), lateral ventricle (latV), and the 
area postrema (AP) were generated with reference to a standard mouse brain atlas 
(Franklin and Paxinos, 1997). These ROIs were selected on the basis that they have been 
shown to be regulated by nutritional status and gut hormone treatment (Parkinson et al., 
2009a).For glutamate experiments, the SCN was also chose because it is in close 
proximity to the median eminence where glutamate gains access to the brain and also 
because iGluRs are expressed in these regions of the mouse brain (O Hara et al 1995; Kia 
et al 2002). Cortical regions of interest were also taken based on the observation that 
MSG disrupts the blood brain barrier (McCAll et al., 1979).  
The changes in SI within these regions due to non-biological factors were corrected for 
by normalising the SI of each target area to that of the saline phantom at the same time 
point (SI target area/SI of phantom). In addition, to correct for slight variations in the 
time taken for the MnCl2 to enter the circulation, the first enhancing time point of each 
scan was defined as the acquisition in which the SI in the lateral ventricle was increased 
>20% over baseline. The acquisitions were then realigned so that the first enhancing 
acquisition was in register across all animals. Signal intensity profiles are illustrated as 
the normalised percentage enhancement (NPE), which is the percentage increase in 
baseline readings recorded 0-10min before manganese infusion normalised to the SI of 
the phantom.  
2.6.11.2 Statistical analysis 
All data are presented as mean ± sem. Differences in SI profile between the ROI in all 
experimental groups were analysed using generalized estimating equations (GEE) and the 
Mann-Whitney-U test in commercial statistical software (Stata 9.1, Statacorp, College 
Station, TX, USA). A p<0.05 was considered statistically significant.  
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2.7 PET-CT experiments on rats subjected to bariatric and sham surgery 
2.7.1 Animals 
Two groups of obese male Wistar rats were randomized to a gastric bypass operation 
(n=8) or sham operation (n=8). Rats were individually housed under a 12h / 12h light-
dark cycle and at a room temperature of 21 ± 2 ºC. Water and standard chow were 
available ad libitum.  All experiments were performed under a license issued by the 
Home Office UK (PL 70-6669). Body weight and food intake were measured daily. 
2.7.2 Surgery 
Surgery was performed according to an established protocol (Bueter et al., 2010a). 
Briefly, the proximal jejunum was divided 15 cm distal to the pylorus to create a 
biliopancreatic limb. After identification of the caecum, the ileum was then followed 
proximally to create a common channel of 25 cm. Here, a 7 mm side-to-side Jejuno-
Jejunostomy between the biliopancreatic limb and the common channel was performed. 
The gastric pouch and alimentary limb was anastomosed end-to side and the gastric 
remnant was closed. Sham-operations consisted out of a 7 mm gastrotomy on the anterior 
wall of the stomach with subsequent closure and a 7 mm jejunotomy with subsequent 
closure. Figure 2.5 shows a schematic illustration of the pre- and postoperative anatomy.  
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Figure 2.5 The Roux-en-Y gastric bypass procedure 
Diagrammatic representation of the gastrointestinal anatomy before (a) and after (b) the 
gastric bypass operation.(A) Biliopancreatic limb (~ 10 cm), (B) Alimentary limb (~50 
cm), (C) Common channel (~25 cm), (D) Caecum. 
 
 
 
 
 
 
 
 
98 
 
2.7.3 Body composition analysis using whole body 1H MR spectroscopy 
Whole body 1H MR spectroscopy for analysis of body composition was carried out on 
postoperative day 45. Animals were anaesthetised with a 2-4% isofluorane-oxygen mix 
maintained throughout the scan via a face-mask, and were scanned on a 4.7T Unity Inova 
MR Scanner (Varian Inc, CA, USA) using a Quad 72 linear whole body coil. 
Temperature and respiration was monitored throughout the scan using monitoring 
equipment (SA Instruments Inc, NY, USA) and animals were maintained at room 
temperature. 1H MR spectroscopy was performed using a single pulse sequence with a 
repetition time (TR) of 10 seconds, a pulse angle of 450, four averages and a spectral 
width of 20 000 Hz. The spectra were analyzed using MestRe-C (Santiago de 
Compostela, Spain). An exponential line broadening was applied, prior to phasing and 
baseline correction and peak integration of the water (reference at 4.7ppm) and lipid 
(reference at 1.2 ppm) were obtained. The whole body percentage adiposity was 
calculated using the following equation: %adiposity = 100x lipid integral/(lipid integral + 
water integral + (0.38xwater integral)). This equation takes into account the ratio of water 
to lean mass in the body which is 0.38. 
2.7.4 PET-CT imaging 
Two days before PET-CT scans animals were transferred to a dedicated housing facility 
adjacent to the PET-CT scanner where animals were acclimatised.  After an overnight 
fast, rats were anaesthetised with a 2-4% isofluorane-oxygen mix maintained throughout 
the scan via a face-mask. Temperature and respiration was measured throughout using 
BioVet software (BioVet Rev 03, m2m Imaging Corp, USA) and animals were 
maintained at 37C. Rats received an i.v. tail vein catheterization followed by i.p. 
administration of saline or the β-3 adrenergic receptor agonist CL316, 243 (1 mg/kg, 
Sigma Aldrich, Dorset, UK) half an hour before PET-CT scans. Studies were performed 
with a combined PET/CT preclinical scanner (Inveon Siemens Preclinical Solutions Inc, 
Munich, Germany). This system has been physically evaluated and characterized in the 
literature to produce PET images of high spatial resolution (1.5 mm FWHM at the centre) 
(Visser et al., 2009). The scanner has an axial length of 127 mm and a crystal ring 
diameter of 161 mm. The CT component of the scanner provides anatomical localization 
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in addition to correction for photon attenuation. For the scans the inveon acquisition 
workplace was used which provides a workflow mechanism where acquisitions required 
can be batched in one imaging session with minimal user intervention. A 3 bed-position 
CT scan was acquired for each animal study where the interscapular region was ensured 
to be in the imaging field of view. CT scanning was performed with a current of 500 µA 
and tube voltage of 80 kVp using 220 projections and an exposure time of 200 ms. An 
overlap of 20% was used between the sequential CT bed positions. For the PET scan 
following the CT scan, the animal bed was shifted to the PET ring of the machine where 
injection of tracer and data acquisition was accomplished. A single bolus i.v. injection of 
30-50 MBq 18F-FDG (PET-NET Solutions Ltd, Middlesex, UK) was injected via the 
lateral tail vein concomittent to the start of PET scanning. A one hour list mode data 
acquisition was used in all studies. Data was then histogrammed with a maximum ring 
difference of 79 and a span of 3. Image reconstruction was performed using Filtered 
backprojection after Fourier rebinding. The attenuation map obtained from the CT 
scanning was used to correct for photon attenuation with a matrix size of 128x128 and a 
pixel size of 0.796 mm.  
For image display, interpretation and quantitative analysis, the PET and CT images were 
loaded onto the inveon research workplace, a processing software program provided by 
the system manufacturer (Bao et al., 2009). Because of the inline nature of PET/CT scans 
acquired on this hybrid system, minimal user intervention was needed to co-register the 
two datasets (Visser et al., 2009). The standardised uptake value (SUV) was used to 
quantify the amount of tracer taken up by the region of interest corresponding to the 
interscapular brown adipose tissue. The equation used to calculate the SUV is as follows: 
SUV=average signal intensity (Mq/ml)/(injected dose(MBq)xweight of the animal 
(g)) 
2.7.5 Northern Blot analysis of UCP-1 mRNA content in brown adipose tissue 
The brown adipose tissue located in the interscapular region of the gastric bypass and 
sham-operated rats was harvested during necropsy on postoperative day 50, weighed and 
snap frozen in liquid nitrogen. Samples were stored at -80 °C until subsequent 
measurement of UCP1 mRNA content by Northern Blotting. A cDNA corresponding to 
100 
 
nucleotides 368-687 of the mouse uncoupling protein-1 (UCP1) (accession# BC012701) 
was generated from total BAT RNA by RT-PCR with the specific primers 5′-
AAGGCCAGGCTTCCAGTACTATTAGG-‘3 (forward) and ‘5- 
GGTTTGATCCCATGCAGATGGCTCTG-‘3 (reverse). Northern blot analysis was 
performed as described previously (Taheri et al., 2001). Total RNA was isolated from 
paired BAT using the single step guanidium thiocyanate/phenol/chloroform method. Fifty 
micrograms of total RNA from each sample was size separated on a denaturing 
MOPS/formaldehyde gel (1% agarose) and transferred to a Hybond-N membrane 
(Amersham International plc, Buckinghamshire, UK). The RNA was fixed by baking at 
80°C for 2 h before probing with a riboprobe corresponding to nucleotides 368-687 of the 
mouse uncoupling protein-1 (UCP1) (accession# BC012701). The riboprobe was 
synthesized using [[alpha]-32P]CTP (Amersham International plc, Buckinghamshire, 
UK) using T7 RNA polymerase (Promega, Southampton, UK). Hybridization was carried 
out overnight at 55°C in 5× standard saline citrate (SSC) (1× SSC contains 0.15 M 
sodium chloride; 15 mM sodium citrate); 5× Dernhardt's; 50% (w/v) deionized 
formamide; 100 µg/ml denatured sonicated herring sperm DNA and 100 µg/ml yeast 
tRNA with 1.5 MBq of labelled probe. Non-specific hybridization was removed by 
increasingly stringent washes, the final one in 0.1× SSC/0.1%(w/v) SDS at 70°C for 30 
min. 
The filters were exposed to storage phosphor screens (Molecular Dynamics, Amersham 
Sciences) and quantified using a Storm imaging system (Molecular Dynamics, 
Amersham Sciences). The ratio of specific message to 28S rRNA was used to quantify 
expression for each tissue sample. 
2.7.6 Statistics 
All data were normally distributed and are expressed as mean ± SEM. For the mouse 
studies PET-CT studies; one-way Anova with Bonferroni post-test was used to test for 
significant differences. For rat studies, student’s t-test for independent samples was used 
to test for significant differences apart from the bodyweight in which generalized 
estimate equation (GEE) was used. P<0.05 was considered significant. 
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3 Introduction 
3.1 PYY3-36 analogues as a novel treatment for obesity 
In the 70s and 80s the development of an antiobesity agent was relatively neglected by 
the pharamaceutical industry largely because obesity was thought to be a psychological 
problem (Cawthorne, 2007). However, given the recent huge surge in obesity coupled 
with the fact that it is now accepted as a disease state, numerous different laboratories are 
actively developing novel treatments.  
The development of a long-lasting PYY3-36 analogue represents a promising obesity 
therapy for numerous reasons. PYY3-36 is a natural hormone and does not cause the 
adverse side effects of other synthetic compounds such as rimonabant or sibrutamine. 
Peripheral administration of PYY3-36 suppresses food intake in various species including 
humans (Batterham and Bloom, 2003; Moran et al., 2005) and importantly obese 
individuals are not resistant to the effects of PYY3-36 on food intake (Batterham et al., 
2003b). A long-lasting GLP-1 analogue (liraglutide) has already successfully completed 
phase II clinical trials for the treatment of obeisty. This has two important implications; 
firstly that development of long-lasting gut hormones to treat obesity has already met 
with success. Secondly, if a long-lasting PYY3-36 analogue was produced, 
coadministration of this analogue with liraglutide could further reduce bodyweight. This 
is supported by the fact that coadministration of PYY3-36 and GLP-1 have additive effects 
on feeding in rodents (Neary et al., 2005). This would also more closely mimic the 
increased levels of PYY3-36 and GLP-1 after Roux-en-Y gastric bypass which is thought 
to mediate in part the dramatic loss of appetite and weight seen in these individuals (Le 
Roux et al., 2006a).  
The effects of PYY3-36 on food intake are transient and chronic studies on rodents have 
involved either the use of osmotic minipumps (Pittner et al., 2004; Vrang et al., 2006) or 
complex infusion paradigms to promote weight loss (Chelikani et al., 2006; Chelikani et 
al., 2007). Therefore, if PYY3-36 is to be used as a therapy for the treatment of obesity, 
prolonging its anorexigenic effect is necessary to prevent the need for repeated 
administration. This can possibly be achieved by various approaches. Increasing the 
affinity and efficacy of PYY3-36 at the Y2 receptor may result in the production of an 
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analogue with more potent and longer lasting effects on food intake. Preventing the 
degradation of PYY3-36 through rational amino acid substitutions may increase the half-
life of the peptide and prolong its effects on feeding. Lastly, incorporation of amino acid 
sequences found in other peptides which confer long-lasting inhibition of feeding into the 
PYY3-36 molecule, may also result in the generation of a long-lasting analogue.  
3.1.1 PYY3-36 dimers 
The Y family of receptors has been suggested to exist as dimers. First speculations of this 
came through the observations that dimeric forms of dual Y1 and Y2 receptor peptide 
antagonists bound to the Y1 and Y2 receptors with considerably higher affinity than the 
monomeric forms of the peptide antagonists (Daniels et al., 1995). Dimeric peptide 
agonists of the Y4 receptor have also been developed which potently decrease food 
intake (Balasubramaniam et al., 2006). These results suggest that binding of both receptor 
sites of dimeric Y1, Y2, and Y4 receptors may be required for receptor 
antagonism/activation. With this evidence in mind I characterised a PYY3-36 analogue 
(PYY2-26 (Cys2)) that forms a homodimer and investigated the Y2 receptor binding 
properties in vitro and its effects on feeding.  
3.1.2 Structure of PYY3-36 
The structure of avian PP was the first of the PP-fold family to be revealed through X-ray 
crystallography (Blundell et al., 1981) followed by the structures of porcine PYY (Keire 
et al., 2000) and human NPY (Darbon et al., 1992) both shown through nuclear magnetic 
resonance (NMR). The PP-fold family have a similar tertiary structure characterized by a 
polyproline helix, a β-turn, and then a α-helix; the so called PP-fold. For PYY1-36, several 
key hydrophobic interactions exist between the two helixes (Pro2-Tyr27, Pro5-Leu25, 
and Pro8-Tyr20) which are thought to stabilize the tertiary structure as revealed through 
NMR (Figure 3.1) (Nygaard et al., 2006). PYY3-36 has a less compact tertiary structure 
postulated to be due to the missing Pro2-Tyr27 interaction.  Therefore, I characterised a 
PYY3-36 analogue (PYY2-36) in which all characterized hydrophobic interactions would be 
maintained and one analogue (PYY2-36 (Cys2, Cys27)) with a covalent interaction 
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between the two helixes and investigated the Y2 receptor binding properties of these 
proposed more compact analogues in vitro and their effects on feeding. 
 
Figure 3.1 The more compact structure of PYY1-36 compared to PYY3-36 
Left: PYY 1-36, Middle: PYY 3-36, Right: diagram of PYY 1-36 showing characterised 
hydrophobic interactions. Residues 1-8 form a polyproline helix (Pro2, Pro5, and, Pro8 
marked in red), residues 9-13 form a β-turn and residues 14-32 form an α-helix. 
Hydrophobic interactions are thought to exist between Pro2 and Tyr27 (green), Pro5 and 
Leu25 (yellow), and Pro8 and Tyr20 (green).  Adapted from Nygaard et al., 2006. 
3.1.3 Metabolism of PYY3-36 
The half-life of PYY3-36 is only 3 minutes in mice (Shechter et al., 2005) and 9 minutes in 
man (Adrian et al., 1986). This short duration is due in part by the rapid breakdown of the 
peptide by membrane bound ectopeptidases expressed in the epithelial cells of the gut 
and kidney (Medeiros and Turner, 1994b). Neutral endopeptidase (NEP) is a membrane 
bound Zn2+ endopeptidase that was first identified in the kidney brush border of rabbits 
(Kerr and Kenny, 1974) and has been shown to cleave PYY3-36 at the Asn29-Leu30 site 
(Medeiros and Turner, 1994a). Neutral endopeptidase preferentially cleaves peptide 
bonds between hydrophobic/aromatic amino acids (Llorens et al., 1980). I therefore 
characterised analogues with substitutions of charged amino acids at positions 29 and 30 
(PYY3-36 (Lys30) and PYY3-36 (Asp29, Lys30)) and determined whether these analogues 
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are resistant to NEP mediated degradation in vitro, their binding properties to the Y2 
receptor in vitro, and whether they exhibited long-lasting actions on food intake.  
3.1.4 Incorporation of conserved amino acid sequences that confer long-lasting 
effects on feeding 
Central and peripheral administration of GLP-1 reduces food intake in rats (Turton et al., 
1996; Chelikani et al., 2005) and peripheral administration of GLP-1 also reduces food 
intake in humans (Flint et al., 1998). Exendin 4 is a biologically active peptide isolated 
from the saliva of the Gila monster heloderma suspectum with sequence homology to 
GLP-1 and binds to the GLP-1 receptor with similar affinity (Eng et al., 1992). Exendin-4 
has been shown to confer longer lasting inhibition of food intake than GLP-1 (Edwards et 
al., 2001). The longer lasting effects on food intake may be due to conserved amino acid 
sequences of the exendin 4 molecule. Indeed it has been reported that there is a four 
amino acid sequence in the mid-region of the exendin 4 molecule that shares homology 
with the peptide found in black widow spider venom α latrotoxin that is thought to confer 
longevity to peptides (Holz and Habener 1998). I thus decided to characterize a PYY3-36 
molecule (PYY3-36 (LT)) (Figure 3.2) that incorporated this amino acid sequence at a 
similar region of the molecule to GLP-1 and investigated its Y2 receptor binding affinity 
in vitro and effects on feeding. Importantly, assessment for the development of any 
symptoms of malaise administration of this peptide causes were performed through 
behavioural studies.  
 
Figure 3.2 The sequence homology of α latroxin, exendin 4, and PYY3-36 (LT). 
Amino acid sequences from the 970th – 976th amino acids of α latrotoxin, 17th - 23rd 
amino acids of exendin 4, and 16th - 22nd amino acids of PYY3-36 (LT). * In common with 
Latrotoxin and ^ in common with exendin 4 (Adapted from Holz and Habener 1998). 
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Aims: 
• To characterise PYY3-36 analogues designed with rational amino acid substitutions 
to confer long-lasting inhibition of feeding.  
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3.2 Results 
3.2.1 Dose-response feeding studies of subcutaneous administration of PYY3-36 
on fasted mice.   
The effects of peripheral administration of PYY3-36 on food intake were dose-dependent 
(Figure 3.3). Subcutaneous administration of 10nmol/kg PYY3-36 (n=7) to overnight 
fasted mice significantly inhibited food intake compared to saline (n=7) (p<0.001) up to 
the 0-1 hour interval (Figure 3.3A).  Subcutaneous administration of 50nmol/kg PYY3-36 
(n=7) to overnight fasted mice significantly inhibited food intake compared to saline 
(n=7) (p<0.01) up to the 1-2 hour interval (Figure 3.3B). Subcutaneous administration of 
500nmol/kg PYY3-36 (n=7) to overnight fasted mice significantly inhibited food intake 
compared to saline (n=7) (p<0.01) up to the 2-4 hour interval (Figure 3.3C). 
Subcutaneous administration of 1000nmol/kg PYY3-36 (n=7) to overnight fasted mice 
significantly inhibited food intake compared to saline (n=7) (p<0.05) up to the 4-8 hour 
interval (Figure 3.3D). Subcutaneous administration of 5000nmol/kg PYY3-36 (n=7) to 
overnight fasted mice significantly inhibited food intake compared to saline (n=7) 
(p<0.001) up to the 4-8 hour interval (Figure 3.3E). Subcutaneous administration of 10 
000nmol/kg PYY3-36 (n=7) to overnight fasted mice significantly inhibited food intake 
compared to saline (n=7) (p<0.001) up to the 8-24 hour interval (Figure 3.3F).  
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Figure 3.3 Dose-response feeding studies for PYY3-36 
Effects of s.c. administration of saline and A) 10nmol/kg PYY3-36, B) 50nmol/kg PYY3-
36, C) 500nmol/kg PYY3-36, D) 1000nmol/kg PYY3-36, E) 5000nmol/kg PYY3-36, and F) 
10000nmol/kg PYY3-36 on food intake in overnight fasted mice, at 0-1h, 1-2h, 2-4h, 4-8h, 
and 8-24h post injection. Results are expressed as mean ± SEM. (*=p<0.05, **=p<0.01, 
and ***= p<0.001 compared to saline as determined by Student’s t-test or one-way 
ANOVA with Bonferroni post-test; n=7 per group). 
 
 
 
B) A) 
C) D) 
E) F) 
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3.2.2 A PYY dimer PYY2-36 (Cys 2): the in vitro hY2 receptor binding properties 
and effects on food intake in fasted mice following subcutaneous 
administration.   
3.2.2.1 Receptor Binding 
PYY2-36 (Cys 2) bound to the hY2 receptor in vitro with an almost 2-fold lower affinity 
than hPYY3-36 with an IC50 of 0.36 ± 0.06nM compared to 0.16 ± 0.02nM for hPYY3-36 
(Figure 3.4).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Receptor binding assay for a PYY dimer; PYY2-36 (Cys2) 
Percentage (%) specific binding of hPYY3-36 (red line) and PYY2-36 (Cys 2) (black line) at 
the hY2 receptor. Increasing concentrations of unlabelled peptide were incubated in a 
fixed amount of 125I PYY1-36 and hY2 receptor membrane preparation. % specific binding 
was calculated as the difference between the amount of 125I PYY1-36 peptide bound in the 
presence of increasing concentrations of unlabelled peptide.  Mean IC50s and SEM were 
calculated from 3 independent assays. 
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3.2.2.2 Feeding studies 
Subcutaneous administration of 50nmol/kg PYY2-36 (Cys 2) (n=7) to overnight fasted 
mice significantly inhibited food intake compared to saline (n=7) (p<0.01) up to the 2-4 
hour interval but not compared to hPYY3-36 (n=7) (Figure 3.5). There was no significant 
difference between treatment groups beyond this time interval. 
 
 
 
Figure 3.5 Effects of a PYY3-36 dimer, PYY2-36 (Cys2), on food intake 
Effect of s.c. administration of saline, 50nmol/kg PYY3-36, or 50nmol/kg PYY2-36 (Cys 2) 
on food intake in overnight fasted mice, at 0-1h, 1-2h, and 2-4h post injection. Results are 
expressed as mean ± SEM. (*=p<0.05, **=p<0.01, and p=<0.001 compared to saline as 
determined by one way ANOVA with Bonferroni post-test; n=7 per group). 
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3.2.3 PYY analogues with proposed stabilized tertiary structures PYY2-36 and 
PYY2-36 (Cys2, Cys27): the in vitro hY2 receptor binding properties and 
effects on food intake in fasted mice following subcutaneous 
administration.   
3.2.3.1 Receptor binding 
PYY2-36 bound to the hY2 receptor in vitro with an IC50 of 0.19 ± 0.07nM (Figure 3.6). 
PYY2-36 (Cys2, Cys27) bound to the hY2 receptor with approximately 3 times lower 
affinity than hPYY3-36 with an IC50 of 0.46±0.01nM (Figure 3.6).  
 
 
Figure 3.6 Receptor binding assay for PYY analogues with stabilised tertiary 
structures; PYY2-36 and PYY2-36 (Cys2, Cys27) 
Percentage (%) specific binding of hPYY3-36 (red line), PYY2-36 (black line) and PYY2-36 
(Cys2, Cys27) (blue line) at the hY2 receptor. Increasing concentrations of unlabelled 
peptide were incubated in a fixed amount of 125I PYY1-36 and hY2 receptor membrane 
preparation. % specific binding was calculated as the difference between the amount of 
125I PYY1-36 peptide bound in the presence of increasing concentrations of unlabelled 
peptide. Mean IC50s and SEM were calculated from 3 independent assays. 
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3.2.3.2 Feeding studies 
3.2.3.2.1 PYY2-36 
Subcutaneous administration of 50nmol/kg PYY2-36 (n=7) to overnight fasted mice 
significantly decreased food intake at the 2-4h interval compared to saline (n=7) 
(p<0.001) and compared to hPYY3-36 (n=7) (p<0.05) (Figure 3.7A).  There was no 
significant difference between treatment groups beyond this time interval. 
3.2.3.2.2 PYY2-36 (Cys2, Cys27) 
 
Subcutaneous administration of 50nmol/kg PYY2-36 (Cys2, Cys27) (n=7) and hPYY3-36 
(n=7) to overnight fasted mice significantly decreased food intake compared to saline 
(n=7) up to the 1-2h interval (p<0.05 for PYY2-36 (Cys2, Cys27) vs saline and p<0.01 for 
hPYY3-36 vs saline) (Figure 3.7B) however there was no significant difference between 
the two treatment groups. There was no significant difference between treatment groups 
beyond this time interval. 
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Figure 3.7 Effects of PYY3-36 analogues, PYY2-36 and PYY2-36 (Cys2, Cys27), with 
proposed more stable tertiary structures on food intake. 
A) Effect of s.c. administration of saline, 50nmol/kg PYY3-36, or 50nmol/kg PYY2-36 on 
food intake in overnight fasted mice, at 0-1h, 1-2h, and 2-4h post injection. B) Effect of 
s.c. administration of saline, 50nmol/kg PYY3-36, or  PYY2-36 (Cys2, Cys27) on food 
intake in overnight fasted mice, at 0-1h, 1-2h, and 2-4h post injection.  Results are 
expressed as mean ± SEM. (*=p<0.05, **=p<0.01, and ***=p<0.001 compared to saline, 
^=p<0.05 compared to hPYY3-36 as determined by one way ANOVA with Bonferroni 
post-test; n=7 per group). 
 
B) 
A) 
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3.2.4 PYY analogues designed to be resistant to NEP degradation; PYY3-36 
(Lys30) and PYY3-36 (Asp29, Lys30): the in vitro degradation by NEP, in 
vitro hY2 receptor binding properties, and effects on food intake in fasted 
mice following subcutaneous administration.   
3.2.4.1 Receptor Binding 
PYY3-36 (Lys30) bound to the hY2 receptor with approximately two times higher affinity 
than hPYY3-36 with an IC50 of 0.09 ± 0.01nM. PYY3-36 (Asp29, Lys30) bound with 100 
times lower affinity than PYY3-36 to the hY2 receptor with an IC50 value of 10 ± 2.8nM 
(Figure 3.8). 
 
Figure 3.8 Receptor binding assay for analogues designed to be resistant to NEP; 
PYY3-36 (Lys30) and PYY3-36 (Asp29 Lys30) 
Percentage (%) specific binding of hPYY3-36 (red line), PYY3-36 (Lys30) (black line), and 
PYY3-36 (Asp29 Lys30) (green line) at the hY2 receptor. Increasing concentrations of 
unlabelled peptide were incubated in a fixed amount of 125I PYY1-36 and hY2R membrane 
preparation. % specific binding was calculated as the difference between the amount of 
125I PYY1-36 peptide bound in the presence of increasing concentrations of unlabelled 
peptide. Mean IC50s and SEM were calculated from 3 independent assays. 
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3.2.4.2 NEP degradation- in vitro digestion studies.  
Incubation of 2.5 nmol of hPYY3-36 with NEP (20ng) over 4 hours resulted in 23.4% 
degradation of parent peptide. PYY3-36 (Asp29, Lys30), and PYY3-36 (Lys30) were 
degraded by 19.9%, and 34.2% respectively when incubated with NEP (Figure 3.9). 
 
                                                              
                                          
 
 
 
 
 
 
 
Figure 3.9 NEP mediated degradation of PYY3-36 and analogues PYY3-36 (Lys30) 
and PYY3-36 (Asp29, Lys30) designed to be resistant to NEP 
Representative RP-HPLC absorption profiles following in vitro digestion of A) 2.5nmol 
of PYY3-36 B) 2.5nmol/kg PYY3-36 (Lys30) and C) 2.5nmol PYY3-36 (Asp29, Lys30) after 
incubation with 20ng recombinant human NEP for 4 hours at 37 0C. Digests were 
analysed by HPLC on a 15-45% water/AcN gradient over 30 minutes.  
 
C) 
B) A) 
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3.2.4.3 Feeding studies 
Subcutaneous administration of 50nmol/kg PYY3-36 (Lys30) (n=7) decreased food intake 
significantly compared to saline (n=7) up to the 2-4 hour interval (p<0.05) but not 
compared to 50nmol/kg hPYY3-36 (n=7) (Figure 3.10A).  There was no significant 
difference between treatment groups beyond this time interval. Subcutaneous 
administration of PYY3-36 (Asp29, Lys30) (n=7) to overnight fasted mice produced no 
significant effects in food intake compared to saline at any time interval (Figure 3.10B).  
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Figure 3.10 Effects of PYY3-36 analogues PYY3-36 (Lys30) and PYY3-36 (Asp29, 
Lys30) designed to be resistant to NEP on food intake. 
A) Effect of s.c. administration of saline, 50nmol/kg PYY3-36, or 50nmol/kg PYY3-36 
(Lys30) on food intake in overnight fasted mice, at 0-1h, 1-2h, and 2-4h post injection.  
B) Effect of s.c. administration of saline, 50nmol/kg PYY3-36, or 50nmol/kg PYY3-36 
(Asp29 Lys30) on cumulative food intake over 24 hours in overnight fasted mice. Results 
are expressed as mean ± SEM. (*=p<0.05 and ***=p<0.001 compared to saline as 
determined by one way ANOVA with Bonferroni post-test; n=7 per group). 
B) 
A) 
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3.2.5 A PYY analogue with a conserved latrotoxin sequence PYY3-36 (LT): the 
in vitro hY2 receptor binding properties and effects on food intake in 
fasted mice following subcutaneous administration.   
3.2.5.1 Receptor binding 
PYY3-36 (LT) bound to the hY2 receptor with approximately 2.5 times lower affinity than 
hPYY3-36 with an IC50 of 0.43 ± 0.02nM (Figure 3.11).  
 
 
 
 
 
Figure 3.11 Receptor binding assay for a PYY analogue with a conserved latrotoxin 
sequence; PYY3-36 (LT) 
Percentage (%) specific binding of hPYY3-36 (red line), PYY3-36 (LT) (black line) at the 
hY2R. Increasing concentrations of unlabelled peptide were incubated in a fixed amount 
of 125I PYY1-36 and hY2 receptor membrane preparation. % specific binding was 
calculated as the difference between the amount of 125I PYY1-36 peptide bound in the 
presence of increasing concentrations of unlabelled peptide.  Mean IC50s and SEM were 
calculated from 3 independent assays. 
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3.2.5.2 Acute feeding studies 
Subcutaneous administration of 50nmol/kg PYY3-36 (n=7) to overnight fasted mice 
significantly decreased food intake compared to saline (n=7) up to the 1-2 hour interval 
(p<0.001). Subcutaneous administration of 50nmol/kg PYY3-36 (LT) (n=7) to overnight 
fasted mice significantly decreased food intake compared to saline up to the 4-8 hour 
interval (p<0.05) (Figure 3.12A). There was no significant difference between treatment 
groups beyond this time interval.  
Since s.c. administration of 50nmol/kg PYY3-36 (LT) inhibited food intake up to the 4-8 
hour interval outlasting all the other peptides previously tested a higher dose was tested to 
ascertain any potential dose-responsive effect on feeding. Subcutaneous administration of 
500nmol/kg PYY3-36 (n=7) decreased food intake significantly compared to saline (n=7) 
up to the 2-4 hour interval (p<0.01). Subcutaneous administration of 500nmol/kg PYY3-36 
(LT) (n=7) decreased food intake significantly compared to saline up to the 8-24 hour 
interval (p<0.05) and also compared to PYY3-36 at this time interval (p<0.001). 
Furthermore, food intake at the 0-24 hour time interval was significantly less for mice 
receiving s.c. 500nmol/kg PYY3-36 (LT) compared to both saline (p<0.0001) and PYY3-36 
(p<0.0001) treated animals (Figure 3.12B).  
To rule out that the inhibition of feeding caused by 500nmol/kg PYY3-36 (LT) was due to 
malaise, a behavioural test was designed to compare it to the visceral toxin LiCl 
(Appendix IV). No malaise-like behaviour was observed with saline vehicle or 
500nmol/kg PYY3-36 (LT) but was observed with LiCl (Figure AIV).  
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Figure 3.12 Dose-responsive effects of PYY3-36 (LT) on food intake. 
A) Effect of s.c. administration of saline, 50nmol/kg PYY3-36, or 50nmol/kg PYY3-36 (LT) 
on food intake in overnight fasted mice, at 0-1h, 1-2h, 2-4h, and 4-8h post injection. B) 
Effect of s.c. administration of saline, 50nmol/kg PYY3-36, or 500nmol/kg PYY3-36 (LT) 
on food intake in overnight fasted mice, at 0-1h, 1-2h, 2-4h and 4-8h post injection.  
Results are expressed as mean ±SEM. (*=p<0.05, **=p<0.01, ***= p<0.001, compared 
to saline and ^^^= p<0.001 compared to PYY3-36 as determined by one way ANOVA 
with Bonferroni post-test; n=7 per group). 
A) 
B) 
 0-1 
   0-1 
 1-2    2-4    4-8 
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3.2.6 The effects of chronic once daily subcutaneous administration of hPYY3-
36 and PYY3-36 (LT) on food intake and bodyweight on diet induced obese 
mice  
Since PYY3-36 (LT) was the best performing peptide in acute feeding studies conducted 
on lean mice, a chronic study on diet induced obese (DIO) mice was performed to assess 
effects on feeding and bodyweight. There was no significant reduction in cumulative 
food intake between the saline (n=8) and the hPYY3-36 (n=8) treated animals over the 28 
day study period.  However, there was a sustained, significant reduction in the cumulative 
food intake of the PYY3-36 (LT) treated animals (n=8) compared to both saline and 
hPYY3-36  treated animals over the 28 day study period (p<0.001) (Figure 3.13A). Mann-
Whitney U tests revealed a significant reduction in cumulative food intake at every time 
interval between PYY3-36 (LT) treated animals (p<0.01) and saline treated controls. There 
was also an equally significant reduction in cumulative food intake from day 1 to day 12 
between PYY3-36 (LT) treated animals and hPYY3-36 animals but the level of significance 
decreased for the remainder of the study from day 13 (p<0.05) however significance at 
this level was maintained until completion of the study (Figure 3.13A). On day 1 of the 
study, s.c. injection of both 500nmol/kg hPYY3-36 and PYY3-36 (LT) significantly reduced 
food intake compared to saline treated controls at the 0-5hour time interval (p<0.05 and 
p<0.001 respectively) and 500nmol/kg PYY3-36 (LT) significantly reduced food intake 
compared to 500nmol/kg hPYY3-36 (p<0.01). On day 10 of the study, there were no 
significant differences in feeding caused by these peptides compared to saline controls 
(Figure 3.13B).  
There was no significant reduction in bodyweight between the saline and the hPYY3-36 
treated animals over the 28 day study period with both groups losing weight throughout 
the course of the study.  However, there was a sustained, significant reduction in 
bodyweight in the PYY3-36 (LT) treated animals compared to saline treated animals over 
the 28 day study period (p<0.05) (Figure 3.14A). Animals lost weight in the first 8 days 
of the study which then plateued for the remainder of the study. Mann-Whitney U tests 
revealed a significant reduction in bodyweight between PYY3-36 (LT) treated animals 
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(p<0.05) and saline treated controls from day 5 until completion of the study (Figure 
3.14A). 
Expressing bodyweight change as percentage lost from the initiation of the study and 
correcting for saline revealed a trend in bodyweight loss showing a persistant negative 
slope that did not plateau (Figure 3.14B). By day 28 of the study PYY3-36 (LT) treated 
animals lost 10.38 ± 2.09% of their bodyweight compared to saline treated controls.   
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Figure 3.13 The effect of chronic administration of hPYY3-36 and PYY3-36 (LT) on 
cummulative food intake in diet induced obese mice. 
A) The effect of chronic once daily s.c. administraiton of vehicle (blue) 500nmol/kg 
hPYY3-36 (red) and PYY3-36 (LT) (grey) on cummulative food intake in diet induced 
obese mice. Results are expressed as mean ± SEM. (*=p<0.05 and **=p<0.01 compared 
to saline and ^=p<0.05 and ^^=p<0.01 compared to hPYY3-36 as determined by GEE and 
Mann-Whitney U tests; n=8 per group). 
B) The effects of administration of saline (white), 500nmol/kg PYY3-36, and 500nmol/kg 
PYY3-36 (LT) on 5 hour food intake on day 1 of the study (left) and day 10 of the study 
(right). Results are expressed as mean ± SEM. (*=p<0.05, **=p<0.01, and ***=p<0.001 
compared to saline and ^=p<0.05 and ^^=p<0.01 compared to hPYY3-36 as determined by 
one way ANOVA with Bonferroni post-test; n=8 per group). 
A) 
B) 
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Figure 3.14 The effect of chronic administration of PYY3-36 and PYY3-36 (LT) on 
cummulative food intake and bodyweight in diet induced obese mice 
A) The effect of chronic once daily s.c. administration of vehicle (blue) 500nmol/kg 
hPYY3-36 (red) and PYY3-36 (LT) (grey) on bodyweight in diet induced obese mice  
B) The effect of chronic once daily s.c. administraiton of vehicle (blue) 500nmol/kg 
hPYY3-36 (red) and PYY3-36 (LT) (grey) on bodyweight (expressed as % change) 
normalized to saline in diet induced obese mice. Results are expressed as mean ± SEM. 
(*=p<0.05 and compared to saline as determined by GEE and Mann-Whitney U tests; 
n=8 per group). 
A) 
B) 
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3.3 Discussion 
The number of individuals in both the developed and underdeveloped world whom are 
obese has grown dramatically over the last half century (World Health Organization. 
Obesity: Preventing and Managing the Global Epidemic 2000). Mortality increases in 
proportion to BMI (Calle et al., 1999) and obesity is second only to smoking in 
preventable causes of death in the United States (Peeters et al., 2003). Current treatments 
result in only a mild weight loss when given over a 52 week period (Torgerson et al., 
2004; Padwel et al., 2003). Gut bypass procedures produce significant sustained weight 
loss (Sjostrom et al., 2004) but are reserved as a last line of treatment for the morbidly 
obese. Therefore, there is a great need to develop novel therapies for obesity. Gut 
hormones are promising therapeutic agents for the treatment of obesity (Field et al., 
2008). PYY3-36 is a gut hormone that has been shown to decrease food intake in various 
species (Batterham et al., 2002; Moran et al., 2005) and to promote weight loss when 
administered chronically to rodents (Pittner et al., 2004; Vrang et al., 2007; Chelikani et 
al., 2006; Chelkani et al., 2007). However, PYY3-36 has a short half-life in man (Adrian et 
al., 1986). Therefore, there is a need to develop long-lasting analogues that are either 
more potent at the Y2 receptor and/or that have longer half-lives in the plasma and can be 
administered less frequently, whilst maintaining stable plasma levels within the 
therapeutic window required to decrease food intake. I have characterised various PYY3-
36 analogues with rational amino acid substitutions and assessed their binding to the Y2 
receptor in vitro, their resistance to NEP in vitro, and their longevity in feeding studies 
compared to PYY3-36. I have revealed that the PYY3-36 dimer, PYY2-36 (Cys 2), and the 
cross-linked PYY analogue, PYY2-36 (Cys2, Cys27), both bind with similar affinity to the 
Y2 receptor as PYY3-36 and exert similar effects to PYY3-36 on food intake when 
administered peripherally to mice. I have also revealed that a PYY analogue with a 
proposed more stable tertiary structure, PYY2-36, bound with similar affinity to the Y2 
receptor as PYY3-36, and in feeding studies exhibited significantly longer lasting actions 
compared to PYY3-36. I have revealed that analogues with rational amino acid 
substitutions to confer resistance to NEP do not exhibit increased longevity in feeding 
studies and that position 29 of the PYY3-36 molecule is critical for PYY3-36 binding to the 
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Y2 receptor and the effects of the peptide on feeding. Moreover, I have characterised an 
analogue, PYY3-36 (LT), which significantly decreased food intake compared to PYY3-36 
in acute feeding studies and which significantly decreased cumulative food intake 
compared to PYY3-36 following once daily administration in a 28 day chronic feeding 
study.  
3.3.1 PYY dimer (PYY2-36 (Cys 2)) 
The development of a dimeric Y2 receptor peptide antagonist which bound to the Y2 
receptor with an affinity 20 times higher than NPY, first suggested that the Y2 receptor 
exists as a dimer (Daniels et al., 1995). The Y1, Y2, and Y5 receptors were shown to 
form homodimers in vitro (Dinger et al., 2003) as well as the Y4 receptor shown through 
bioilluminesence resonance energy transfer (BRET) (Berglund et al., 2003). I therefore 
characterised a PYY dimer, PYY2-36 (Cys 2), and tested its affinity to the Y2 receptor and 
its effects on food intake when administered peripherally. Surprisingly, in contrast to the 
finding of Daniels et al, in receptor binding assays PYY2-36 (Cys 2) bound with 
approximately a two-fold lower affinity to the Y2 receptor than PYY3-36. One potential 
explanation for this observation is that Daniels et al used 9 amino acid dimers whilst 
PYY2-36 (Cys 2) is a 35 amino acid dimer. Therefore, PYY2-36 (Cys 2) may not assume 
the correct orientation to bind to both binding sites of the Y2 receptor dimer with high 
affinity.  
In a recent study the Y2 receptor homodimer was shown to associate with two 
heterotrimeric G-proteins suggesting that binding of both receptor sites may result in 
greater signal transduction than occupation of one receptor site (Parker et al., 2008). The 
techniques I employed for my experiments could not reveal whether both receptor sites of 
the Y2 receptor were occupied by PYY2-36 (Cys 2). However, at least one receptor site 
must have been occupied as PYY2-36 (Cys 2) did display a similar bioefficacy in feeding 
studies.  It would be interesting to measure the efficacy of PYY2-36 (Cys 2) compared to 
PYY3-36 in vitro to test if there are any differences in activation of the Y2 receptor 
between monomeric ligands and dimeric ligands. This can be achieved with assays that 
measure intracellular cAMP levels following stimulation of adenylate cyclase with 
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forskolin (Seamon and Daly, 1981) and the inhibition of adenylate cyclase with Y2 
receptor agonists.  
3.3.2 PYY analogues with proposed stabilized tertiary structures: PYY2-36, and 
PYY2-36 (Cys2, Cys27) 
I next characterised analogues of PYY3-36 which had extended amino termini (PYY2-36, 
and PYY2-36 (Cys2, Cys27)). PYY2-36 was predicted to have a more stabilised tertiary 
structure according to the observations made by Nygaard et al (Nygaard et al., 2006). 
Using nuclear magnetic resonance (NMR) they demonstrated that the PYY1-36 molecule 
had a significantly greater number of long range intramolecular interactions compared to 
PYY3-36. This is a result of the Pro2-Tyr27 hydrophobic interaction in the PYY1-36 
molecule that is lost with PYY3-36 (Nygaad et al., 2006) due to cleavage of the first two 
amino acids by DPPIV (Grandt et al., 1994). Furthermore, substitution of Tyr27 to Ala 
decreases the binding affinity of PYY to the Y2 receptor 10 fold (Lindner et al., 2008) 
which could in part be due to loss of the hydrophobic interaction with Pro2. PYY2-36 
(Cys2, Cys27) was also designed to test whether a covalent interaction between amino 
acids at position 2 and position 27, which normally exhibit relatively weaker hydrophobic 
interactions, would improve the Y2 receptor binding and/or bioefficacy in vivo. 
The receptor binding assays revealed that PYY2-36 bound to the Y2 receptor with similar 
affinity to PYY3-36. On the other hand it has been shown by others that PYY2-36 binds to 
the Y1 receptor with significantly lower affinity than PYY1-36 (Thue Schwartz). This 
would sugget that PYY3-36 is a selective Y2 receptor agonist which is also the case for 
PYY3-36 (Gehlert et al., 1994). This is important as if affinity to the Y1 receptor was 
maintained, any anorexigenic effect caused by activating the Y2 receptor may be 
counteracted by activation of the Y1 receptor which normally results in a feeding 
response (Mullins et al., 2001).  
In feeding studies PYY2-36 displayed greater longevity than PYY3-36 decreasing food 
intake significantly compared to saline up to 2-4 hours and also significantly decreasing 
food intake compared to PYY3-36 itself. One potential explanation for this result is that 
PYY2-36 exhibits greater efficacy at the Y2 receptor and it would be interesting to test if 
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the efficacy of PYY2-36 at the Y2 receptor in vitro is greater than PYY3-36 with the system 
mentioned above. 
In receptor binding assays, PYY2-36 (Cys2, Cys27) bound to the Y2 receptor with 
approximately half the affinity of PYY3-36. In feeding studies, PYY2-36 (Cys2, Cys27) 
significantly decreased food intake compared to saline up to 1-2 hours similar to PYY3-36. 
This result reveals that PYY2-36 (Cys2, Cys27) retains biological activity and that 
permanently stabilising the PP-fold does not significantly affect the binding and efficacy 
of PYY at the Y2 receptor. This argues against the conclusions of Lerch et al whom 
reasoned that PYY3-36 does not assume the PP-fold when binding to the Y family of 
receptors (Lerch et al., 2004). Using NMR they demonstrated that the hydrophobic 
residues of the C-terminal α-helix of PYY embeds in lipid membranes, whilst the N 
terminal poly-proline helix freely diffuses in solution and they hypothesized that this is 
the state of the molecule when it binds to its receptors.  The lack of an available crystal 
structure of the Y2 receptor makes it difficult to gain insight into the sequence of events 
that takes place when the PYY3-36 molecule actually binds and then activates the Y2 
receptor, but the results with PYY2-36 (Cys2, Cys27) suggest that the amino and carboxy 
termini do not necessarily separate from one another for either of these processes.   
3.3.3 PYY3-36 analogues designed to be resistant to NEP mediated degradation 
I next characterised analogues with rational amino acid substitutions that according to 
published literature may be rendered resistant to NEP mediated degradation and which 
could potentially increase the half-life of PYY3-36. Medeiros et al described the 
breakdown of PYY3-36 by incubation with a brush border kidney preparation (Medeiros et 
al., 1994) known to contain NEP (Kerr and Kenny, 1974). PYY3-36 was degraded in this 
preparation which was prevented by the NEP inhibitor phospharamidon. These results 
were interpreted to suggest that NEP metabolizes PYY3-36 in the kidney brush border. It 
was then demonstrated through the use of mass spectrometry that the potential site of 
cleavage was at the Asn29-Leu30 peptide bond, both amino acids with neutral or 
hydrophobic qualities which are preferred cleavage sites for NEP (Llorens et al., 1980). 
Two analogues were designed; one with a positively charged amino acid residue at 
position 30 (PYY3-36 (Lys30)) and one with a negatively charged amino acid residue at 
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position 29 combined with Lys30, PYY3-36 (Asp29, Lys30), and were tested for binding 
to the Y2 receptor, resistance to NEP, and longevity in feeding studies.  
Surprisingly both PYY3-36 (Lys30) and PYY3-36 (Asp29, Lys30) were susceptible to 
degradation by human NEP. This was unexpected because as previously mentioned, NEP 
preferentially cleaves peptide bonds between hydrophobic or neutral amino acids 
(Llorens et al., 1980) and Lys is positively charged in physiological pH whilst Asp is 
negatively charged. This result is in contrast to those for Medeiros et al but may be 
explained in the differences in my techniques. Medeiros et al used the rat kidney brush 
border preperation whereas I used purified recombinant human NEP. It is possible that 
human NEP does not metabolise the peptide bond between Asn29-Leu30 and that other 
unidentified enzymes in the kidney brush border that are inhibited by phosphoramidon 
metabolises PYY3-36 at this site. NEP may therefore cleave PYY3-36 at other peptide 
bonds and this can be tested by analysing the breakdown products of PYY3-36 following 
incubation with human NEP by matrix assisted laser desorption ionization time of flight 
(MALDI-TOF) mass spectrometry.  
In receptor binding studies, PYY3-36 (Lys30) bound with approximately 1.75 times higher 
affinity to the Y2 receptor than PYY3-36, and PYY3-36 (Asp29, Lys30) bound with an 
affinity two orders of magnitude lower to the Y2 receptor than PYY3-36. The latter result 
suggests that substitution of Asn29 for Asp produces an analogue with drastically lower 
affinity to the Y2 receptor and Asn29 is necessary for high affinity binding to the Y2 
receptor.  
In feeding studies, PYY3-36 (Arg30) and PYY3-36 (Lys30) decreased food intake to a 
similar extent to PYY3-36. PYY3-36 (Asp29, Lys30) did not decrease food intake compared 
to saline at any time interval confirming that the anorexigenic effect of PYY3-36 requires 
the binding and activation of the Y2 receptor as PYY3-36 does not inhibit food intake in 
Y2 receptor KO mice (Batterham et al., 2002).  
 
 
130 
 
3.3.4 A PYY analogue with a conserved latrotoxin sequence 
Exendin 4 is a potent GLP-1 receptor agonist isolated from the saliva of the Gila monster 
heloderma suspectum (Eng et al., 1992). As exendin 4 has a glycine in position 2 it is 
rendered resistant to DPPIV and consequently has a longer half-life than GLP-1 (Young 
et al., 1999). However, the resistance to DPPIV may not account solely for the 
differences in biological activity between the peptides. A recent study revealed that ICV 
administration of exendin 4 is far more potent than ICV GLP-1 in reducing food intake 
and is not prevented by coadministration with a GLP-1 receptor antagonist (Barrera et al., 
2009). Therefore other aspects of the exendin molecule may account for the increased 
activity of the peptide such as binding to a unique receptor system. It has been reported 
that there is a four amino acid sequence in the mid-region of the exendin 4 molecule that 
shares homology with the peptide sequence found in the black widow spider venom α 
latrotoxin (Holz and Habener 1998). I characterized a PYY3-36 molecule with this 
sequence incorporated into the analogous region of the PYY3-36 molecule to generate 
PYY3-36 (LT). In feeding studies, 50nmol/kg PYY3-36 (LT) decreased feeding compared 
to saline up to the 4-8 hour time interval outlasting any of the other peptides tested. 
Increasing the dose to 500nmol/kg revealed an even greater anorexigenic effect that 
lasted up until the 8-24 hour time interval. This effect is equivalent to a 20 times higher 
dose than PYY3-36. The inhibition in feeding is unlikely to be accounted for in differences 
to binding to the Y2 receptor as receptor binding assays actually showed a slightly 
decreased affinity PYY3-36 (LT) compared to PYY3-36. The potent inhibition of feeding is 
also unlikely due to any visceral malaise caused by PYY3-36 (LT) as deduced by 
behavioural studies comparing it with the visceral toxin LiCl.  
PYY3-36 (LT) was then tested in a chronic feeding study in DIO mice and was shown to 
produce a sustained inhibition of cumulative food intake over the period of the 28 day 
study compared to saline treated controls and to PYY3-36. PYY3-36 on the other hand did 
not produce any significant inhibition in cumulative food intake. The acute inhibition of 
feeding produced by both peptides was seen in the first day with PYY3-36 (LT) inhibiting 
feeding significantly compared to PYY3-36. By the 10th day of the study however, the 
acute effect was lost suggesting a tolerance which often occurs with peptides. For 
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example, the early promise of using CCK as a treatment for obesity was significantly 
reduced when it was demonstrated that continuous administration led to tolerance 
(Crawley et al., 1983). Studies have revealed transient effects on food intake when PYY3-
36 is administered chronically (Vrang et al., 2006; Chelikani et al., 2006; Chelikani et al., 
2007). Since bodyweight decreases during PYY3-36 treatment, decreased leptin levels may 
explain this phenomenom. In a study conducted in rats, leptin levels were shown to 
decrease post osmotic minipump implantation of PYY3-36. Supplementing with leptin 
treatment extended the anorexigenic effects of PYY3-36 from 2 days to 6 days which was 
the duration of the study (Unniappan and Kieffer, 2008). Downregulation of receptors is 
also thought to be responsible in part for tolerance (Grady et al., 1997). Experiments have 
revealed a rapid internalization of the Y2 receptor expressed in human embryonic kidney 
(HEK) cells following prolonged exposure to NPY. This was shown through yellow 
fluorescent protein (YFP) tagged Y2 receptor which was initially localised to the cell 
membrane but then internalised to cytoplasmic compartments following continued 
presence of NPY (Lindner et al., 2009).  
There was an initial precipitous drop in bodyweight in all groups in the feeding study. 
This can be accounted for by the initial stress the animals experience by the injections. 
However, this drop was most pronounced for PYY3-36 (LT) and which can be explained 
for by the potent inhibition of feeding this peptide exerts at the initial phase of the study. 
Despite the fact animals developed a tolerance to the peptide, no rebound increase in 
feeding was observed at later phases of the study.  The decrease in bodyweight was only 
significant in the PYY3-36 (LT) treated groups for the duration of the study. When 
corrected for saline and expressed as percentage decreased a sustained loss of 10% BW 
was shown to be achieved with PYY3-36 (LT) which is the hallmark required in preclinical 
studies in Europe for the development of anti-obesity drugs (Cawthorne, 2007).  
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3.3.5 Future Studies 
PEGylation of PYY3-36 at its amino terminus dramatically increases its half life in vitro 
and in vivo (Schechter et al., 2005; Ortiz et al., 2007) and it would be interesting to test 
the effects of PEGylation of PYY3-36 (LT) on feeding. Having demonstrated effectiveness 
of PYY3-36 (LT) in mice, acute and chronic feeding studies need to be designed on other 
species such as rats and potentially clinical studies can be conducted on man. Important 
mechanistic studies need to be carried out. Plasma kinetic studies can reveal whether 
PYY3-36 (LT) has a longer half-life in the plasma compared to PYY3-36. Feeding studies 
on Y2 receptor deficient animals can be performed to assess whether PYY3-36 (LT) is 
working exclusively via the Y2 receptor similar to PYY3-36 (Batterham et al., 2002).  
Quantitative gene expression studies such as real time polymerase chain reaction (RT-
PCR) can be carried out to assess changes in the expression of oreixigenic and/or 
anorexigenic peptides in the hypothalamus. Metabolic cage studies can reveal whether 
changes in bodyweight can be attributed to any changes in energy expenditure. If so, the 
involvement of brown adipose tissue (BAT) can be confirmed with micro positron 
emission tomography computed tomograpy (PET-CT) and also by measuring uncoupling 
protein 1 (UCP1) protein levels in BAT.  
A long-lasting GLP-1 analogue (liraglutide) has also been developed which has been 
successful in reducing bodyweight in phase II clinical trials (Astrup et al., 2009). Since 
the acute effects on food intake of dual administration of PYY3-36 and GLP-1 are additive 
(Neary et al., 2005), the effects on food intake and bodyweight of coadministration of a 
long-lasting GLP-1 analogue with a long-lasting PYY3-36 analogue potentially would 
decrease bodyweight even further then either treatment alone. This would also mimic 
more closely the postprandial hormonal profile in patients after RYGB (Le Roux et al., 
2006a).  
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Chapter 4: 
MEMRI studies  
on the mouse brain  
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4 Introduction 
As discussed in the first chapter, the hypothalamus and brainstem are critically involved 
in energy homeostasis and circulating factors such as gut hormones and nutrients mediate 
their effects on appetite in part through interaction with these regions of the CNS. Having 
developed a long-lasting PYY3-36 analogue, I wanted to test whether peripheral 
administration of this peptide differentially influences hypothalamic and brainstem 
neuronal activity in vivo compared to PYY3-36 which may explain its greater longevity in 
feeding studies. Our laboratory have previously used manganese enhanced MRI 
(MEMRI) as a tool to reveal differences in hypothalamic and brainstem neuronal acivity 
in mice in response to nutritional interventions and gut hormone treatment (Kuo et al., 
2006; Kuo et al., 2007; Choudhri et al., 2008; Parkinson et al., 2009b). However, 
MEMRI experiments at lengthier time periods after gut hormone treatment have not been 
previously performed. I therefore performed MEMRI experiments on mice that have 
received s.c. injections of PYY3-36 and PYY3-36 (LT) and scanned them at various 
timepoints after peptide treatment to assess for differences in temporal patterns of 
neuronal activity. I also performed pharmacological experiments to assess whether 
MEMRI is capable of revealing specific receptor subtype activation or antagonism using 
the food additive monosodium glutamate (MSG) and the glutamate receptor system, 
which mediates the majority of excitatory neurotransmission in the CNS, as a model.   
4.1 Principles of MRI 
In 1946 Felix Bloch and Edward Percell discovered the phenomena of nuclear magnetic 
resonance. By using an external magnetic field, they exploited the magnetic moments 
intrinsic to elements with odd numbered nuclei. This magnetic moment is generated by 
the net spin of the protons of the nucleus which generates a current and an associated 
magnetic moment. These magnetic moments normally cancel each other out in a sample 
because their directions are random. However when placed in an external magnetic field, 
a net magnetization vector (NMV) is generated as most magnetic moments align with the 
external magnetic field (in the low-energy state) although a minority align against the 
external magnetic field (in the high-energy state). The NMV is however not totally in line 
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with the longitudinal plane due to the phenomenon of precession (Figure 4.1A). The 
frequency of the precession depends on the nucleus in question and the strength of the 
external magnetic field and is defined as the Larmour frequency. By using a 
radiofrequency (RF) coil to apply an additional 900 RF pulse equal to the Larmour 
frequency, the nuclei resonate in which the NMV is in line with the transverse plane due 
to the magnetic moments aligning with or against the external magnetic field in equal 
amounts (Figure 4.1B). The recovery/relaxation along the longitudinal plane is called T1 
recovery (spin lattice relaxation). The relaxation in the transverse plane or T2 recovery 
(spin-spin relaxation) consists of the de-phasing of individual precessing spins that 
combine to make the NMV (Figure 4.1C). The rate of T1 and T2 recoveries varies with 
the local chemical and physical nature of the specimen and as such, can be exploited to 
give contrast to the image. The dissipation of energy in the form of T1 and T2 recovery 
and decay within each voxel is recorded by the RF coil. This data is then interpreted and 
via complex Fourier transformation an MRI image is generated. 
 
 
 
Figure 4.1 The principles of MRI. 
(A) The net magnetization vector (NMV) precesses around the main magnetic field (B0) 
in the longitudinal plane. (B) Upon application of an RF pulse applied at 90° to the NMV 
and at the same precessional frequency, the absorption of the energy causes the NMV to 
flip into the transverse plane. (C) After the RF pulse, the NMV returns or ‘relaxes’ back 
to the original state. 
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In the 70s Pal Lauterbur performed the seminal but remarkably simple experiment that 
enabled NMR to image objects beyond the one dimensional plane (Lauterbur, 1973). He 
managed to achieve this by using two water filled cylinders and two magnetic fields of 
varying intensities. The magnetic gradient along the axis caused the water molecules of 
the separate cylinders to precess at a different larmour frequency. Thus varying RF pulses 
were required to cause the water molecules to resonate in the two cylinders and a 2D 
image was generated of the two cylinders.  Within a modern MRI scanner, three variable 
gradient magnets alter the magnetic fields along the x, y or z axes. The gradient magnets 
alter the main magnetic field on a precise level allowing “slicing” in any direction to take 
place within the sample. In each of these slices there are a predetermined number of 
voxels that contain a certain number of protons. Gradient magnets create a unique 
magnetic environment for each voxel and a like Lauterbur’s cylinders a unique Lamour 
frequency. Individual locations within a specimen can consequently be identified by the 
frequency or phase of the NMV precession, allowing the precise targeting of specific 
regions for imaging.  
The TR, or repetition time, is the elapsed time between successive RF excitation pulses. 
A short TR increases T1 effects whilst a long TR maximises T2 effects. So by adjusting 
the timing of RF pulses it is possible to weight the image so that the contrast in the MRI 
signal comes from the local differences in T1 or T2 within the specimen (Westbrook and 
Kaut Roth, 2005; Buxton, 2001). T1-weighted scans use a short TR and is optimized for 
fatty tissue for example adipose tissue or white matter in the brain. T2-weighted scans use 
a long TR and are optimized for water such as CSF in the ventricles of the brain or liquid 
accumulation in the lungs of patients suffering from oedema.   
4.2 Manganese-enhanced MRI (MEMRI) 
Manganese enhanced MRI (MEMRI) is an application of MRI that takes advantage of the 
paramagnetic properties of administered manganese (Mn2+) to generate contrast. The 
unpaired electrons of the Mn2+ ions alter the relaxation properties of protons in water 
which is evident in T1-weighted images (Mendonca-Dias et al., 1983). In fact, Lauterbur 
used MnCl2 solutions in his pioneering experiments to generate contrast (Lauterbur, 
1973). Due to the uptake of Mn2+ by neurons, which increases during neuronal activity, 
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and also the transport of Mn2+ along neurons, MEMRI has been successfully employed 
for the assessment of neuronal architecture, neuronal activity, and neuronal connectivity 
in vivo in various species however due to the toxicity of the Mn2+ ion, MEMRI has not 
yet been applied to human subjects (Parkinson et al., 2009a).  
4.2.1 Neuronal activity studies 
The Mn2+ ion is often referred to as a calcium (Ca2+) analogue. This is because L-type 
voltage gated Ca2+ channels are permeable to Mn2+ (Drapeau and Nachshen, 1984). Since 
voltage gated Ca2+ channels are activated during action potential firing of neurons, Mn2+ 
ions are thought to accumulate in neurons in proportion to neuronal activity which would 
be detected by MEMRI as increased signal intensity (SI). Consistent with this, neuronal 
activation caused by forepaw stimulation or systemic glutamate injection in rats with 
BBB disruption caused increased SI in T1-weighted images of the brain due to increased 
Mn2+ accumulation into neurons via voltage gated Ca2+ channels (Lin and Koretsky, 
1997). Conversely, systemic administration of the L-type calcium channel blocker 
diltiazem was shown to abolish the MEMRI signal generated in the somatosensory cortex 
of rats during forepaw stimulation due to decreased Mn2+ accumulation into neurons via 
voltage gated Ca2+ channels (Lu et al., 2007). MEMRI has since been used to assess 
neuronal activation following various pharmacological and physiological stimuli 
including mesolimbic activation following cocaine administration (Lu et al., 2007) and 
olfactory bulb activation following olfactory stimulation (Chuang et al., 2009b). These 
studies provide important information on the effects of various pharmacological and 
physiological interventions on the brain and enable researchers to perform preliminary 
analyses prior to human studies with other techniques used to assess neuronal activation.  
4.2.2 Other techniques used to assess neuronal activity 
There are various other techniques used to assess neuronal activity such as functional 
MRI (fMRI), Fos immunohistochemistry (IHC), and electrophysiology. MEMRI has 
been shown by several studies to correlate well with these techniques 
fMRI takes advantage of the paramagnetic properties of deoxyhaemoglobin which 
decreases contrast evident in T2-weighted images (Ogawa et al., 1990). It is thought that 
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as neurons become more active O2 consumption is increased which leads to a transient 
focal increase in deoxyhaemoglobin causing an ‘initial dip’ in SI in fMRI images. 
However, oxygenated blood soon follows (in the order of seconds) which increases the SI 
in active regions. This is known as the blood oxygenation level effect (BOLD) 
(Logothetis, 2008). Forepaw stimulation in rats reveals similar patterns of increased SI 
and BOLD signal in the somatosensory cortex in both MEMRI and fMRI images 
respectively (Duong et al., 2000). 
Immunohistochemistry for the nuclear protein Fos is used as a marker of neuronal 
activity due to the accumulation of Ca2+ by active neurons which results in the 
transcription of the c-fos gene (Sagar et al., 1988). Administration of hypertonic saline to 
rats induces Fos expression in neurons of the supraoptic nucleus (Kawasaki et al., 2005) 
and also increases SI in the same region in MEMRI scans (Morita et al., 2002).  
Patch clamp electrophysiology is the gold-standard technique for measuring neuronal 
activity which takes advantage of changes in membrane potential as anions and/or cations 
enter or exit a neuron (Hille, 2001). Bath application of ghrelin to hypothalamic slices 
stimulates neurons in the ARC as deduced by electrophysiological studies (Cawley et al., 
2003) and consistent with this peripheral administration of ghrelin to mice increases SI in 
the ARC (Kuo et al 2007). 
4.2.3 Strengths of MEMRI 
MEMRI has certain advantages over the other techniques used to assess neuronal activity 
and does not suffer from some of the disadvantages inherent in these techniques. 
The changes in SI in fMRI scans are due to changes in BOLD signal; the molecular and 
cellular basis of which is not fully understood (Attwell and Iadecola, 2002). Additionally 
changes in cerebral blood oxygenation can occur independent of changes in neuronal 
activity and provide false positives (Sirotin and Das, 2009). The study of neuronal 
activation in the hypothalamus, which is so important for the understanding of energy 
homeostasis, is difficult to assess using fMRI due to signal artifacts generated by 
significant air cavities in this region (Ojemann et al., 1997). However detailed studies of 
hypothalamic activation have been achieved with MEMRI (Parkinson 2009a). 
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Fos IHC also suffers from the drawbacks that neuronal activity doesn’t always result in 
Fos expression and Fos expression can be induced in the absence of neuronal activity 
(Hoffman and Lyo, 2002). Experiments assessing neuronal activity on fasted and fed 
mice have proved to be reproducible using MEMRI whilst Fos studies report no effects 
(Timofeeva and Richard, 2001), increases (Riediger et al., 2004), and decreases (Miller et 
al., 2004) in expression of Fos in response to the same intervention in the ARC. MEMRI 
also provides the advantage of measuring the duration and intensity of a stimulus in real 
time which is not achievable with Fos studies and is technically easier to perform. 
Electrophysiology provides unparralelled spatial and temporal resolution but most studies 
are conducted on brain slices in vitro. This means that many important neuronal 
connections may be severed in the process and therefore a true representation of what 
happens in vivo may be overlooked. In vivo electrophysiology techniques are in place but 
they are excessively invasive and deeper brain structures such as the hypothalamus are 
almost impossible to investigate. MEMRI provides the advantage that it is non-invasive 
unlike electrophysiology and allows the tracking of neuronal activity in real time albeit 
with less temporal and spatial resolution.  
4.2.4 Weaknesses of MEMRI 
MEMRI is a powerful tool that can track neuronal activity in vivo but is not without its 
disadvantages. One major drawback to MEMRI is that Mn2+ is toxic and chronic 
overexposure causes nigrostriatal degeneration with associated parkinsonian like 
symptoms in various species (Crossgrove and Zheng, 2004) which prevents the use of 
MEMRI in humans. However, recent exciting data provide optimism for the use of 
MEMRI in humans. It was shown in rats that peripheral administration of a clinical dose 
of an FDA approved Mn2+ based contrast agent, Telsascan (10μmol/kg), effectively 
revealed light adaptation in the outer retina that results in decreased Mn2+ accumulation 
during the day compared to the night (Tofts et al., 2010). 
Manganese does not readily cross the BBB and therefore only has limited access to the 
CNS (Yokel, 2009). Traditionally, detailed examination of brain activation with MEMRI 
has required disruption of the BBB with mannitol (Lin and Koretsky 1997; Morita et al., 
2002). These problems are being overcome with fractionated systemic Mn2+ infusion 
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paradigms with lower concentrations of Mn2+ that minimise toxicity and enable even 
distribution of Mn2+ in the brain (Bock et al., 2009; Gruenecker et al., 2010).  
Animals need to be anaesthetised during MEMRI scans which invariably influence 
neuronal activation (Franks, 2008) which has significant implications if one is trying to 
assess the effects on neuronal activation of various stimuli. Also, despite the higher 
spatial and temporal resolution more powerful magnets afford which is in the order of 2.5 
microns, MEMRI does not match the cellular resolution of Fos immunohistochemistry 
and electrophysiology and the submillisecond temporal resolution of electrophysiology.  
4.2.5 Methods of Mn2+ administration and mechanisms of transport in neurons 
Manganese can be administered as MnCl2 or Manganese Citrate and the Mn2+ ion is 
liberated when in aqueous solution. MEMRI studies have been conducted when MnCl2 is 
administered intravenously, intraperitoneally, or subcutaneously in mice with all forms of 
administration achieving high levels of contrast in the brain (Kuo et al., 2005). MEMRI 
studies have also been conducted following direct application of MnCl2 to the eye 
(Bearer et al., 2007), nose (Chuang et al., 2009b), or brain (Simmons et al., 2008). 
Manganese is mainly taken up by active neurons although there are reports of inactive 
neurons taking up Mn2+ such as in the retinal ganglion cells of blind mice (Bearer et al., 
2007). This may be due to divalent cation ion transporters such as Mn2+ uptake regulator 
or divalent metal transporter 1 (Yokel, 2009). Once inside the neuron, Mn2+ can remain 
unbound in the cytosol or bind to various organelles such as the endoplasmic reticulum or 
mitochondria. Indeed the binding of Mn2+ to larger molecules enhances its ability to 
increase SI (Kang and Gore, 1984). Manganese complexed with mitochondria can then 
travel in the retrograde direction toward the cell body by associating with dyneins 
(Hafezparast et al., 2003) or in the anterograde direction away from the cell body by 
associating with kinesins (Vale et al., 1985) (Figure 4.2).  
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Figure 4.2 Axonal Mn2+ uptake and transport. 
(1) Mn2+ ions enter the cell via L-type voltage gated Ca2+ channels. (2) After entry into 
the neuron Mn2+ enters the organelles such as mitochondria. (3) The Mn2+ is then 
transported along the axon via microtubules. (4) The Mn2+ is then released at the synaptic 
cleft and taken up by the next neuron in the circuit. 
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4.2.6 Neuronal architecture studies 
The neuronal architecture of the rodent brain has been assessed with MEMRI. Initial 
studies revealed that neuroarchitecture of the cortex and cerebellum of C57BL/6 mice 
compares well between MEMRI images and conventional brain atlases. In the same study 
a comparison between C57BL/6 mice and BALB/C mice with MEMRI revealed 
differences in neuroarchiture such as sizes of the ventricles and anatomy of the forebrain 
(Natt et al., 2002). A later study demonstrated that peripheral administration of MnCl2 to 
rats produced detailed images of the olfactory bulb layers, cortical layers in the frontal 
and somatosensory cortex, and the cerebellum (Aoki et al., 2004).  These studies reveal 
that MEMRI provides a non-invasive method of assessing neuronal architecture which 
potentially has applications in phenotyping and in assessment of disease states.  
4.2.7 Tract-tracing studies 
Due to the transport of Mn2+ through neurons, MEMRI has also been used as a tool to 
assess neuronal connectivity and neuronal tracts in various species. The optic nerve has 
been extensively studied since visual pathways are well understood. Interestingly, 
transport of Mn2+ along the axons of retinal ganglion cells following intravitreal MnCl2 
administration, does not require neuronal activity but across synapses onto second order 
neurons of the optic radiation requires neuronal activity (Bearer et al., 2007).  In the 
CNS, direct comparison has been made between the traditional retrograde neuronal tract 
tracer wheat germ agglutinin coupled with horse radish peroxidase and Mn2+ in macaque 
monkeys. Injections of both tracers into striatum revealed striatonigral and 
striatothalamic pathways (Saleem et al., 2002). These studies show that MEMRI 
compares well with a more traditional technique to study neuronal tracts and provides the 
advantage of being non-invasive. 
Since axonal transport of Mn2+ depends on functional Tau protein, MEMRI has been 
used effectively in assessing taupathies such as Alzeimers disease. In a mouse model of 
Alzheimers disease Mn2+ transport rate was significantly reduced from the nasal 
epithelium through olfactory sensory neurons to mitral cells in the olfactory bulb and 
finally third order neurons in the pirifrom cortex (Bertrand et al., 2010). These results 
also show that MEMRI can be used to assess neuropathologies in vivo.  
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4.2.8 MEMRI use in energy homeostasis 
Studies by our laboratory were performed to test whether nutritional status in an 
organism affects hypothalamic neuronal activity in vivo. The MEMRI experiments were 
conducted in fasted versus fed mice without BBB disruption. There was increased SI in 
the ARC, VMN, and PVN in the fasted animals compared to fed ones suggesting that 
neurons in these regions are more active following nutrient deprivation (Kuo et al., 2006). 
These patterns of Mn2+ uptake were then taken to be the signature of neuronal activation 
between fed and fasted states and studies on fed and fasted mice were then performed 
following peripheral administration of various gut peptides to ascertain if this profile of 
Mn2+ uptake can be modulated.  
Oxyntomodulin and GLP-1 are two peptide hormones released by the intestinal L-cell 
that inhibit food intake. Both are thought to bind to the GLP-1 receptor but interestingly 
seem to have different mechanisms of action. Oxyntomodulin works by interacting with 
ARC neurons (Dakin et al., 2001) whilst GLP-1 seems to work by interacting with PVN 
neurons (McMahon and Wellman, 1997). Consistent with this, MEMRI studies reveal 
that i.p. administration of oxyntomodulin to fasted mice specifically decreases the SI in 
the ARC to fed levels whilst i.p. administration of GLP-1 to fasted mice specifically 
decreases the SI in the PVN to fed levels (Chaudhri et al., 2006). The orexigenic peptide 
ghrelin induces Fos expression in NPY neurons of the ARC (Wang et al., 2002) and 
electrophysiological studies reveal that ghrelin increases the action potential firing of 
AgRP/NPY neurons (Cawley et al., 2003). Consistent with these findings, i.p. ghrelin to 
fed mice significantly increases MEMRI SI in the ARC to fasted levels in a dose 
dependent manner (Kuo et al., 2007). However, it must be noted that the modulation of 
MEMRI SI here is a result of the net change of neuronal activity of populations of 
neurons in the ARC. MEMRI does not afford the spatial resolution or the capacity to 
differentiate between neurons of different phenotypes. Based on the mentioned 
observations, it seems that the MEMRI signal in the ARC is driven to a greater extent by 
the activity of NPY/AgRP neurons rather than POMC/CART neurons although this 
remains to be formerly assessed.  
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4.2.9 MEMRI and Glutamate 
Glutamate is the major fast excitatory neurotransmitter in the brain and activates 
ionotropic glutamate receptors (iGluRs) which comprise NMDA receptors and 
AMPA/Kainate receptors and metabotropic glutamate receptors (mGluRs). The iGluRs 
differ in their pharmacological profiles and in their permeation properties (Figure 4.3) 
(Watkins and Jane, 2006). The NMDA receptor is Ca2+ permeable (Cull-Candy et al., 
2001) whilst AMPA/Kainate receptors are generally only permeable to monovalent 
cations (Cull-Candy et al., 2006). Due to the permeability of the NMDA receptor to Ca2+ 
it has been implicated in various physiological and pathophysiological processes such as 
memory formation and pain processing (Cull-Candy et al., 2006).    
Glutamatergic neuronal terminals are present throughout the rat hypothalamus (van den 
Pol, 1991) where glutamate receptors play a major role in neuroendocrine responses (van 
den Pol et al., 1990). For example, microinjection of AMPA into the PVN has been 
shown to cause oxytocin release from magnocellular neurons (Parker and Cowley, 1993) 
and peripheral and ICV administration of NMDA to mice causes gonadotrophin releasing 
hormone release via activation of neurons in the ARC and preoptic area respectively (de 
Tassigny et al., 2010). Ionotropic glutamate receptor subunits are abundantly expressed in 
various hypothalamic nuclei in the rat brain including the ARC, PVN, VMN, and SCN 
(van den Pol et al., 1994; Eyigor et al., 2001). In the mouse hypothalamus, iGluRs have 
also been shown to be expressed in the ARC, SCN, and VMN (Kia et al., 2002; O'Hara et 
al., 1995).  
NMDA receptors are permeable to Mn2+ (Mayer and Westbrook, 1987), and so it is 
reasonable to assume that activation of these receptors in vivo can be detected sensitively 
with MEMRI. Indeed peripheral administration of NMDA receptor agonists and 
antagonist to rats increases and decreases MEMRI SI in various regions of the brain 
respectively whilst AMPA receptor agonists and antagonists are without effect (Itoh et 
al., 2008). These results suggest that MEMRI is sensitive to pharmacological activation 
of NMDA receptors but not to AMPA receptors. 
 
 
145 
 
 
 
Figure 4.3 Schematic representation of AMPA receptors and NMDA receptors 
AMPA and NMDA receptors are multimeric ion channels comprised of GluR1-4 
subunits and NR1 and NR2A-D subunits respectively. A) Glutamate and AMPA activate 
AMPA receptors which results in permeation of Na+ and K+into neurons and resultant 
membrane depolarisation. Glutamate, NMDA, and glycine activate NMDA receptors 
which results in permeation of Ca2+ and Mn2+ into neurons and resultant membrane 
depolarisation. B) NBQX competitively antagonises AMPA receptors which results in 
the prevention of glutamate/AMPA induced receptor activation and Na+/K+influx into 
neurons and membrane depolarisation. MK-801 and Mg2+ non-competitively antagonise 
NMDA receptors thereby blocking Mn2+/Ca2+ influx into neurons and membrane 
depolarisation.  
A) 
B) 
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As mentioned in the first chapter, peripheral administration of the food additive 
monosodium glutamate (MSG) to neonatal animals ablates neurons in the ARC (Burde et 
al., 1971; Olney, 1969). This has also been demonstrated in adult mice (Lehmann and 
Jonsson, 1992). The neurodegeneration caused by MSG is thought to be due to 
accumulation of circulating glutamate in the ARC and excessive Ca2+ influx into neurons 
from direct NMDA receptor activation as it is prevented by an NMDA receptor 
antagonist but not an AMPA receptor antagonist (Lehmann and Jonsson, 1992; Olney et 
al., 1981). Therefore based on these observations, I hypothesized that MEMRI can reveal 
the excitatory effects of MSG on ARC neurons in vivo prior to neurodegeneration as 
increased SI in MEMRI images and that coadministration of an NMDA receptor 
antagonist would prevent this increase.  
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Aims of studies 
• To assess potential differences of peripheral administration of PYY3-36 and 
PYY3-36 (LT) on hypothalamic and brainstem neuronal activity at various 
timepoints after treatment through the use of MEMRI. 
• To demonstrate that MEMRI is capable of detecting receptor subtype 
specific activation through investigating the effects on the hypothalamus of 
peripheral administration of the food additive MSG alone and with 
glutamate receptor subtype specific antagonists.  
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4.3 Results 
4.3.1 Study 1: The effects of varying temperature on Mn2+ uptake in the brain 
of adult mice as measured by T1-weighted MEMRI. 
For the MEMRI experiments various regions of interest (ROIs) in the brainstem, 
hypothalamus, and cerebral cortex were selected. Figure 4.4 shows the differences in 
MEMRI SI pre and post MnCl2 infusion in these ROIs. 
When conducting pilot MEMRI studies, I realized that temperature is a key variable on 
MEMRI SI in the brain and its effects have not been investigated formally by our group. 
To assess the effects of temperature on Mn2+ uptake in the brain, mice were either 
scanned at room temperature (25 0C) or at 37 0C. Scanning mice at 37 0C (n=5) resulted 
in a significantly greater SI in the ARC (p<0.05), VMN (p<0.0001), and PVN (p<0.01) 
and a trend towards an increase in the lateral ventricle (p=0.054) (Figure 4.5A-F) 
compared to mice scanned at room temperature (n=5) in T1-weighted MEMRI images. 
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                                         Before MnCl2                              After MnCl2 
 
 
Figure 4.4 Transverse T1-weighted MEMRI images of the hindbrain and forebrain 
from representative saline treated mice scanned before and 90 minutes after MnCl2 
infusion. 
Regions of interest corresponding to the Area Postrema (A-B), Arcuate nucleus (ARC) 
and ventromedial nucleus (VMN) (C-D), the suprachiasmatic nucleus (SCN), 
paraventricular nucleus (PVN), lateral ventricle (L. Ventricle), sensory cortex (S. 
Cortex), and temporal cortex (T. Cortex) (E-F) before (A,C, and E) and after (B,D, and 
F) i.v. infusion of 100mM MnCl2. 
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Figure 4.5 T1-weighted MEMRI signal intensity profiles in anaesthetised adult mice 
scanned at room temperature and at 37 0C. 
Time course of normalised T1-weighted MEMRI SI change after i.v. 100mM MnCl2 
infusion recorded in the (A) ARC, (B) PVN, (C) VMN, and (D) Lateral Ventricle in 
anaesthetised adult mice scanned at room temperature (25 0C) (n=5) or 37 0C (n=5). NPE 
– normalised percentage enhancement. The arrow indicates the start of i.v. MnCl2 
infusion, the hatched bar indicates the duration of the i.v. infusion. ****= p<0.0001, 
**=p<0.01 and *=p<0.05. Statistical differences determined by GEE. Results are mean ± 
SEM.  
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4.3.2 Study 2: The effects of fasting on Mn2+ uptake in the hypothalamus and 
brainstem of adult mice as measured by T1-weigthed MEMRI. 
To confirm the reproducibility of the MEMRI technique, I performed scans in both fed 
and fasted states in order to assess changes in hypothalamic neuronal activation between 
nutritional states (Kuo et al., 2006). Fasting significantly increased the SI in the ARC 
(p<0.0001), VMN (p<0.01), and PVN (p<0.01) compared to fed animals (Figure 4.6 A-
C). There was also a significant increase in MEMRI SI in the lateral ventricle of fasted 
compared to fed animals (p<0.01) (Figure 4.6 D). However, there were no significant 
changes measured in the area postrema (p=0.654) (Figure 4.6 E).  
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Figure 4.6 T1-weighted MEMRI signal intensity profiles after s.c. administration of 
vehicle in ad libitum fed and fasted anaesthetised adult mice. 
Time course of normalised T1-weighted MEMRI SI change after i.v. MnCl2 infusion 
recorded in the (A) ARC, (B) PVN, (C) VVN, (D) Lateral Ventricle and (E) Area 
Postrema, in anaesthetised adult mice receiving s.c. injections of saline in ad libitum fed 
(n=5) or fasted conditions (n=5). NPE – normalised percentage enhancement. The arrow 
indicates the start of i.v. MnCl2 infusion, the hatched bar indicates the duration of the i.v. 
infusion. ****=p<0.0001 and **=p<0.01. Statistical differences determined by GEE. 
Results are mean ± SEM.  
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4.3.3 Study 3: The effects of subcutaneous administration of Pancreatic 
Polypeptide on Mn2+ uptake in the hypothalamus and brainstem of fasted 
adult mice as measured by T1-weighted MEMRI. 
Having demonstrated the reproducibility of the MEMRI technique, I wanted to determine 
whether the anorexigenic peptide and Y4 receptor agonist PP causes effects on 
hypothalamic and brainstem SI in fasted mice similar to other anorexigenic gut hormones 
(Chaudhri et al., 2006). Subcutaneous administration of 500nmol/kg PP to fasted mice 
(n=4) significantly reduced the SI in the ARC (p<0.01), VMN (p<0.0001) and PVN 
(p<0.05) compared to saline treated controls (n=5) (Figure 4.7 A-C). No significant 
differences were detected in the lateral ventricle (p=0.910) or area postrema (p=0.755).  
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Figure 4.7 T1-weighted MEMRI signal intensity profiles after s.c. administration of 
500nmol/kg PP or saline in anaesthetised fasted adult mice. 
Time course of normalised T1-weighted MEMRI SI change after i.v. MnCl2 infusion 
recorded in the (A) ARC, (B) PVN, (C) VMN, and (D) Lateral Ventricle, and (E) Area 
Postrema in anaesthetised fasted adult mice receiving s.c. injections of 500 nmol/kg PP 
(n=4) or saline (n=6). NPE – normalised percentage enhancement. The arrow indicates 
the start of i.v. MnCl2 infusion, the hatched bar indicates the duration of the i.v. infusion. 
****=p<0.0001, **=p<0.01 and *=p<0.05 vs saline control. Statistical differences 
determined by GEE. Results are mean ± SEM.  
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4.3.4 Study 4: The effects of subcutaneous administration of PYY3-36 and PYY3-
36 (LT) on Mn2+ uptake in the hypothalamus and brainstem of fasted 
adult mice as measured by T1-weighted MEMRI 
To determine whether the prolonged anorexigenic effect following s.c. administration of 
500nmol/kg PYY3-36 (LT) compared to 500nmol/kg PYY3-36 (Figure 3.12), is due to 
associated changes in hypothalamic and brainstem neuronal activity, fasted mice were 
injected with either saline, PYY3-36 or PYY3-36 (LT) and scanned for two hours 30 
minutes post-injection (t=1), 3 hours post-injection (t=2), or 6 hours post-injection (t=3). 
At t=1, there were no significant differences in SI in any of the ROIs between the groups 
(Table 4.1) (Figure 4.8A, D, and G). At t=2, there was a statistically significant decrease 
in SI in the ARC of animals treated with PYY3-36 (LT) compared to saline and PYY3-36 
treated animals (p<0.05) (Figure 4.8B). There was a trend towards a reduction in SI in the 
lateral ventricle (p=0.051) (Figure 4.9F) and PVN (p=0.052) (Figure 4.8H) with PYY3-36 
(LT) treated animals compared to saline treated controls (Table 4.1). There were no 
significant differences in any of the other ROIs between the groups (Table 4.1). At t=3, 
there were no significant differences in SI profile in any of the ROIs between the groups 
(Table 4.1) (Figure 4.8C, 4.8F, and 4.8I and Figure 4.9C and 4.9F). 
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Figure 4.8 T1-weighted MEMRI signal intensity profiles in the ARC, VMN, and 
PVN at various time intervals post subcutaneous administration of 500nmol/kg PYY 
3-36 (black), 500nmol/kg PYY 3-36 (LT) (red) or saline (grey) in anaesthetised adult 
mice. 
Time course of normalised T1-weighted MEMRI SI change after i.v. MnCl2 infusion 
recorded in A-C) the arcute nucleus (ARC), D-F) the ventromedial nucleus (VMN), and 
G-I) the paraventricular nucleus (PVN) in anaesthetised adult mice receiving s.c. 
injections of 500nmol/kg PYY 3-36 (n=4-6), PYY 3-36 (LT) (n=4-6), or saline (n=4-6). t=1, 
A), D), and G), represents the timepoint 30 mins after s.c. injection to 150 mins after s.c. 
injection. t=2, B), E), and H), represents the timepoint 2 hours after s.c. injection to 5 
hours after s.c. injection. t=3, C), F), and I), represents the timepoint 6 hours after s.c. 
injection to 8 hours after s.c. injection. 
NPE – normalised percentage enhancement, n.s.- not significant. The arrow indicates the 
start of i.v. MnCl2 infusion, the hatched bar indicates the duration of the i.v. infusion. 
*=p<0.05 vs saline and ^=p<0.05 vs 500nmol/kg PYY3-36. Statistical differences 
determined by GEE. Results are mean ± SEM.  
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Figure 4.9 T1-weighted MEMRI signal intensity profiles in the Area Postrema and 
lateral ventricle at various time intervals post subcutaneous administration of 
500nmol/kg PYY 3-36 (black), 500nmol/kg PYY 3-36 (LT) (red) or saline (grey) in 
anaesthetised adult mice. 
Time course of normalised T1-weighted MEMRI SI change after i.v. MnCl2 infusion 
recorded in A-C) the Area Postrema (AP) and D-F) the lateral ventricle in anaesthetised 
adult mice receiving s.c. injections of 500nmol/kg PYY 3-36 (n=4-6), PYY 3-36 (LT) (n=4-
6), or saline (n=4-6). t=1, A) and D), represents the timepoint 30 mins after s.c. injection 
to 150 mins after s.c. injection. t=2, B) and E) represents the timepoint 2 hours after s.c. 
injection to 5 hours after s.c. injection. t=3, C) and F), represents the timepoint 6 hours 
after s.c. injection to 8 hours after s.c. injection. 
NPE – normalised percentage enhancement, n.s - not significant. The arrow indicates the 
start of i.v. MnCl2 infusion, the hatched bar indicates the duration of the i.v. infusion. 
Statistical differences determined by GEE. Results are mean ± SEM.  
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 Region of Interest (ROI) 
t=1 ARC PVN VMN LV AP 
PYY3-36 vs Saline 0.325 0.796 0.946 0.832 0.457 
PYY3-36 (LT) vs Saline 0.213 0.334 0.528 0.106 0.175 
PYY3-36 (LT) vs PYY3-36 0.516 0.824 0.685 0.085 0.599 
t=2 ARC PVN VMN LV AP 
PYY3-36 vs Saline 0.677 0.405 0.09 0.604 0.547 
PYY3-36 (LT) vs Saline 0.035 0.053 0.176 0.051 0.818 
PYY3-36 (LT) vs PYY3-36 0.045 0.207 0.862 0.052 0.284 
t=3 ARC PVN VMN LV AP 
PYY3-36 vs Saline 0.253 0.527 0.372 0.508 0.933 
PYY3-36 (LT) vs Saline 0.405 0.092 0.870 0.897 0.507 
PYY3-36 (LT) vs PYY3-36 0.795 0.172 0.365 0.219 0.771 
 
Table 4.1 Comparison of p-values generated by generalised estimated equation for 
the various regions of interest in saline treated, PYY3-36 treated, and PYY3-36 (LT) 
treated mice at three different time intervals post injection. 
A statistical comparison of normalised T1-weighted MEMRI SI change after i.v. MnCl2 
infusion in fasted saline treated (n=4-6), 500nmol/kg PYY3-36 treated (n=4-6), and 
500nmol/kg PYY3-36 (LT) treated mice (n=4-6) recorded in the arcuate nucleus (ARC), 
paraventricular nucleus (PVN), ventromedial nucleus (VMN), (LV) Lateral Ventricle, 
and (AP) Area Postrema. t=1 is the timepoint 30 mins after s.c. injection to 150 mins 
after s.c. injection. t=2 is the timepoint 2 hours after s.c. injection to 5 hours after s.c. 
injection t=3 is the timepoint 6 hours after s.c. injection to 8 hours after s.c. injection 
The values represent p-values generated by GEE from statistical comparison of the SI 
profiles of all groups. 
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4.3.5 Study 5: The effects of intraperitoneal administration of varying doses of 
MSG on Mn2+ uptake in the hypothalamus of adult mice as measured by 
T1-weighted MEMRI. 
Having demonstrated the sensitivity of MEMRI to nutritional intervention and gut 
hormone treatment, I wanted to perform pharmacological experiments to assess whether 
MEMRI can detect receptor subtype activation. I performed these experiments with MSG 
which has a documented excitatory effect in the ARC (Olney et al., 1969) and which is 
thought to be due to activation of the NMDA receptor subytype (Olney et al., 1981). 
Intraperitoneal administration of MSG caused significant changes in SI in various ROIs. 
The higher dose of MSG caused an evident sharp increase in SI in the region 
corresponding to the entire cerebral cortex (Figure 4.10). This increase initially occurred 
at the base of the brain (the regions of the ARC and SCN) and then spread in a radial 
manner towards the superior saggital sinus. 
Intraperitoneal injection of 100mg MSG (n=5) caused a significant increase in SI in the 
ARC (p<0.01) (Figure 4.11A) and lateral ventricle (p<0.001) (Figure 4.11F) compared to 
saline treated controls (n=5), and caused a trend towards an increased SI in the SCN 
(p=0.07) (Figure 4.11B). There was no significant difference measured in the PVN, 
VMN, and temporal cortex (Table 4.2) (Figure 4.11C-E).  
Intraperitoneal injection of 300mg MSG (n=5) caused a significant increase in SI in the 
ARC (Figure 4.11A) (p<0.001), SCN (Figure 4.11B) (p<0.01), and lateral ventricle 
(Figure 4.11F) (p<0.001) compared to saline treated controls (n=5) but had no significant 
effect in the PVN and VMN (Table 4.2) (Figure 4.11C and Figure 4.11D). There was a 
significant increase in SI in the regions corresponding to the temporal cortex (p<0.0001) 
and somatosensory cortex (p<0.05) compared to saline treated controls (Figure 4.11E and 
4.11G). There was also a significant increase in SI compared to 100mg treated animals in 
the temporal (p<0.0001) and somatosensory cortices (p<0.05). There was a trend towards 
an increase compared to 100mg MSG treated animals in the ARC (p=0.09) and SCN 
(p=0.09).  
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Saline                  100mg MSG          300mg MSG 
 
Figure 4.10 Transverse T1 weighted MEMRI images of the forebrain from 
representative mice treated with varying doses of MSG. 
Mice treated with i.p. saline (A-E), 100mg MSG (F-J), and 300mg MSG (K-O) 0, 30, 
60, 90, and 120 mins after the start of manganese infusion. ARC: Arcuate nucleus, VMN: 
Ventromedial hypothalamic nucleus, Ph.: Phantom. 
 t=120 mins 
t=90 mins 
 t=60 mins 
 t=30 mins 
   t=0 mins 
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Ph 
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Figure 4.11 T1-weighted MEMRI signal intensity profiles after i.p. administration of 
100mg MSG, 300mg MSG, or vehicle in anaesthetised adult mice 
Time course of normalised T1-weighted MEMRI SI change after i.v. 100mM MnCl2 
infusion recorded in the (A) ARC, (B) SCN, (C) PVN, (D) VMN, (E) T Cortex, (F) 
Lateral Ventricle, and (G) S Cortex in anaesthetised adult mice receiving i.p. injections of 
100mg MSG (n=5), 300mg MSG (n=5), or vehicle control (n=5).NPE – normalised 
percentage enhancement. The arrow indicates the start of i.v. MnCl2 infusion, the hatched 
bar indicates the duration of the i.v. infusion. ****= p<0.0001, *** = p<0.001,** = 
p<0.01, and * = p<0.05 vs. control; ^^^^= p<0.0001, ^^^ = p<0.001,^^ = p<0.01, and ^ = 
p<0.05 vs. 100mg MSG. Statistical differences determined by GEE. Results are mean ± 
SEM. 
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 Region of Interest (ROI) 
 ARC PVN VMN Ventricle SCN T.C S.C 
100mg MSG vs 
Saline 
0.001 0.878 0.165 0.0001 0.064 0.798 0.973 
300mg MSG vs 
Saline 
0.002 0.894 0.116 0.0001 0.006 <0.0001 0.014 
100mg MSG vs 
300mg MSG 
0.090 0.743 0.372 0.988 0.090 <0.0001 0.234 
 
Table 4.2 Comparison of changes in signal intensity over time by GEE in saline 
treated and MSG treated mice. 
A statistical comparison of normalised T1-weighted MEMRI SI change after i.v. MnCl2 
infusion in fasted saline treated (n=5), 100mg MSG treated (n=5), and 300mg MSG 
treated mice (n=5) recorded in the ARC, PVN, VMN, Lateral Ventricle, SCN, temporal 
cortex, and somatosensory cortex. The values represent p-values generated by GEE from 
statistical comparison of the SI profiles of all groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
163 
 
4.3.6 Study 6: The effects of intraperitoneal administration of MSG and the 
AMPA receptor antagonist NBQX upon Mn2+ uptake in the 
hypothalamus of adult mice as measured by T1-weighted MEMRI 
Intraperitoneal injection of 1mg of the AMPA receptor antagonist NBQX prior to i.p. 
injection of 100mg MSG (n=5) caused a significant increase in SI observed in the SCN 
(p<0.05) (Figure 4.12B) and lateral ventricle (p<0.05) (Figure 4.12F) compared to saline 
treated animals (n=5). There was a significant decrease in MEMRI SI in the VMN 
(p<0.05) and PVN (p<0.05) (Figure 4.12D and Figure 4.12C). There was no significant 
effect observed in the remaining ROIs between the groups (Table 4.3).  
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Figure 4.12 T1-weighted MEMRI signal intensity profiles after i.p. administration of 
1mg NBQX followed by 100mg MSG or vehicle in anaesthetised adult mice 
Time course of normalised T1-weighted MEMRI SI change after i.v. MnCl2 infusion 
recorded in the (A) ARC, (B) SCN, (C) PVN, (D) VMN, (E) Cortex, (F) Lateral 
Ventricle in anaesthetised adult mice receiving i.p. injections of 1mg NBQX followed by 
100mg MSG (n=5) or vehicle control (n=5). NPE – normalised percentage enhancement. 
The arrow indicates the start of i.v. MnCl2 infusion, the hatched bar indicates the duration 
of the i.v. infusion. **** =p<0.0001, *** = p<0.001, **p<0.01, *=p<0.05 vs. control and 
*=p<0.05 vs. 100mg MSG. Statistical differences determined by GEE. Results are mean 
± SEM. 
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 Region of Interest (ROI) 
 ARC PVN VMN Ventricle SCN T.C 
100mg MSG + 
1mg NBQX vs 
Saline 
0.660 0.100 0.046 0.023 0.016 0.402 
100mg MSG + 
1mg NBQX vs 
100mg MSG 
0.127 0.031 0.224 0.290 0.576 0.492 
 
Table 4.3 Comparison of changes in signal intensity over time by GEE in saline 
treated and dual treated NBQX and MSG mice. 
A statistical comparison of normalised T1-weighted MEMRI SI change after i.v. MnCl2 
infusion in fasted saline treated (n=5), 100mg MSG treated (n=5), and 100mg MSG and 
1mg NBQX treated mice (n=5) recorded in the ARC, PVN, VMN, Lateral Ventricle, 
SCN, and temporal cortex. The values represent p-values generated by GEE from 
statistical comparison of the SI profiles of all groups. 
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4.3.7 Study 7: The effects of intraperitoneal administration of varying doses of 
the ionotropic glutamate receptor agonists NMDA and AMPA on Mn2+ 
uptake in the hypothalamus of adult mice as measured by T1-weighted 
MEMRI. 
Intraperitoneal injection of 1mg NMDA (n=4) did not cause any significant changes in SI 
in any of the ROIs (Figure 4.13A-F) compared to saline treated controls (n=5) (Table 
4.4). Intraperitoneal injection of 10mg NMDA (n=5) caused significant increases in SI in 
the ARC (p<0.0001) (Figure 4.13A) and lateral ventricle (p<0.0001) (Figure 4.13F) 
compared to saline treated controls (n=5) and an increase in the lateral ventricle 
compared to 1mg NMDA (p<0.001) (Figure 4.13F). There were no significant effects 
seen in the PVN, VMN, and cortex between the two treatment groups (Table 4.4) (Figure 
4.13C, 4.13D, and 4.13E).  
Intraperitoneal injection of 1mg AMPA (n=4) caused an increase in SI in the ARC 
(p<0.0001) (Figure 4.14A), SCN (p<0.05) (Figure 4.14B), and lateral ventricle (p<0.001) 
(Figure 4.13F). There were no significant effects seen in the PVN, VMN, and cortex 
(Table 4.5) (Figure 4.14C, 4.14D, and 4.14E). Intraperitoneal injection of 5mg AMPA 
(n=3) caused significant increases in SI in the ARC (p<0.0001) (Figure 4.14A), SCN 
(p<0.01) (Figure 4.14B) and lateral ventricle (p<0.05) (Figure 4.14F) compared to saline 
treated controls (n=5) and an increase in the ARC compared to 1mg AMPA (p<0.01) 
(Figure 4.14A). There were no significant effects seen in the PVN, VMN, and cortex 
(Figure 4.14C, 4.14D, and 4.14E).  
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Figure 4.13 T1-weighted MEMRI signal intensity profiles after peripheral 
administration of 1mg NMDA, 10mg NMDA or vehicle in adult mice 
Time course of normalised T1-weighted MEMRI SI change after i.v. MnCl2 infusion 
recorded in the (A) ARC, (B) SCN, (C) PVN, (D) VMN, (E) Cortex, and (F) Lateral 
Ventricle in adult mice receiving i.p. injections of 1mg NMDA, 10mg NMDA or vehicle 
control (n=4-5/group). NPE – normalised percentage enhancement. The arrow indicates 
the start of i.v. MnCl2 infusion, the hatched bar indicates the duration of the i.v. infusion. 
****p<0.0001, *** = p<0.001, **p<0.01, *p<0.05 vs. control and ^^^ = p<0.001 vs 1mg 
NMDA. Statistical differences determined by GEE. Results are mean ± sem.  
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 Region of Interest (ROI) 
 ARC PVN VMN Ventricle SCN T.C 
1mg NMDA vs 
Saline 
0.566 0.876 0.073 0.823 0.536 0.287 
10mg NMDA vs 
Saline 
<0.0001 0.700 0.244 <0.0001 0.152 0.801 
1mg NMDA vs 
10mg NMDA 
0.119 0.588 0.652 0.0004 0.831 0.366 
 
Table 4.4 Comparison of changes in signal intensity over time by GEE in saline 
treated and NMDA treated mice. 
A statistical comparison of normalised T1-weighted MEMRI SI change after i.v. MnCl2 
infusion in fasted saline treated (n=5), 1mg NMDA treated (n=4), and 10mg NMDA 
treated mice (n=5) recorded in the ARC, PVN, VMN, Lateral Ventricle, SCN, and 
temporal cortex. The values represent p-values generated by GEE from statistical 
comparison of the SI profiles of all groups. 
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Figure 4.14 T1-weighted MEMRI signal intensity profiles after peripheral 
administration of 1mg AMPA, 5mg AMPA, or vehicle in adult mice 
Time course of normalised T1-weighted MEMRI SI change after i.v. MnCl2 infusion 
recorded in the (A) ARC, (B) SCN, (C) PVN, (D) VMN, (E) Cortex, and (F) Lateral 
Ventricle in adult mice receiving i.p. injections of 1mg AMPA, 5mg AMPA or vehicle 
control (n=3-5/group). NPE – normalised percentage enhancement. The arrow indicates 
the start of i.v. MnCl2 infusion, the hatched bar indicates the duration of the i.v. infusion. 
****p<0.0001, *** = p<0.001, ** = p<0.01, * = p<0.05 vs. control; ^^^^p<0.0001, ^^^ = 
p<0.001, ^^ = p<0.01, ^ = p<0.05 vs. 1mg AMPA. Statistical differences determined by 
GEE. Results are mean ± SEM.  
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 Region of Interest (ROI) 
 ARC PVN VMN Ventricle SCN T.C 
1mg AMPA vs 
Saline 
<0.0001 0.716 0.330 0.0002 0.041 0.684 
5mg AMPA vs 
Saline 
<0.0001 0.815 0.729 0.014 0.001 0.974 
1mg AMPA vs 
5mg AMPA 
0.004 0.960 0.733 0.093 0.700 0.579 
 
Table 4.5 Comparison of changes in signal intensity over time by GEE in saline 
treated and AMPA treated mice. 
A statistical comparison of normalised T1-weighted MEMRI SI change after i.v. MnCl2 
infusion in fasted saline treated (n=5), 1mg AMPA treated (n=5), and 5mg AMPA treated 
mice (n=3) recorded in the ARC, PVN, VMN, Lateral Ventricle, SCN, and temporal 
cortex. The values represent p-values generated by GEE from statistical comparison of 
the SI profiles of all groups. 
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4.3.8 Study 8: The effects of intraperitoneal administration of the NMDA 
receptor antagonist MK-801 and the AMPA receptor antagonist NBQX 
on Mn2+ uptake in the hypothalamus of adult mice as measured by T1-
weighted MEMRI. 
Intraperitoneal injection of 1mg MK-801 (n=5) significantly reduced the SI in the cortex 
(p<0.05) (Figure 4.15E) and PVN (p<0.05) (Figure 4.15C). There were no significant 
effects measured in the other ROIs (Table 4.6).  
Intraperitoneal injection of 1mg NBQX (n=4) caused significant increases in SI in the 
ARC (p<0.0001) (Figure 4.16A) and lateral ventricle (p<0.001) (Figure 4.16F) compared 
to saline treated controls (n=5). There were no significant effects measured in the other 
ROIs (Table 4.6).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
172 
 
 
 
Figure 4.15 T1-weighted MEMRI signal intensity profiles after peripheral 
administration of 1mg MK-801 or vehicle in adult mice 
Time course of normalised T1-weighted MEMRI SI change after i.v. MnCl2 infusion 
recorded in the (A) ARC, (B) SCN, (C) PVN, (D) VMN, (E) Cortex, and (F) Lateral 
Ventricle in adult mice receiving i.p. injections of 1mg MK-801 (n=5) or vehicle control 
(n=5). NPE – normalised percentage enhancement. The arrow indicates the start of i.v. 
MnCl2 infusion, the hatched bar indicates the duration of the i.v. infusion. *=p<0.05 vs 
control. Statistical differences determined by GEE. Results are mean ± SEM.  
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Figure 4.16 T1-weighted MEMRI signal intensity profiles after peripheral 
administration of 1mg NBQX or vehicle in adult mice 
Time course of normalised T1-weighted MEMRI SI change after i.v. MnCl2 infusion 
recorded in the (A) ARC, (B) SCN, (C) PVN, (D) VMN, (E) Cortex, and (F) Lateral 
Ventricle in adult mice receiving i.p. injections of 1mg NBQX (n=4) or vehicle control 
(n=5). NPE – normalised percentage enhancement. The arrow indicates the start of i.v. 
MnCl2 infusion, the hatched bar indicates the duration of the i.v. infusion. ****p<0.0001 
and *** = p<0.001 vs. control. Statistical differences determined by GEE. Results are 
mean ± SEM.  
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 Region of Interest (ROI) 
 ARC PVN VMN Ventricle SCN T.C 
1mg MK-801 vs 
Saline 
0.875 0.046 0.259 0.329 0.259 0.021 
1mg NBQX vs 
Saline 
<0.0001 0.924 0.187 0.0002 0.315 0.683 
 
Table 4.6 Comparison of changes in signal intensity over time by GEE in saline 
treated 1mg MK-801 treated, and 1mg NBQX treated mice. 
A statistical comparison of normalised T1-weighted MEMRI SI change after i.v. MnCl2 
infusion in fasted saline treated (n=5), 1mg MK-801 treated (n=5), and 1mg NBQX 
treated mice (n=4) recorded in the ARC, PVN, VMN, Lateral Ventricle, SCN, and 
temporal cortex. The values represent p-values generated by GEE from statistical 
comparison of the SI profiles of all groups. 
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4.3.9 Study 9: The effects of intraperitoneal MSG administration on blood 
brain barrier permeability shown though Evans Blue dye penetration into 
the adult mouse brain. 
The massive increase in SI in cortical regions observed by MEMRI following 300mg 
MSG treatement may be explained by BBB disruption. To test this possibility, mice were 
treated with either 300mg MSG (n=5) or saline vehicile (n=4) and received an 
intravenous injection of Evans Blue dye. Coronal sections of the brain that matched those 
analysed from the MEMRI scans revealed that there was no difference in Evans Blue dye 
penetration across the BBB between saline or MSG injected animals (Figure 4.17).   
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Figure 4.17 The effects of intraperitoneal injection of glutamate on BBB 
permeability in adult C57BL/6 mice. 
Coronal brain sections of mice treated with either i.p. vehicle control A) or 300mg MSG 
B) and intravenous infusion of 30mg/kg Evans Blue dye.   
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4.4 Discussion 
MEMRI has been used effectively for the study of neuronal architecture, neuronal 
activity, and neuronal tract tracing in various species in vivo (Parkinson et al., 2009a). 
The aims of the present experiments were to test whether PYY3-36 and PYY3-36 (LT) 
exhibited differential temporal effects on hypothalamic and brainstem neuronal activity 
and whether MEMRI is capable of detecting receptor subtype activation using MSG and 
the glutamate receptor system. Various striking observations were made that both 
strongly suggested that MEMRI is a sensitive tool to track neuronal activity in vivo but 
that also revealed significant limitations of the MEMRI technique as discussed below.  
4.4.1 The effects of varying temperature on Mn2+ uptake in the brain of adult 
mice as measured by T1-weighted MEMRI. 
In the initial set of experiments, I observed that scanning mice at 37 0C resulted in 
significantly increased MEMRI SI throughout the hypothalamus but with most 
pronounced effects in deeper nuclei such as the VMN and the PVN compared to animals 
scanned at room temperature. Interestingly, there were no significant differences 
observed in the lateral ventricle between mice scanned at 37 0C and at room temperature. 
These results suggest that Mn2+ transport inside the brain rather than to the brain is 
affected by temperature. Mn2+ accumulates in neurons in part via permeation through L-
type voltage gated Ca2+ channels. Indeed the magnitude of Ca2+ conductances through 
these channels is dramatically influenced by temperature and this is likely the case also 
for Mn2+. Also, Mn2+ is believed to be actively transported once inside neurons (Pautler 
and Koretsky, 2002) possibly by the molecular motors which comprise the dyneins and 
the kinesins (Shea and Flannigan, 2001). Increasing the temperature is likely to increase 
the kinetics of these molecules such that Mn2+ transport in neurons is more rapid. The net 
result of increased uptake of Mn2+ by neurons and transport across neuronal tracts would 
likely account for the widespread increase in SI observed.  These results highlight the 
importance of measuring temperature during MEMRI experiments so that results from 
different studies can be compared accurately. Performing scans at 37 0C is desirable since 
Mn2+ concentrations in the brain are much higher which allows for active neurons to take 
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up more of the paramagnetic agent and hence enable changes in neuronal activity to be 
measured with more sensitivity. 
4.4.2 The effects of fasting on Mn2+ uptake in the hypothalamus and brainstem 
of adult mice as measured by T1-weighted MEMRI. 
Previous MEMRI studies conducted in our laboratory have demonstrated that feeding 
states regulate MEMRI SI in the hypothalamus. Fasting increases MEMRI SI in the 
ARC, VMN, and PVN compared to the fed (Kuo et al., 2006; Kuo et al., 2007). The 
region-specific changes in hypothalamic neuronal activity during the transition from a 
fasted to fed state are likely to be a composite of various post-prandial events. These 
include corresponding changes in circulating gut hormone levels, expression of 
hypothalamic neuropeptides and a number of post-prandial processes, such as vagal 
stimulation induced by gastric distension, gastric emptying and gastric acid secretion 
(Parkinson et al., 2009a). I confirmed that fasting increases the SI in the ARC, VMN, and 
PVN compared to fed animals. This demonstrates the reproducibility of the MEMRI 
technique when it comes to this behavioural intervention which has been difficult to 
attain with Fos studies. However, the increase in the ventricles I observed following 
fasting have not been observed previously and are difficult to explain.  
4.4.3 The effects of peripheral administration of pancreatic polypeptide on 
Mn2+uptake in the hypothalamus and brainstem of fasted adult mice as 
measured by T1-weighted MEMRI.  
I also tested whether the anorexigenic hormone PP influences MEMRI SI in the 
hypothalamus and brainstem. I found that s.c administration of 500nmol/kg PP 
significantly reduces the SI in the ARC as well as the VMN and PVN in fasted mice back 
to the fed state. The observations in the ARC are consistent with in vitro 
electrophyisiolgical studies on mouse ARC neurons which showed that PP decreased 
Ca2+ channel conductances and inhibited neuronal action potential firing frequency via 
activation of the Y4 receptor (Acuna-Goycolea et al., 2005). These results along with 
those obtained from the electophysiological and MEMRI studies with ghrelin show that 
there is reproducibility with the two techniques used to assess neuronal activity. In a 
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recent study, PP was shown not to inhibit feeding in the MC4R KO mouse (Lin et al., 
2009) suggesting an ARC-PVN mechanism of action which is also consistent with my 
results. The observation in the VMN seen with PP is also consistent with a recent study 
showing that peripheral administration of PP in mice regulates VMN neuronal activity; 
an effect loss with Y4 receptor KO (Sainsbury et al., 2010).  
The MEMRI experiments revealed no significant effect of 500nmol/kg PP in the area 
postrema suggesting the anorexigenic effect of this dose of PP is not via an aversive 
mechanism. It has previously been shown that MEMRI is sensitive to the activation of 
AP neurons as LiCl caused a significant increase in SI in this region (Parkinson et al 
2009b) which rules out the possibility that the technique is not sensitive to the activation 
of these neurons.  
The MEMRI experiments revealed there was no significant effect of 500nmol/kg PP in 
the lateral ventricle which further attributes changes in SI in the hypothalamus to 
neuronal activity. This is also consistent with the lack of Y4 receptors seen in cerebral 
vasculature which could regulate cerebral bloodflow and MEMRI SI in the ventricles 
(Abounader et al., 1999).   
4.4.4  The effects of subcutaneous administration of PYY3-36 and PYY3-36 (LT) 
on Mn2+ uptake in the hypothalamus and brainstem of fasted adult mice 
as measured by T1-weighted MEMRI 
Previous MEMRI studies were only ever conducted immediately after the injections of 
peptide (Kuo et al., 2007; Choudhri et al., 2007) and a lengthier tracking of the effects of 
these peptides on hypothalamic neuronal activity has not been performed. I therefore 
designed studies in which mice were scanned at three time periods after injection. The 
first time period was 30 minutes after injection to 2.5 hours after injection, the second 
time period was 3 hours after injection to 5 hours after injection and the third time period 
was 6 hours after injection to 8 hours after injection. The MEMRI studies revealed a 
significant reduction in MEMRI SI in the ARC at the second time interval for PYY3-36 
(LT) treated animals compared to saline and PYY3-36 treated animals. This matched the 
divergence of the behaviour observed at this time period between PYY3-36 and PYY3-36 
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(LT) in the feeding studies. These results suggest that the superior effects of PYY3-36 
(LT) over PYY3-36 are possibly due to effects on the hypothalamic neuronal activity it 
exerts. This may be due to PYY3-36 (LT) circulating for longer time periods and 
accumulating in ARC neurons at sufficient concentrations to activate the Y2 receptor 
which is expressed in the mouse ARC (Stanic et al., 2004). The ARC is a major centre 
regulating energy balance and is thought to be necessary for both leptin’s and ghrelin’s 
effects on feeding (Tamura et al., 2002; Tang-Christensen et al., 1999). In rats peripheral 
administration of PYY3-36 is no longer anorexigenic when a Y2 receptor antagonist is 
microinjected in the ARC (Abbott et al., 2005b). This suggests that direct signalling in 
the ARC via Y2 receptor activation is necessary for the peripheral effects of PYY3-36 on 
appetite. Electrophysiolgocical studies with PYY3-36 on the effects on the mouse ARC are 
highly contradictory with reports of stimulation of POMC neurons (Batterham et al., 
2002) and inhibition of POMC neurons (Acuna-goycolea et al., 2004). Also, Fos studies 
provide conflicting results on the effect of PYY3-36 on ARC neurons with one study 
showing a reversal of Fos expression following fasting (Riediger et al., 2004) and another 
showing the expression of Fos following PYY3-36 treatment (Halatchev and Cone 2004). 
However, the former Fos study focused on medial ARC neurons which were inhibited 
and the latter on lateral neurons which were stimulated. Therefore the net activity of both 
populations of neurons would cancel each other out which is consistent with my MEMRI 
studies with PYY3-36.  
Behavioural studies suggest that the ARC is not an important direct site of action for 
PYY3-36 in mice which is also consistent with the results obtained from the MEMRI 
studies. The anorexigenic effect of peripheral administration of PYY3-36 is retained in 
both the MC4R (Challis et al., 2004) and the POMC KO (Halatchev and Cone 2004) 
mice suggesting at least that the hypothalamic POMC system is not involved in 
anorexigenic effects of PYY3-36. An extrahypothalamic mechanism of action for PYY3-36 
is supported by the fact that in mice PYY3-36 crossess the BBB (Onaka et al., 2002). Also, 
in a rat relapse model, peripheral administration of PYY3-36 reverses high fat food 
consumption and this was reversed by systemic but not ARC injections of a Y2 receptor 
antagonist. The authors went on to suggest an extrahypothalamic mechanism of action for 
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PYY3-36 in this paradigm (Ghitza et al., 2007). Finally, a recent fMRI study conducted in 
humans receiving intravenous infusions of PYY3-36 at a dose which inhibits food intake 
showed that neurons in the orbitofrontal cortex, a region implicated in the hedonic 
aspects of feeding, were shown to be inhibited (Batterham et al., 2008). These results 
suggest an extrahypothalamic mechanism of action for PYY3-36 in mice in inhibiting food 
intake and possibly also in rats and humans with regards to the hedonic aspects of 
feeding.  
It has been shown that PYY3-36 causes a conditioned taste aversion in mice and induction 
of Fos in the area postrema following peripheral administration at high doses (Halatchev 
et al 2005). My studies contrasted sharply with these results as there were no differences 
in MEMRI SI in the area postrema observed at any time interval between any of the 
groups. This is consistent with the behavioural studies I performed with 500nmol/kg 
PYY3-36 (LT) which did not produce any symptoms of malaise in mice. Interestingly, 
exendin 4 induced Fos expression in the brainstem is lost in the GLP-1R KO animal 
suggesting the GLP-1R mediates this effect rather than the latrotoxin sequence found in 
the molecule (Baggio et al 2008). These results suggest that PYY3-36 and PYY3-36 (LT) 
are not acting via an aversive pathway but rather at hypothalamic or extrahypothalamic 
sites involved in energy balance. 
PYY3-36 (LT) also caused a strong trend towards a decreaed SI in the PVN back to the fed 
state but not in the VMN at the second timepoint. This is consistent with the Y2 receptor 
being expressed in the PVN but not in the VMN in the mouse (Stanic et al., 2004). 
Therefore as is the case in the ARC, PYY3-36 may accumulate at sufficient concentrations 
in these regions to activate the Y2 receptor.  
PYY3-36 (LT) also caused a strong trend towards a decreased SI in the lateral ventricle at 
the second timepoint. This is unlikely due to changes in neuronal activity and possibly 
due to the vasoactive effect of Y2 receptor agonists on cerebral blood vessels that may 
affect the flow of Mn2+ in the brain (You et al., 2001). However, the fact that the decrease 
in SI in the ARC closely matched the behaviour of mice treated with PYY3-36 (LT) 
suggests a genuine effect on neuronal activity as opposed to changes in blood flow to the 
brain.  
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4.4.5 The effects of intraperitoneal administration of MSG and ionotropic 
glutamate receptor agonists and antagonists on Mn2+ in the brain of adult 
mice shown through MEMRI. 
The neurons of the ARC are exquisitely sensitive to the excitatory effects of circulating 
glutamate and this seems likely due to the activation of NMDA receptors rather than to 
AMPA receptors (Olney et al 1982; Lehmann and Jonsson 1992). To confirm these 
observations using MEMRI, I performed MEMRI experiments on mice and administered 
various doses of MSG and iGluR agonists and antagonists. The results revealed that Mn2+ 
accumulation in the ARC in response to MSG is likely via AMPA receptor activation and 
that AMPA is more potent in increasing SI than NMDA.    
Peripheral administration of 100 mg MSG and 300mg MSG caused significant increases 
in MEMRI SI in the ARC, SCN, and lateral ventricle and the effect in the ARC and SCN 
was dose dependent. The increase in SI in the ARC is consistent with the documented 
excitatory effect of MSG in the ARC in mice (Olney et al., 1969; Lehmann and Jonsson 
1992). There were no changes seen in the PVN and VMN which may be due to their 
distance from the ME, their relative expression of iGluRs, or the active uptake of 
glutamate by transporters that minimize the levels of extracellular glutamate (Hawkins, 
2009). There was also a profoundly increased SI seen throughout the entire cerebral 
cortex with the high dose MSG. Interestingly, the temporal sequence of the changes was 
such that regions further away from the ME progressively showed changes in the 
MEMRI SI. As glutamate is a negatively charged amino acid that does not cross the BBB 
(Hawkins, 2009), these results would suggest that glutamate diffuses from the median 
eminence (and other circumventricular organs located at the base of the brain) and first 
activates neurons in the ARC and SCN which is in closest proximity to the ME, and then 
the temporal and parietal lobes which are further away from the ME respectively. This 
could be confirmed using magnetic resonance spectroscopy techniques which can assess 
concentrations of amino acid neurotransmitters in the brain in vivo (Van Eijsden et al., 
2010).  
To determine which iGluR mediates the increase in MEMRI SI seen with MSG, I 
performed experiments with coadministration of iGluR antagonists. Coadministration of 
183 
 
1mg of the NMDA receptor antagonist MK-801 with 100mg MSG unfortunately resulted 
in lethality even when doses 100 fold lower of MK-801 were used. Therefore, I could not 
test whether any changes in MEMRI SI in the hypothalamus caused with 100mg MSG is 
due to NMDA receptor signalling. In in vitro studies MK-801 protected ARC neurons 
from the excitotoxicity of MSG (Olney et al., 1981) and in in vivo studies on neonatal and 
adult mice, peripheral administration of MK-801 protected from the excitotoxic effects of 
MSG (Lehmann and Jonsson 1992). Therefore it was hypothesized that MK-801 would 
reverse any increase SI in the ARC due to the excitatory effects of MSG. The possible 
cause of the lethality in mice from this treatment is the combination of anaesthesia, 
MnCl2 infusion and MSG and MK-801 treatment. In rats coadministration of MK-801 
with glutamate abolished the increase in MEMRI SI seen in the brain with peripheral 
glutamate administration alone (Itoh et al., 2008). Since the ARC was not taken as a 
region of interest in those studies, it remains to be determined the role of the NMDA 
receptor in generating MEMRI SI in the ARC in vivo in response to ciculating glutamate. 
Coadministration of 1mg of the AMPA receptor antagonist NBQX with 100mg MSG 
surprisingly completed abrogated the increase in SI in the ARC generated by treatment 
with 100mg MSG. A less significant increase in SI in the lateral ventricle compared to 
saline treated animals was also observed. These results suggest that increased SI in the 
ARC in response to peripheral administration of MSG is dependent on AMPA receptor 
activation. These observations are consistent with earlier studies on excitotoxicity of 
ARC neurons. Adults are less vulnerable to the damage caused by MSG (Walker and 
Lupien, 2000) and this may be due to a developmental change in the expression of 
NMDA receptors which are implicated in neuronal cell death (Stout et al 1998) to the 
expression of AMPA receptors. Itoh et al did not observe any changes in the effect of 
peripherally administered glutamate on MEMRI SI in rat brain with coadministration of 
NBQX however as mentioned they did not take the ARC as an ROI in their studies. 
Various doses of iGluR agonists alone were then assessed for their effects on MEMRI SI 
in the hypothalamus and lateral ventricle. Intraperitoneal administration of 1mg NMDA 
did not produce any significant effects whilst 10mg NMDA did produce a significant 
increase in the ARC and lateral ventricle suggesting that functional NMDA receptors are 
184 
 
expressed in the ARC of adult mice. This is consistent with the recent observations that 
peripheral administration of similar doses of NMDA to mice exclusively induces Fos 
expression in the ARC (de Tassigny et al., 2010). This is also consistent with the 
observation that peripheral administration of glutamate increases the MEMRI SI in the 
brain (Itoh et al., 2008). The accumulation of Mn2+ could be a result of increased 
neuronal excitation by NMDA leading to voltage gated Ca2+ channel gating and Mn2+  
permeation into cells (Parkinson et al., 2009a; Drapeau and Nachshen, 1984) and/or 
direct permeation of Mn2+  through the NMDA receptor (Mayer and Westbrook, 1987).  
Interestingly a 10 fold lower dose of AMPA was sufficient to increase the SI in the ARC, 
SCN, and lateral ventricle. This would suggest that AMPA receptor neurotransmission 
dominates in the ARC of adult animals and is consistent with the dual administration 
studies. Itoh et al reported that peripheral administration of AMPA produced no changes 
in SI in various brain regions such as the hippocampus, the cerebellum, and the amygdala 
(Itoh et al., 2008). However, as mentioned these studies did not take the ARC as a region 
of interest.   
Administration of iGluR antagonists alone were then assessed for their effects on 
MEMRI SI in the CNS. Peripheral administration of MK-801 significantly decreased the 
SI in the PVN and cortex. This could be due to MK-801 blocking any NMDA receptor 
mediated excitation of neurons leading to Mn2+ accumulation via voltage gated Ca2+ 
channels and/or blocking permeation of Mn2+ through the NMDA receptor. These 
observations are consistent with Itoh et al whom reported decreased MEMRI SI in the 
brain in response to MK-801 (Itoh et al., 2008). However, peripheral administration of 
NBQX caused a dramatic increase in the ARC and lateral ventricle. This result was 
particularly surprising since coadministration of MSG and NBQX resulted in no 
significant changes in the ARC. If NBQX excited neurons in this context, then one would 
have expected an additive effect when both reagents were coadministered. Alternatively, 
it may be that inhibition of ARC neurons can also result in increased SI and the temporal 
summation of inhibition and excitation results in no net changes in neuronal activity and 
hence no net changes in SI.   
185 
 
4.4.6 Non-neuronal effects 
The changes in the lateral ventricles seen with the various treatments used in these studies 
are intriguing and are unlikely to be due to neuronal activity. They could be due to 
changes in the concentrations of Mn2+ in the plasma, changes in bloodflow to/within the 
brain and/or disruption of the blood-CSF barrier and/or BBB.  
Changes in Mn2+ concentration in the plasma could be due to activation or antagonism of 
glutamate receptors expressed in peripheral organs (Gill and Pulido, 2001). The effect of 
NBQX alone causing a dramatic increase in SI in the ventricle and ARC could be due to 
antagonism of AMPA receptors in the periphery, increased Mn2+ concentration in the 
plasma and ultimately increased Mn2+ concentration in the brain. Coadministration of 
MSG could activate glutamate receptors in the periphery to cause Mn2+ efflux from the 
plasma and hence result in a balance between the two processes and no net effects seen in 
the brain. One way to test for this would be to perform serial blood sampling following 
treatment and to measure Mn2+ concentrations. However, this would be difficult to 
perform in the mouse because of the limited blood volume they possess and such 
experiments are more suited for rats. With any changes in Mn2+ observed following 
various treatments, changes in SI in the brain can be normalised to this with complex 
mathematical models (Leuz et al., 2010).  
Changes in cerebral blood flow could be attributable to the effects of glutamate on 
cerebral vascular tone traditionally associated with NMDA receptor activation (Meng et 
al., 1995). Consistent with this, administration of NMDA alone increased SI in the lateral 
ventricles in the present studies and in the studies of Itoh et al (Itoh et al 2008). This 
would raise concerns that changes in MEMRI SI could simply be due to changes in 
bloodflow to a region of the CNS. However, in a study conducted in the olfactory bulb of 
rats, iron oxide accumulation in blood vessels did not match Mn2+ accumulation 
suggesting that changes in MEMRI SI are not accounted for solely by blood flow changes 
(Chuang et al., 2010). Furthermore, the changes caused by NBQX were limited to the 
ARC and ventricles. Deeper nuclei such as the PVN and VMN were unaffected which 
were shown to be modulated by other treatments. Therefore, if the changes seen with 
NBQX in the ARC were due to changes in blood flow, then this would rule out changes 
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seen with other treatments in the PVN and VMN being attributed to bloodflow. A reason 
why the ARC is more susceptible to changes in blood flow is that it is much more heavily 
vascularised than other regions of the hypothalamus.   
Peripheral administration of 300mg of MSG produced an enhancement that was most 
pronounced in the outermost layer of the brain close to where blood vessels are 
encapsulated by the meninges suggesting disruption of the BBB. Indeed topical 
application of glutamate to the exposed cortex and the generation of nitric oxide (NO) has 
been shown to disrupt the BBB (Mayhan and Didion, 1996), as well as glutamate 
released by neurons in response to hypoxia (Dempsey et al., 2000). If the BBB was 
disrupted however, then a global increase in SI in the brain from treatment with MSG 
would be expected as was observed in the first ever MEMRI study conducted (Lin and 
Koretsky, 1997). However this was not observed in my study. Furthermore, i.v. infusion 
of Evans Blue dye to mice treated with 300mg MSG did not result in greater penetrance 
in the brain compared to saline treated controls. A potential explanation for the 
discrepancy between these observations and those made in the above mentioned studies is 
that they were performed using direct application of glutamate to exposed cortical 
neurons or synaptically released glutamate, which would achieve far higher local 
concentrations than those reached by peripherally administered MSG and which would 
reach the threshold required to disrupt the BBB.  
Alternatively, the blood-CSF barrier may have been disrupted in response to glutamate 
receptor activation. This was the conclusion of Itoh et al as they also observed consistent 
changes in MEMRI SI in the lateral ventricle in response to glutamate and NMDA (Itoh 
et al., 2008). In contrast in the present studies, I observed an increase in SI in the entire 
cerebral cortex. This could be a consequence of activation of both NMDA and AMPA 
receptors by glutamate as either specific agonist alone did not produce such a response. 
Alternativley activation of metabotropic glutamate receptors may mediate this effect. 
Indeed glutamate has been shown to accumulate in the choroid plexus, where CSF is 
produced, following peripheral administration (Hawkins et al., 1995). Metabotropic 
glutamate receptors are expressed in the choroid plexus and their activation has been 
proposed to result in pathological processes (Gillard et al., 2003). A disruption in the 
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blood-CSF barrier is possible with 300mg MSG as the increases in SI in the ARC and 
SCN were transient. This is consistent with Mn2+ diffusing away from the ARC rather 
than accumulating and being trapped in neurons in the ARC. One way to test whether 
Mn2+ is in the CSF is to scan the mice 24 hours after treatments. Any signs of tract 
tracing (eg cortico thalamic tracts) would confirm neuronal uptake. However, if Mn2+ is 
in the CSF, then it would simply diffuse away and the intense SI would disappear 
(Chuang et al., 2009a). These results highlight a major limitation to the MEMRI 
technique. Despite the fact that intracellular Mn2+ produces greater contrast than 
extracellular (Kang and Gore, 1984), there is still no way to determine whether SI is due 
to intracellular or extracellular Mn2+. This issue was addressed by an elegant set of 
studies in which Mn3+ is complexed with the iron binding protein transferrin. This 
enables the uptake of the Mn (III)-transferrin complex into cells by transferring receptor 
1 and once inside Mn3+ is liberated and is rapidly reduced to Mn2+. In this way, Mn2+ 
does not assume its paramagnetic properties until it is inside a cell (Sotak and Koretsky 
2010). The disadvantage to this technique is that uptake is no longer via VGCCs and 
therefore is not a measure of neuronal activity and this method is more suited for tract 
tracing studies.  
4.4.7 Future studies 
The MEMRI experiments with PYY3-36, PYY3-36 (LT) and PP need to be repeated with 
other methods used to assess neuronal activity such as Fos IHC and autoradiograpy 
studies that measure glucose uptake by active neurons. The results from these studies 
would confirm whether changes in MEMRI SI are due to neuronal activity. Chronic Mn2+ 
infusion paradigms enable the assessment of neuronal activity in reward centres of the 
brain. It would be interesting to test the effects of gut peptides in regions of interest such 
as the ventral tegmental area or ventral stiatum. 
The effects seen in the lateral ventricles following glutamate receptor agonists warrant 
further investigation. It would be interesting to test the effects of MSG or NMDA on 
neuronal nitric oxide synthase KO mice. Any loss of the changes in MEMRI SI with 
MSG or NMDA treatment would further suggest that NO mediated vasodilation accounts 
for the changes seen with these agonists. It would also be interesting to perform MEMRI 
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experiments on mice that have received MSG treatment at the neonatal period. As this 
results in ablation of ARC neurons (specifically the AgRP/NPY population (Bergen et a., 
1998; Broberger et al., 1998)), scanning these animals under basal conditions and 
measuring Mn2+ uptake in the ARC would provide useful information about the role of 
AgRP/NPY neurons play in generating MEMRI SI in the ROI.  
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PET-CT studies on RYGB rats 
investigating  
BAT activity in vivo 
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5 Introduction 
The work in the previous chapter demonstrated the utility of MEMRI as a tool to assess 
hypothalamic and brainstem neuronal activation in response to nutritional states, gut 
hormone and food additive treatment. I next wanted to assess the effects on the brain of 
the most effective form of obesity treatment; RYGB. However, although we managed to 
develop a rat model of RYGB, we were unable to develop a similar model in mice and 
the MEMRI protocol is only suited to assess mouse hypothalamic neuronal activity.  
Therefore, as part of the phenotypic characterisation of the RYGB model I decided to 
focus on another organ involved in energy homeostasis, BAT, and use positron emission 
tomography computed tomography (PET-CT) as a modality to assess its activity in vivo 
after surgery. 
5.1.1 Roux-en-Y gastric bypass (RYGB) 
Roux-en-Y gastric bypass is the single most effective means of producing a sustained 
weight loss in human subjects (Sjostrom et al., 2004). However, according to NICE 
recommendations, it is reserved as a last line treatment for the morbidly obese and 
therefore is not readily available. An understanding of the molecular, cellular, and 
systems changes after surgery may help in the development of novel anti-obesity drugs 
that mimic the post-surgery state.  
The RYGB procedure entails almost entire removal of the stomach leaving only the 
gastric pouch, the entire duodenum and proximal jejunum and sparing the distal jejunum 
and ileum. An anastomosis is formed between the gastric pouch and the mid-jejunum 
forming a continuous tract (Figure 5.1) (Mun et al., 2001). Patients typically lose up to 
40% bodyweight within the first two years of RYGB surgery and this stabilises to 30% 
up to ten years post surgery (Sjostrom et al., 2004).  
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Figure 5.1 The Roux-en-Y Gastric Bypass procedure. 
An anastomosis is formed between the gastric pouch and the distal small intestine 
bypassing the rest of the stomach and the proximal small intestine. Adapted from Kenler 
et al., 1990. 
 
5.1.2 Rat models of RYGB 
Rodent models of RYGB on obese Zucker rats (Xu et al., 2002), Sprague Dawley rats 
(Meguid et al., 2004), and Wistar rats (Bueter et al., 2010b) have also been generated. 
These models enable a more detailed examination of the molecular, cellular, and systems 
changes that occur after RYGB that cannot be performed on human subjects.  The rat 
procedure mimics the human procedure in that there is an initial precipitous drop of 
approximately 35% bodyweight within 2 weeks of the surgery and then this stabilises to 
around 25% thereafterwards (Guijarro et al., 2007).  
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5.1.3 Mechanisms of weight loss following RYGB 
The mechanisms underlying the superiority in inducing and maintaining body weight loss 
following surgery remains a matter of controversy and active investigation. Initially, it 
was widely assumed that weight loss after gastric bypass was simply due to mechanical 
restriction and malabsorption alone (Greenway, 1996). However, recent studies have 
indicated that there are more complex mechanisms by which gastric bypass decreases 
caloric intake; such as reduced hunger (le Roux et al., 2006a), increased satiety (le Roux 
et al., 2007), altered taste (Burge et al., 1995; Scruggs et al., 1994), as well as reduced 
preference for foods with a high fat and sugar content (Olbers et al., 2006).  
Anecdotally, patients after RYGB appear to be more tolerant to exposure to cold 
temperatures thus the question arises whether RYGB may also enhance cold induced 
thermogenesis. In addition, it has been demonstrated that RYGB in rats not only 
prevented the expected decrease in energy expenditure subsequent to body weight loss, 
but actually increased energy expenditure and this was not accounted for by increased 
physical activity (Bueter et al., 2010b). It was shown that maintenance as well as diet-
induced thermogenesis following a 5g test meal was higher after RYGB compared to 
body weight-matched controls (Bueter et al., 2010b).  
Brown adipose tissue is a thermogenic organ, mediating both cold induced and diet 
induced thermogenesis and plays a role in promoting a negative energy balance (Lowel 
and Spiegelman 2000). The RYGB procedure may influence BAT to affect these 
processes thereby contributing to weight loss.  
5.1.4 Brown adipose tissue (BAT) 
In contrast to white adipose tissue (WAT) which is the major site of energy stores, BAT 
is an organ involved in the dissipation of energy in the form of heat. As well as 
differences in function, BAT differs from WAT in morphology, developmental origins, 
and distribution.  
Brown adipose tissue is heavily vascularised and innervated by the sympathetic nervous 
system, is brown in colour due to high mitochondrial content and is multilocular as 
opposed to unilocular as is the case with white adipocytes (Enerback, 2010). Brown 
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adipose tissue is embryologically distinct from WAT and is thought to have a common 
lineage to skeletal muscle as shown through lineage tracing experiments (Seale et al., 
2008) whilst WAT is derived from committed preadipocytes of mesodermal origin that 
have not converted into myblosts (Gesta et al., 2007). White adipose tissue is distributed 
throughout the body in subcutaneous and visceral depots. However, BAT has a markedly 
different distribution with documented species differences. In rodents it is well 
established that there is an interscapular BAT depot (Conti and Cinti, 2010). In man 
interscapular BAT was thought only to be present in the newborn infant as deduced from 
anatomical observations (Nedergaard et al,. 2007). However, it has recently been shown 
through a series of PET-CT and biopsy studies that functional BAT is expressed in adult 
man in supraclavicular, paraverterbral and suprarenal depots (Figure 5.2) (Cypess et al., 
2009; Virtanen et al., 2009). Brown adipocytes are also found interspersed amongst white 
adipocytes following chronic sympathetic nervous system activation due to chronic cold 
exposure or β3 adrenergic receptor activation in mice and rats (Guerra et al., 1998; Cousin 
et al., 1992) and also in humans (Lean et al., 1986). Interestingly, the lineage of these 
adipocytes is distinct from those of the interscapular depot. Interscapular BAT as 
mentioned is derived from myogenic precursors and is dependent on the presence of the 
transcription factor PRDM16 (Seale et al., 2008). Brown adipocytes interspersed amongst 
white adipocytes arise from white adipocyte differentiation due to the activation of the 
enzyme cyclooxygenase 2 (COX2) and the generation of prostaglandins which bind to 
and activate the nuclear receptor peroxisome proliferated associated receptor γ (PPARγ) 
(Vegiopoulos et al., 2010).  
The activation of BAT is absolutely dependent on the presence of thyroid hormone (T3) 
as hypothyroid rats do not exhibit thermogenic responses to cold even during 
noradrenaline infusion (Ribeiro et al., 2000). Traditionally it was thought that T3 was 
produced and acted locally in BAT to increase thermogenesis in concert with sympathetic 
nervous system (SNS) activation (Silva and Larsen, 1983). However, it has recently been 
shown that circulating T3 also acts in the VMN to increase BAT activity via increased 
SNS activity. This was shown by direct application of T3 to the VMN and deletion of the 
thyroid hormone receptor (TR) via AS AAV injected into the VMN (Lopez et al. 2010).   
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Figure 5.2 Distribution of BAT in humans 
The major BAT depots are; (A) thyroid/tracheal, (B) mediastinal, (C) 
paracervical/supraclavicular, (D) parathoracical,  and (E) supra and perirenal. In the 
infant, a kite-shaped thin layer of interscapular BAT has been described (in light brown). 
Taken from Enerback, 2010. 
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5.1.4.1 Uncoupling protein 1 (UCP1) 
The capacity of BAT to produce heat is due to the specific expression of the 
mitochondrial protein uncoupling protein 1 (UCP1) (Bouillaud et al., 1985; Jacobsson et 
al., 1985). Uncoupling protein 1 is a 32 kDa protein expressed in the inner mitochondrial 
membrane and dissipates the proton gradient generated by the oxidation of glucose. As 
protons move along their electrochemical gradient from the inter mitochondrial space 
back into the matrix heat is released as a byproduct. The expression of UCP1 is regulated 
by chronic SNS activity and TR and PPARγ binding to the UCP1 enhancer (Lowel and 
Spiegelman, 2000). The activation of UCP1 is not fully understood but is known to 
require activation of the β3 adrenergic receptor with subsequent lipolysis and free fatty 
acids binding directly to the protein. Free fatty acids are thought to displace nucleotides 
that allosterically inhibit UCP1 resulting in UCP1 activation (Nedergaard and Cannon, 
2010). Uncoupling protein 1 has been shown to be necessary for both temperature 
induced and diet thermogenesis (Enerback et al., 1997; Feldmann et al., 2009). 
Uncoupling protein 2 (Fleury et al., 1997) and uncoupling protein 3 (Vidal-Puig et al., 
1997) have also been characterized which are found in WAT and skeletal muscle 
respectively and may also play a role in thermogenic processes. This is supported by the 
fact that UCP1 KO mice have markedly elevated UCP2 in WAT (Enerback et al., 1997). 
5.1.5 Role of BAT in energy homeostasis 
Studies support that BAT promotes a negative energy balance. Ablation of BAT through 
the use of diphtheria toxin in mice results obesity (Lowell et al., 1993) and expansion of 
the BAT depot through i.v. injection of AAV expressing the mRNA of the protein bone 
morphogenetic factor 7 (BMP 7) increases energy expenditure and protects from diet 
induced obesity (Tseng et al., 2008). Therefore, activating BAT may serve as a potential 
treatment for obesity. Specific β3 adrenergic receptor agonists that stimulate BAT in 
rodents were developed in the early 80s that cause weight loss and were proposed anti-
obesity agents (Arch et al., 1984). However, clinical trials using these agonists were 
disappointing as patients did not exhibit significant weight loss and there were also 
undesired side-effects (Connacher et al., 1992). This may have been due to the fact that 
agonists of the murine receptors were used that are not as selective for the human 
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receptor (Laurent et al., 1989; Granneman et al., 1992). More specific agonists for the 
human β3 adrenergic receptor have been developed but did not result in weight loss 
following a chronic 3 week study (Weyer et al., 1998). For these reasons, the interest in 
the use of β3 adrenergic receptor agonists to treat obesity has diminished (Weyer et al., 
1999). Recently a glucagon-GLP-1 receptor coagonist was shown to cause a massive 
30% weight loss in DIO mice which was accounted for almost entirely by increased 
energy expenditure which is likely BAT mediated (Day et al., 2009). This can be 
assessed with techniques such as PET-CT. This molecule may also be effective in 
humans without the undesirable side effects of other molecules that increase energy 
expenditure. 
5.1.6 Principles of positron emission tomography- computed tomography 
(PET-CT) 
Positron emission tomography is an imaging modality that allows the indirect measure of 
metabolic activity of a tissue in vivo using administered positron emitting tracers. These 
tracers are compounds such as deoxyglucose that are coupled to positron emitting 
radioisotopes such as 18F forming 18Fluorodeoxyglucose (18F-FDG). 18F-FDG is the most 
often used tracer in PET studies and has a half life of 120 minutes. 18F-FDG is taken up 
by metabolically active cells and following phosphorylation by glucokinase is trapped 
intracellularly. This allows the activity of tissue to be measured and for this reason 18F-
FDG has been traditionally used in nuclear medicine to diagnose cancer as cancer cells 
are highly metabolically active.  
19F is the naturally occurring isotope of fluorine and has 9 protons and 10 neutrons. 18F is 
synthesized by an apparatus known as a cyclotron and has 9 protons and 9 neutrons and 
thus is relatively proton rich and is unstable. This excess proton escapes the nucleus as a 
neutrally charged neutron and a positively charged positron. As the positron travels 
further from the parent nucleus it loses kinetic energy through interactions with 
surrounding matter and eventually comes to a halt where it will react with a usually 
stationary electron (some mms away from the positron emitting nucleus). This results in 
the annihilation of the two species and the emission of two photons 180 degrees apart that 
are in the γ frequency of electromagnetic radiation (Figure 5.3A). The photons released 
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from the annihilation event then interact with scintillation detectors in the PET scanner 
(Figure 5.3B). Since the γ rays normally travel in opposite directions, the source of the 
radiation can be localized although complex programs are often in place to correct for 
acolinear, random and scattering events. The scintillation detectors are inorganic crystals 
(such as NaI) that have fully occupied outer electron shells (valence electron) but the 
inner electron shell is not fully occupied. As the valence electron is excited by a photon it 
moves to the inner shell and then steadily returns emitting light in the process. This light 
is detected by a photo-detector which provides an indirect measure of annihilation events 
from a sample. Ultimately, the resolution that PET affords (due to the size of the crystal 
blocks) is not as high as MRI and is in the region of 1-2 mm for pre-clinical scanners and 
4-6 mm for clinical scanners. 
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Figure 5.3 The concepts of PET 
A) A positron emitting radionuclide emits a positron which after travelling a few mms in 
a sample collides with an electron which results in their annihilation and the release of 
two gamma rays 180 degrees apart from each other. B) These gamma rays are detected 
by gamma ray detectors in a PET scanner. 
 
PET-CT is the combination of two imaging modalities and has only emerged in the last 
two decades. CT is a technique that allows imaging of the skeletal system as well as soft 
tissues such as adipose tissue. It works by the use of X rays which are a form of 
electromagnetic radiation of a lower frequency than γ rays. X rays displace electrons in a 
sample from the outer shell to the inner shell. This results in the release of a photon 
which has energy dependent on the physical nature of the sample and therefore provides 
contrast based on this. PET-CT has been used very effectively in studying BAT in 
humans and experimental animals. 
A) B) 
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5.1.7 PET-CT studies and brown adipose tissue  
5.1.7.1 Human studies 
Blockade of the sympathetic nervous system, which is essential for BAT activity, reduces 
18F-FDG uptake by BAT in man (Parysow et al., 2007). Additionally, keeping individuals 
warm for the hour prior to the scan reduces the uptake of 18F-FDG by BAT (Christensen 
et al., 2006). In a recent study 18F-FDG uptake was observed in the supraclavicular region 
in mild cold conditions but not in warm conditions confirming the earlier observations 
described above. Furthermore, the investigators performed a thorough analysis of the 
supraclavicular BAT obtained from biopsies of subjects whom underwent the scans. 
Western blot analysis and immunocytochemistry confirmed UCP1 protein expression in 
BAT producing irrevocable evidence that BAT is expressed in adult man (Virtanen et al., 
2009).  
5.1.7.2 Rodent studies 
The development of micro PET-CT scanners has enabled the study of BAT physiology in 
rodents. Such studies also reveal the increased uptake of 18F-FDG in the interscapular 
BAT in rats following cold conditions and that administration of the adrenergic receptor 
antagonist propanolol decreases 18F-FDG uptake in interscapular BAT (Tatsumi et al., 
2004). The effects of anterior hypothalamic injection of insulin on energy expenditure 
and BAT activity has been investigated in rats. Insulin increased energy expenditure and 
the activity of interscapular BAT shown through increased 18F-FDG uptake (Sanchez-
Alavez et al., 2010). Limitted PET-CT studies investigating BAT have been conducted 
on mice. As expected, both cold conditions and feeding the mice prior to the scan 
resulted in optimal uptake of 18F-FDG (Fueger et al., 2006). This is consistent with the 
cold and diet induced thermogenesis already described. In an approach to test the 
functionality of engineered BAT generated through transfection of the transcription 
factors PRDM16 and CEBPβ into fibroblasts, PET-CT experiments revealed 18F-FDG 
uptake by the inoculated tissue in mice (Kajimura et al., 2009). These studies reveal the 
strengths of PET in assessing BAT location and activity in vivo.  
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Aims: 
• To assess whether BAT activity is increased following RYGB in rats through the 
use of PET-CT and the metabolic tracer 18F-FDG and whether this correlates with 
a molecular marker of BAT activity. 
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5.2 Results 
5.2.1 Body weight of gastric bypass and sham operated rats after surgery  
Since a mouse model of gastric bypass was not available, I further characterized the rat 
model of RYGB. 
Figure 5.4A shows the body weight changes for gastric bypass rats and sham operated 
rats for 50 days post surgury. No significant differences for preoperative body weight 
between gastric bypass rats (n=8) and sham operated rats (n=8) were observed (day 0: 
sham: 376.2 ± 7.8 g vs. gastric bypass: 399.8 ± 12.6 g, p=0.143).  After a short period of 
post surgical weight loss, sham-operated controls gained weight for the rest of the study. 
In contrast, gastric bypass animals during the first 30 days after surgery lost 25% of their 
bodyweight and then plateaued to a final bodyweight of approximately 300 g. Body 
weight was significantly lower in gastric bypass rats compared to the sham-operated 
animals (p<0.0001). Mann-Whitney U tests revealed a significant reduction in 
bodyweight between gastric bypass and sham operated animals from day 15 until 
completion of the study. 
5.2.2 Spontaneous food intake of gastric bypass and sham operated rats after 
surgery 
Differences in food intake followed similar patterns as the body weight development. 
Figure 5.4B shows the average daily food intake for both groups throughout the complete 
observation period (day 1 to day 50 after surgery). Average daily food intake was 
consistently lower after gastric bypass compared to sham-operated rats (sham: 31.5 ± 
0.35 g vs. gastric bypass: 19.9 ± 0.58 g, p<0.001).  
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Figure 5.4 Bodyweight and food intake reductions in gastric bypass and sham 
operated rats 
A) Body weight change and B) average daily food intake of sham-operated rats (white 
bars, n=8) and gastric bypass rats (black bars, n=8) throughout the entire observation 
period of 50 days. ****=p<0.0001, ***=p<0.001, and **p<0.01 as determined by GEE 
with Mann-Whitney U tests for bodyweight and Student’s t-test for food intake. Data are 
shown as mean values ± SEM. 
A) 
B) 
203 
 
5.2.3 Whole body nuclear magnetic resonance of gastric bypass and sham 
operated rats 
Figure 5.5A and 5.5B shows whole body T1-weighted images of sham operated gastric 
bypass rats respectively. As shown in Figure 5.6A, gastric bypass rats (n=8) had a 
significantly lower percentage of whole body adiposity as determined through 1H-NMR 
spectroscopy compared to sham-operated rats (n=8) (sham: 11.1 ± 1.7 % vs. bypass: 3.0 
± 0.6 %, p=0.001). As shown in Figure 5.6B, this equated to a significantly lower lean 
mass of 252.7 ± 16.5 g for the bypass rats compared to 346.4 ± 6.6 g sham-operated rats 
(p<0.001). 
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Figure 5.5 Representative T1-weighted MRI images of A) sham-operated rats and B) 
gastric bypass operated rats.  
(Top: Rostral, Bottom: Caudal). 
 
 
B) A) 
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Figure 5.6 Whole body adiposity of gastric bypass and sham operated rats 
A). % whole body adiposity calculated for sham operated rats (white bars, n=8) and 
gastric bypass rats (black bars, n=8) B). Lean bodyweight was calculated and plotted for 
sham operated rats (white bars, n=8) and gastric bypass rats (black bars, n=8). *=p<0.05 
and ***=p<0.001 as determined by Students t-test. Data are shown as mean values ± 
SEM 
 
 
 
B) 
A) 
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5.2.4 Weight of BAT from gastric bypass and sham operated rats 
The average weight of BAT was significantly higher in sham-operated rats (n=8) in 
comparison to gastric bypass rats (n=8) (Figure 5.7A) (sham: 0.46 ± 0.02 g vs. bypass: 
0.36 ± 0.02 g, p= 0.007). However, there was no difference in BAT weight relative to 
total body weight between the two groups (Figure 5.7B) (sham: 0.13± 0.01 % vs. bypass: 
0.12 ± 0.01 g, p= 0.131). 
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Figure 5.7 Weights of interscapular BAT from gastric bypass and sham operated 
rats.  
A). Mass of BAT taken from sham operated rats (white bars, n=8) and gastric bypass rats 
(black bars, n=8) B). % bodyweight of BAT for sham operated rats (white bars, n=8) and 
gastric bypass rats (black bars, n=8). **=p<0.01 as determined by Student’s t-test. Data 
are shown as mean values ± SEM 
 
 
 
 
 
B) 
A) 
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5.2.5 PET-CT scans of sham operated and gastric bypass treated rats treated 
with a β3 adrenergic receptor agonist 
Figure 5.8 shows representative PET-CT images of sham operated and gastric bypass rats 
that have received i.p. administration of the β3 receptor agonist CL316, 243 followed by 
i.v. administration of 30-50MBq 18F-FDG. 
Figure 5.19A shows that sham-operated rats (n=8) had an SUV of 2.81 ± 0.58 and gastric 
bypass rats (n=8) had an SUV of 2.56 ± 0.46 following i.p. administration of CL316, 243 
with no significant difference between the groups (p=0.732). Figure 5.19B shows that by 
calculating SUV according to lean mass, a trend towards an increased uptake of 18F-FDG 
in bypass rats compared to sham-operated rats is observed (sham-operated rats; SUV of 
3.89 ± 0.86 and gastric bypass rats; SUV of 4.99 ± 0.85), however this did not attain 
statistical significance  (p=0.732). 
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Figure 5.8 Representative fused PET-CT images of bypass and sham operated rats  
Sagittal fused PET-CT images of sham-operated rats A) and gastric bypass rats B) (40 
days after surgery). Rats received i.p. administration of the β3 adrenergic receptor agonist 
1 mg/kg CL316, 243 followed 30 minutes with i.v. administration of 30-50 MBq 18F-
FDG at the commencement of scanning. The green cursor in each image highlights the 
interscapular BAT (top: caudal, bottom: cranial). 
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Figure 5.9 Standardize uptake values (SUV) of 18F-FDG uptake in the brown 
adipose tissue of β3 adrenergic receptor agonist treated sham-operated (white) and 
gastric bypass rats (black). 
A) SUV calculated according to actual body mass for sham operated rats (white bars, 
n=8) and gastric bypass rats (black bars, n=8). B) SUV calculated according to lean body 
mass for sham-operated rats (white bars, n=8) and gastric bypass rats (black bars, n=8) 
Data are shown as mean ± SEM. 
 
 
B) 
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5.2.6 UCP-1 mRNA levels of BAT from sham operated and gastric bypass rats 
There was no difference in the UCP-1 mRNA content of the BAT between the two 
groups (Figure 5.10A) (sham: 49.5±13.2 vs. bypass: 43.7±13.1, p=0.773) or in relation to 
the BAT weight (Figure 5.10B) (sham: 109.5 ± 32.3/ g BAT vs. bypass: 128.8 ± 42.8/ g 
BAT, p=0.723).   
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Figure 5.10 Northern Blot analysis of UCP-1 content in BAT of sham operated and 
RYGB rats 
A) Absolute UCP-1 mRNA content in BAT from sham operated rats (white bars, n=8) 
and gastric bypass rats (black bars, n=8) B) UCP-1 mRNA content relative to the BAT 
weight for sham operated rats (white bars, n=8) and gastric bypass rats (black bars, 
n=8).Data are shown as mean ± SEM.         
 
 
A) 
B) 
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5.3 Discussion 
Roux-en-Y gastric bypass is the most effective means of producing a sustained weight 
loss in humans (Sjostrom et al., 2004). Rodent models of the procedure have been 
produced which enable a more detailed understanding of how the procedure works at a 
molecular, cellular, and systems level. I have confirmed the effects of RYGB on food 
intake and bodyweight in a rat model of RYGB. I have also confirmed that the procedure 
decreases overall body fat mass through the use of NMR. Since RYGB has been shown 
to increase diet induced thermogenesis in rats (Bueter et al., 2010b) a phenomenon 
thought to be mediated by sympathetic nervous system induced activation of BAT 
(Rothwell and Stock, 1979), I performed PET-CT studies to assess BAT activity after 
surgery and measured UCP1 levels. I have shown that PET-CT can be used to assess the 
functionality of BAT in rats and that the gastric bypass procedure does not result in more 
active BAT or increased UCP1 levels. 
5.3.1 Effect of bariatric surgery and sham surgery on food intake, bodyweight 
adiposity, and BAT size in rats 
My results with a rat model of gastric bypass are consistent with previous findings that 
gastric bypass surgery is an effective means to reduce body weight and especially to 
maintain body weight loss through reduced food intake (le Roux et al., 2006a). One 
potential mechanism by which gastric bypass achieves this is by adjusting the leptin “set 
point” at which a critical concentration of plasma leptin is perceived by the hypothalamus 
as a state of energy insufficiency (Flier, 1998). In this situation, decreased leptin levels 
would not be perceived as a state of energy insufficiency in gastric bypass rats, and 
consequently compensatory mechanisms including increased food intake and/or 
decreased energy expenditure remain absent. However, it needs to be determined how the 
leptin set point may be adjusted. Possible mechanisms include increased leptin receptor 
expression in the rat hypothalamus after gastric bypass (Guijarro et al., 2007) or a higher 
affinity of leptin to these receptors (Flier, 1998). Indeed the vastly superior effects on 
inducing bodyweight loss of coadministration of the pancreatic hormone amylin with 
leptin compared to leptin administration alone is accounted for in part by increased leptin 
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receptor expression and enhanced leptin receptor signalling in the hypothalamus (Turek 
et al., 2010).  
Alternatively, the “starvation response” opposing weight loss usually triggered by lower 
leptin levels is overridden by increased levels of circulating anorexigenic gut hormones. 
Gastric bypass increases postprandial levels of the ileal hormones PYY3-36 and GLP-1 (le 
Roux et al., 2006). Since peripheral administration of PYY3-36 and GLP-1 to obese 
individuals decreases food intake (Batterham et al., 2003b, Nasland et al., 2004) and 
coadministration of these peptides has an additive effect on feeding in rodents (Neary et 
al., 2004),  the decreased feeding following gastric bypass may be accounted for in part 
by the changes in the profiles of these hormones.  
I further confirmed that body weight loss after gastric bypass was associated with a 
significant loss of adipose tissue mass (Zheng et al., 2009). This is likely the consequence 
of decreased feeding as the organism resorts to fat stores as a source of energy. This 
occurs prior to the onset of gluconeogenesis and the breakdown of lean tissue. 
Nevertheless, this seems to have also occurred as lean body mass was significantly 
reduced in RYGB rats.  
5.3.2 Effect of bariatric surgery on β3 adrenergic agonist induced 18F-FDG  
uptake by BAT in rats shown through PET-CT 
I have shown through PET-CT that 18F-FDG uptake by BAT following administration of 
a specfic β3 adrenergic receptor agonist is not increased following gastric bypass surgery 
compared to sham operated controls. I also found no difference in UCP-1 mRNA 
expression in BAT between gastric bypass rats and sham-operated controls. This suggests 
that mechanisms other than increased activity of BAT are responsible for the higher 
levels of energy expenditure that have been observed after gastric bypass surgery in rats 
(Bueter et al., 2010b; Stylopoulos et al., 2009). It has been previously demonstrated that 
gastric bypass rats have a higher total energy expenditure when compared to ad libitum 
fed and body weight-matched sham controls (Bueter et al., 2010b; Stylopoulos et al., 
2009). As gastric bypass rats showed a greater cumulative increase in total oxygen 
consumption after a 5 g test meal than the control groups, it was therefore suggested that 
differences in diet-induced thermogenesis may also play a role (Bueter et al., 2010b). The 
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increase in total energy expenditure may be due to a higher energy requirement after 
bypass surgery. In fact, significant morphometric changes of the small intestine after 
gastric bypass surgery have been demonstrated (Nadreau et al., 2006) and it has been 
shown that there is up to a 72% increase of the total small bowel weight after surgery 
(Bueter et al., 2010a). Thus, it can be speculated that gut hypertrophy potentially explains 
the higher maintenance energy requirement contributing to body weight loss after gastric 
bypass. The increase in diet induced thermogenesis after gastric bypass surgery is 
difficult to explain. It may be that the energy used by the gut for peristaltic movement of 
food is increased due to the increased size of the muscle lining (Bueter et al., 2010a). 
Interestingly, the role of BAT in diet induced thermogenesis has recently come under 
question (Kozak, 2010) which is consistent with my results. This is because the increased 
oxygen consumption following feeding in rats is not accounted for by increased oxygen 
utilization by BAT (Ma et al., 1988). Also, hypothyroid animals which have defective 
cold induced thermogenesis, still exhibit diet induced thermogenesis (Curcio et al., 1999). 
Therefore other tissues are possibly responsible for diet induced increases in oxygen 
upake (in other words diet induced thermogenesis). However it does seem that in mice 
diet induced thermogenesis is a BAT mediated phenomenom as KO of the BAT specific 
protein UCP1 results in a loss in this process (Feldmann et al 2009). Additionally, PET-
CT scans in fed mice compared to fasted mice show increase 18F-FDG uptake in BAT 
convincingly demonstrating that BAT is activated by feeding (Fueger et al 2006). 
Therefore, it is possible that the role of BAT in diet induced thermogenesis shows species 
differences.      
A limitation to the present study is that potential changes in neuronal circuitry and 
hormonal influences on BAT following gastric bypass surgery may have been overlooked 
due to the way the BAT was stimulated. I stimulated BAT via peripheral administration 
of a β3 adrenergic receptor agonist which according to the literature is a satisfactory 
means of testing for diet induced thermogenesis (Feldmann et al., 2009). However, 
further experiments designed to activate BAT via temperature which engages sensory 
primary afferent fibres and neurons in the anterior hypothalamus to stimulate the 
sympathetic nervous system (Sanchez-Alavez et al., 2010) need to be performed to 
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confirm that adaptive thermogenesis does not change post bypass surgery in rats. Also 
performing fed vs fasted experiments need to be carried out. Rats were fasted for the 
present studies because experiments utilizing 18F-FDG investigating BAT activity are 
typically conducted in the fasted state so that circulating glucose does not compete with 
18F-FDG (Virtanen et al., 2006). However, substantial 18F-FDG uptake by BAT has been 
observed in the fed state in mice and therefore uptake of 18F-FDG by this organ seems to 
be maintained in the presence of circulating glucose (Feugar et al, 2006).  
My studies were conducted on rats on a regular fat diet and diet induced thermogenesis in 
rodents has traditionally been tested for following consumption of a HFD (Rothwell and 
Stock, 1979; Feldmann et al., 2009). Nevertheless, diet induced thermogenesis is still 
observed when placing animals on a regular fat diet (Bueter et al., 2009) albeit to a lesser 
extent (Feldmann et al., 2009). It would be interesting to test if placing gastric bypass rats 
on a HFD would further exacerbate differences in diet induced thermogenesis compared 
to sham operated controls and whether this would be a BAT mediated phenomenom. 
I used the SUV method to quantify BAT uptake of 18F-FDG which is a semi-quantitative 
technique. This is because it does not take into account fully the levels of 18F-FDG in the 
plasma following administration but rather only the accumulation in the BAT. This may 
overlook the uptake of 18 F-FDG by other organs that may decrease the concentrations of 
18F-FDG in the plasma and thus the availability for BAT uptake. Obtaining Ki values 
using the arterial input function is an effective method to control for concentrations of 
18F-FDG in the plasma. However, this necessitates a clear delineation of the left ventricle. 
Unfortunately, in numerous of my PET-CT images, the left ventricle was difficult to 
visualize and so this method of quantification was not possible to perform. It may be that 
by obtaining the Kis may reveal significant differences between the gastric bypass and 
sham operated groups in the uptake of 18F-FDG. However, since the Northern Blot 
analysis revealed no differences in UCP-1 levels which account for glucose uptake by 
BAT (Inokuma et al., 2005), this seems unlikely to be the case.   
In conclusion, gastric bypass does not appear to increase the activity of BAT in rats 
suggesting that other mechanisms are in place to explain the increased energy 
expenditure after bypass surgery. The present results do not support that similar PET/CT 
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experiments be performed in humans which would involve an unnecessary exposure to 
radiation.  
5.3.3 Future Studies 
Now that the PET-CT technique is optimised for measuring BAT activity in rats various 
studies can be performed. As mentioned, the effects of bariatric surgery on temperature 
induced BAT activity through the use of PET-CT remains to be determined. The effects 
of gut hormones such as ghrelin, PYY3-36 and GLP-1 on BAT activity in vivo have yet to 
be determined and PET-CT experiments can reveal their effects on this thermogenic 
organ. Once a mouse model of RYGB is generated, potential species differences in BAT 
activity after RYGB between mice and rats can be ascertained. Also, MEMRI 
experiments can be performed to assess changes in hypothalamic activity between sham-
operated and gastric bypass operated mice as initially intended.  
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6 Final conclusions 
The modulation of circulating gut hormones to alter satiety may provide an effective 
means of treating obesity. The work contained within this thesis has involved studying 
the effects of peripherally administered PYY3-36 and various PYY3-36 analogues on 
appetite regulation and energy homeostasis in rodent models. I have focused in particular 
on the acute and chronic actions of PYY3-36 (LT), a long-lasting PYY3-36 analogue. In 
addition, I have confirmed manganese-enhanced-magnetic-resonance imaging (MEMRI) 
as an effective technique for tracking the effects of gut hormones upon neuronal activity 
in real time within areas of the CNS which affect appetite. I have also developed the 
technique so that a lengthier tracking of neuronal activity can be achieved following gut 
hormone treatment and also so that pharmacological studies can be performed to assess 
which receptor subtype may mediate changes in MEMRI SI in response to nutrient 
treatment. The latter studies also highlighted major limitations of the MEMRI technique 
when it comes to the assessment of neuronal activity in vivo. Finally, I have shown 
through the use of positron emission tomography computed tomography (PET-CT) that 
brown adipose tissue (BAT) activity is not increased in a rat model of roux-en-Y gastric 
bypass (RYGB) surgery. I have also shown that the levels of uncoupling protein 1 
(UCP1) which is a molecular marker of BAT activity are not increased following RYGB 
showing concordance between the in vivo metabolic imaging technique and the molecular 
technique for assessment of BAT activity.   
6.1  PYY3-36 and PYY3-36 (LT) 
Peripheral administration of PYY3-36 has been shown by several groups to reduce short-
term food intake (Batterham et al., 2002; Challis et al., 2003; Halatchev et al., 2004; 
Martin et al., 2004; Riediger et al., 2004; Talsania et al., 2005). I have confirmed these 
data by showing acute, peripheral injections of PYY3-36 reliably and dose-dependently 
reduces food intake in the fasted state in mice. The chronic PYY3-36 studies presented 
were less successful at replicating the sustained reductions in food intake and body-
weight in the literature (Batterham et al., 2002; Challis et al., 2003; Adams et al., 2006; 
Pittner et al., 2004). One explanation for this lack of effect may be due to the differences 
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in the infusion paradigms employed by other investigators. I used once daily injection of 
PYY3-36 whilst others have used either continuous infusions or surgically implanted 
osmotic minipumps (Pittner et al., 2004; Vrang et al., 2006; Chelikani et al., 2006; 
Chelikani et al., 2007).   
The work I have carried out characterising the analogues of PYY3-36 with rational amino 
acid substitutions indicated that PYY3-36 (LT), a molecule with structural homology to the 
long lasting GLP-1 analogue exendin 4, demonstrated a 20-fold increase in anorexigenic 
efficacy over PYY3-36. In chronic feeding studies in diet induced obese mice, once daily 
peripheral administration of PYY3-36 (LT) caused a 10% reduction in bodyweight which 
is the requirement of anti-obesity drugs in Europe. If this peptide reproducibly reduces 
weight in other species such as rats, it would be very promising to test it in lean and 
obese individuals.   
6.2 Manganese enhanced magnetic resonance imaging (MEMRI) 
The application of MEMRI to the study of appetite regulation has allowed the recording 
of the real time effects on neuronal activity of gut peptides within the CNS. I have 
extended previous observations by revealing that MEMRI SI in the hypothalamus is 
dramatically influenced by temperature. I have also confirmed the reproducibility of the 
MEMRI technique by replicating fasted vs fed studies and further validated the current 
MEMRI model of the effects of anorexigenic peptides on hypothalamic SI with the 
established anorexigen pancreatic polypeptide (PP). Furthermore, I investigated the 
effects of a pharmacological dose of PYY3-36 and the long-lasting PYY3-36 analogue 
PYY3-36 (LT) on hypothalamic MEMRI SI at several different timepoints after treatment. 
The MEMRI studies revealed that the long-lasting PYY3-36 analogue PYY3-36 (LT) 
decreased the SI in the ARC of fasted mice back to the fed state at a timepoint that 
matched the divergence in behaviour observed with the two treatments. It may be that 
PYY3-36 (LT) circulates for longer time periods in the plasma which allows sufficient 
concentrations of PYY3-36 (LT) to accumulate in the ARC to inhibit these neurons via the 
autoinhibitory Y2 receptor.  
Pharmacological experiments were also performed with the food additive monosodium 
glutamate (MSG). MSG dose-dependently increased the SI in the ARC and this effect 
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was reversed by coadministration of an AMPA receptor antagonist. I have shown that 
administration of both AMPA and NMDA increase the SI in the ARC consistent with 
their excitatory effects in the CNS. The increase in the cortical regions with high dose 
MSG strongly point to extracellular Mn2+ accumulation and reemphasize the need to be 
able to differentiate between intracellular and extracellular Mn2+.  Importantly, all of 
these treatments also influenced MEMRI SI in the ventricles. The most striking 
observation was that administration of the AMPA receptor antagonist alone, which was 
predicted to decrease the MEMRI SI in the ARC, actually increased it significantly and 
also in the lateral ventricle. This has implications on the use of MEMRI as a tool to assess 
neuronal activity. These changes could be due to numerous factors such as changes in the 
levels of Mn2+ in the blood, changes in cerebral bloodflow, and changes in the blood CSF 
barrier. One way to correct for this is to normalise changes in SI in the brain to changes 
in the CSF and/or normalise changes in the brain to changes in the concentration of Mn2+ 
in the plasma. With these measures in effect, this would firmly place MEMRI as a 
modality that measures neuronal activity as opposed to a method that simply measures 
the distribution of Mn2+ in the brain.    
6.3 Positron emission tomography computed tomography (PET-CT) 
The study of BAT physiology in vivo has become of great interest since the observation 
of functional BAT in adult humans (Cypess et al., 2009; Virtanen et al., 2009). Rodent 
models of the RYGB procedure have been developed and this has allowed for detailed 
investigations as to how the procedure affects whole body physiology which could 
possibly assist in the development of treatments that mimic the post surgery state. I have 
confirmed that the rat model results in a reduction in food intake post operatively and 
produces a sustained reduction in bodyweight. Through the use of PET-CT and 
measuring UCP1 levels, I have shown that no effects on BAT were caused by the 
procedure suggesting that the increased energy expenditure previously observed is due to 
some other physiological process. Despite these negative results, PET-CT can be used to 
assess the activity of BAT in other physiological and pathophysiological settings. 
Furthermore, the effects of potential anti-obesity drugs such as PYY3-36 (LT) on BAT 
activity can be assessed in vivo with this methodology.  
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Appendix I - Solutions used in this thesis 
Biuret reagent: 
Dissolve 1.50 g CuSO4, 6 g KNaC4H4O6.4H2O, 30.0 g NaOH, 1.00 g KI and 15.0 g 
deoxycholate in 900 ml water. Warm to dissolve salts. Make up to 1 L with water.  
20 mM HEPES pH 11: 
Dissolve 4.76 g HEPES in 900 ml water. Adjust to pH 11 with 0.5 M NaOH. Make up to 
1 L with water.  
50 mM HEPES pH 7.4: 
Dissolve 11.9 g HEPES in 900 ml water. Adjust pH 7.4 with HCl. Make up to 1 L with 
water. 
1 M Magnesium chloride: 
Dissolve 203.3 g MgCl2.6h2O in 1 L water. 
0.1 M PEI: 
Dissolve 450 mg PEI in 80 ml water. Adjust pH 7.0 with HCl. Make up to 100 ml with 
water. Filter solution.  
Phosphate buffer (RIA buffer): 
48 g of Na2HPO4.2H2O, 4.13 g KH2PO4, 18.61 g C10H14H2O8Na2.2H2O, 2.5 g NaN3 were 
dissolved in 5 L of GDW, which had been boiled and allowed to cool, the pH was 
measured to confirm it was 7.6 ± 0.1 and the buffer was stored at 4°C. 
Phosphate buffer with gelatine: 
The buffer was produced as above with 12.5 g of gelatine dissolved in the boiling GDW 
then cooled before the addition of the other ingredients. 
0.14 M Sodium borate buffer pH 8.3: 
Dissolve 5.32 g Na2B4O7 in 800ml water. Adjust pH 8.3 with HCl. Make up to 1 L with 
water.   
0.15 M Sodium chloride: 
Dissolve 8.78 g NaCl in 800 ml water. Make up to 1 L with water. 
0.015 M Sodium citrate: 
Dissolve 3.21 g C3H4OH(COOH)2COONa in 800 ml water. Make up to 1 L with water. 
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10 M Sodium hydroxide: 
Dissolve 400.0 g NaOH in 800 ml water. Make up to 1 L with water.  
100mM Tris-HCl pH8.0: 
Dissolve 12.1g trizma base in 800 ml water. Adjust to pH 8.0 with HCl. Make up to 1 L 
with water.  
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Appendix II - Primer sequences used in this thesis 
Gene and accession number  Primer sequence 
UCP 1 
BC012701 5’ AAGGCCAGGCTTCCAGTACTATTAGG 
             3’ GGTTTGATCCCATGCAGATGGCTCTG 
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Appendix-III Radioimmuoassay methods 
General Principle of Radioimmunoassay (RIA) 
RIA was used to measure specific binding of Iodinated PYY. The RIAs were all 
performed under the guidance and supervision of Professor M. Ghatei (Professor of 
Regulatory Peptides, Metabolic Medicine, Division of Investigative Science, Imperial 
College London) who monitored the specificity and sensitivity of all the “in-house” 
RIAs.  
Radioimmunoassay (RIA) is a technique for measuring low levels of biological 
substances in small volume tissue and plasma samples. The principle of RIA is 
competition between unlabelled antigen (in the sample) and radiolabelled antigen to bind 
to a fixed concentration of antibody. The most commonly used radiolabel is 125I, and 
antibodies are often obtained from rabbit immunisation with antigen/peptide plus 
adjuvant (though polyclonal antibodies from other species and monoclonal antibodies can 
be used). The concentrations of radiolabelled antigen and antibody remain constant. 
Increasing the concentration of unlabelled antigen will therefore decrease the binding 
sites available for binding to the radiolabelled antigen. Thus the amount of radiolabelled 
antigen bound to the antibody is inversely proportional to the amount of unlabelled 
antigen in the sample being examined. A series of reference standards or a ‘standard 
curve’ is constructed of known concentrations of the peptide. Once equilibrium has been 
achieved, the amount of antibody bound to antigen, and the amount of free antibody and 
antigen are constant. Separation of the unbound radiolabelled antigen from the 
radiolabelled antigen-antibody complex and counting the proportion of radiolabel present 
in the two fractions enables direct measurement of the amount of unlabelled antigen that 
has bound to the antibody. By reference to the standard curve, the concentration of 
unknown samples can be calculated.  
*Ag + Ab + Ag ↔ *AgAb + Ag Ab  
*Ag = radiolabelled antigen 
Ag = unlabelled antigen 
Ab = antibody 
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Each RIA has optimum conditions in terms of buffer, volume, antibody titre, incubation 
time, temperature and separation method used. Phosphate and sodium barbitone buffers 
are used for a wide range of RIAs. Assays are often incubated at 4°C for 3-5 days.  
The simplest method of separation of free radiolabelled antigen from the antibody 
complex is adsorption, for example with charcoal. Dextran is added to a charcoal 
suspension to block the larger holes in the porous charcoal. The suspension is then added 
to the RIA tubes, where it traps the free radiolabelled antigen. The tubes are then 
centrifuged and the supernatant (bound antibody complex) and carbon pellet (free 
radiolabelled antigen) separated by aspiration, and counted in a gamma counter.  
Quality control is essential in RIA. Inter-assay variation can be calculated by assaying 
aliquots of the same sample in each assay performed and comparing the concentrations 
obtained in each. To measure and correct for baseline drift, tubes with no sample (‘zero’ 
tubes) are placed at regular intervals throughout the assay and a standard curves are 
performed at the beginning and end of each assay. 
The general structure of the RIA is outlined in Table A1, which shows the content of the 
tubes according to their designation. The following tubes are important for the 
assessment and performance of the assay: 
Non-specific binding: The lower the non-specific binding the better, this assesses the 
integrity of the label. 
½ X: This assesses whether greater sensitivity can be achieved by adding half the volume 
of label. 
2 X: This assesses whether greater sensitivity can be achieved by adding double the 
volume of label. 
Zero: Zero tubes are run at frequent intervals throughout the assay. The binding allows 
assessment of assay drift. 
Excess antibody: This assesses the immunological integrity of the labelled peptide.  
Quality Controls: Quality control includes previously aliquoted samples containing high 
and low levels of the antigen. These tubes allow the assays to be standardised. 
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Tube number Designation 
1-2 Non-specific binding 
3-4 ½ X 
5-6 2 X 
7-8 Zero 
9-10 Zero 
11-12 Standard 1 
13-14 Standard 2 
15-16 Standard 3 
17-18 Standard 4 
19-20 Standard 5 
21-22 Standard 6 
23-24 Standard 7 
25-26 Standard 8 
27-28 Standard 9 
29-30 Standard 10 
31-34 Zero 
35- …. Samples 
Zeros Two zeros every 50 samples 
Standard curve  
Final two tubes Excess 
Table AI  The general structure of the radioimmunoassay 
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Appendix IV – Mouse behavior studies 
Previous published work by members of the group investigated mouse behavior 
following administration of GLP-1 and exendin-4. A brief summary of the experimental 
design and results are included below for studies with PYY3-36 and PYY3-36 (LT).  
Observational analysis of mouse behavior 
All mice were singly housed and the acclimatization process and preparation for studies 
was the same as that for mice taking part in feeding studies. Lithium chloride was used as 
a positive control for illness/aversive behaviour. This was given at a dose of 127 mg/kg 
by i.p. injection (a dose shown by several studies to produce a sensation of visceral 
illness (Cannon et al., 2005; Lachey et al., 2005).  
Mice were fasted from 16:00 the preceding day and following i.p. injections, mice were 
returned as usual to their home cages. A colleague who was blinded to the treatment they 
had received assessed their behavior over the subsequent 60 minutes using a previously 
established protocol for rodent behavior analysis (Neary et al 2005). The observer 
assessed the behavior in each mouse for 15 seconds every 5 minutes. These 15-second 
periods were subdivided into three 5-second periods. In each of these periods the 
observer selected the behavior which most closely represented that of the animal under 
observation. The behavior options were feeding, drinking, sitting, climbing, locomotion, 
grooming, head down, sleeping, burrowing, pica, tremors, and rearing.  
The effects of saline vehicle and PYY3-36 (LT) were examined under the same 
experimental conditions. Lithium chloride was used as a positive control in this 
experiment as it is a know cause of visceral illness behavior. Administration of peptide 
resulted in a marked reduction in the amount of time spent engaged in feeding behavior 
and drinking compared to saline treatment and an increase in burrowing and grooming. 
Increase in ‘head down’ behavior (which is thought to be a marker for the sensation of 
visceral illness) increased compared to saline treatment only in the lithium chloride group 
with decreases also in feeding, rearing, and locomotion (Kruskall-Wallis test). (Figure 
AIV). 
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Figure AIV. Behavioural effects in mice after administration of Saline, LiCl, and 
PYY3-36 (LT). 
Behaviours were analysed for up to 60 minutes after i.p. injection for LiCl and s.c. 
injection for saline and PYY3-36 (LT) (LiCl 127 μg/kg and PYY3-36 (LT) 500nmol/kg).  
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Appendix V – PP feeding study 
An acute feeding study with 500nmol/kg PP (Bachem) was designed as in section 2.5.1.1. 
Subcutaneous administration of 500nmol/kg PP (n=9) to overnight fasted mice 
significantly inhibited food intake compared to saline (n=9) (p<0.001) up to the 4-8 hour 
interval (Figure AV). PP treated mice ate significantly more than saline treated mice at 
the 8-24 hour interval (p<0.05). However, food intake over the 24 hour period was 
significantly less for PP treated mice (p<0.001). 
 
Figure AV. Effect of 500nmol/kg PP on food intake in fasted mice.  
Effect of SC administration of saline (n=9), and 500nmol/kg PP (n=9) on food intake in 
overnight fasted mice, at 0-1h, 1-2h, 2-4h, 4-8h, 8-24h, and 0-24h post injection.  
*=p<0.05 and ***=p<0.001 compared to saline paired t-test.  
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Appendix VI - Amino Acid codes 
Amino acid:             Three letter code:       Single letter code: 
Glycine   Gly   G 
Proline    Pro   P 
Alanine   Ala   A 
Valine    Val   V 
Leucine   Leu   L 
Isoleucine   Ile   I 
Methionine   Met   M 
Cysteine   Cys   C 
Phenylalanine   Phe   F 
Tyrosine   Tyr   Y 
Tryptophan   Trp   W 
Histidine   His   H 
Lysine    Lys   K 
Arginine   Arg   R 
Glutamine   Gln   Q 
Asparagine   Asn   N 
Glutamic Acid   Glu   E 
Aspartic Acid   Asp   D 
Serine    Ser   S 
Threonine   Thr   T 
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Appendix VII - List of suppliers 
Amersham Biosciences, Buckinghamshire, UK 
ATCC-LGC Standards, Middlesex, UK 
Bachem Ltd, St Helens, UK 
Bayer Ltd, Bury St Edmunds, UK 
Becton Dickinson and CO, NJ, USA 
Biovet Corp, USA 
Cambridge Bioscience, Cambridge, UK 
Charles River, Bicester, UK 
DuPont Ltd, Hertfordshire, UK 
Eppendorf, Hamburg, Germany 
Graphpad Prism, Graphpad Software, CA, USA 
Harlan, UK 
Harvard Apparatus, MA, USA 
IKA Werke GmbH and Co. KG, Staufen, Germany 
Image J, NIH, USA 
Inveon Siemens Preclinical Solutions Inc, Munich, Germany 
Invitrogen Ltd, Paisley, UK 
Jencons Scientific Ltd, Befordshire, UK 
Magnetic Resonance Laboratories, Oxford, UK 
MestRe-C, Santiago de Compostela, Spain 
Meyer Instruments Inc, TX, U.S.A 
Millipore Limited, Watford, UK 
MP Biomedicals, Cambridge, UK 
NE Technology Ltd, Reading Berkshire, UK 
Olympus UK Limited, Essex, U.K 
PAA labs, Somerset, UK 
PET-NET Solutions Ltd, Middlesex, UK 
Phenomenex, Macclesfield, UK 
Promega, Southampton, UK 
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R & D Systems Ltd, Abingdon, UK 
Rathburn Chemicals Ltd, Walkerburn, Scotland 
SA Instruments Inc, NY, USA 
Shimadzu, Kyoto, Japan 
Sigma-Aldrich Ltd, Dorset, UK 
Special Diet Services, Essex, UK 
Statacorp, College Station, TX, USA 
Sterilin Limited, Caerphilly, UK 
Thermo-scientific, Rokilde, Denmark 
Tocris Bioscience, Bristol, UK 
Varian Inc, CA, USA 
VWR International Ltd, Dorset, UK 
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